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This study seeks to explore spray congealing as an efficient technology 
to embed drugs in meltable lipid matrices such as fatty alcohols, fatty acids, 
fatty esters and glycerides, and produce solid lipid microparticles. These 
meltable materials from different chemical classes possess a variety of 
physicochemical properties. Polymeric additives, polyvinyl-2-pyrrolidone-
vinyl-acetate (PVP/VA) and ethyl cellulose (EC) were added to the lipid 
matrix to act as release- modifying agents by their effects on matrix viscosity 
and characteristics of the resultant spray-congealed microparticles. 
Intermolecular interactions between the lipid-based material and additive were 
also investigated using spectroscopic techniques. 
 
The viscosity-temperature relationship of the lipid-based materials was 
investigated, culminating in the development of a new model which could 
better describe the relationship than existing viscosity-temperature models. A 
temperature-independent rheological parameter, Tp, was derived.  The Tp 
values were found to correlate better than viscosity with the size of the 
resultant spray-congealed microparticle. The Tp value, which is characteristic 
of the lipid-based material, was affected by the polymeric additives. It can 
therefore be used for the optimization of lipid-based formulations to produce 
spray-congealed microparticles of the desired size range. 
 
The spray congealing process caused polymorphic changes to glyceryl 
dibehenate and the model drug, ibuprofen. Further changes during storage for 
x 
 
up to a year were monitored. The polymeric additives were found to affect the 
stability of the polymorphs to different extents. PVP/VA and EC expanded the 
unit cell dimensions of cetyl alcohol but had negligible effect on stearic acid. 
They can also either accelerate or decelerate the polymorphic transformations 
in glyceryl dibehenate. 
 
The different solid lipid microparticles showed varying ability to 
sustain the release of ibuprofen. The effect on drug release was influenced by 
the nature of lipid-based material, microparticle size, drug-matrix miscibility 
and nature of additives added. Unlike cetyl alcohol, stearic acid and glyceryl 
dibehenate were useful as lipid matrix materials for the production of 
sustained release microparticles. Larger solid lipid microparticles (with higher 
additive concentration) generally led to slower drug release. PVP/VA and EC 
were useful as release modifying agents but their effects were not easily 
generalizable. From the scanning electron microscope (SEM) images of the 
microparticles taken pre- and post-dissolution together with drug release 
modelling, it appeared that the drug release mechanisms differed for the 
microparticles prepared using different lipid matrices. For solid lipid 
microparticles prepared using stearic acid or glyceryl dibehenate, diffusion 
was found to be the main release mechanism. For cetyl alcohol, drug release 
was characterized by an initial burst release of the bulk of the encapsulated 
drug followed by a loss of integrity of the microparticle structure which led to 
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A1. Lipid excipients in oral solid dosage forms 
 
A1.1. Lipid-based excipients 
 
Pharmaceutical grade lipid-based excipients are derived mainly from the 
food industries where they are frequently employed as emulsifiers, solubilizers 
and stabilizers as well as lubricants. Lipids for use in pharmaceutical industry 
are sometimes modified and their applications include overcoming certain drug 
delivery challenges, especially those related to taste masking, stability 
enhancement and drug dissolution
1
. The growing interest in utilizing lipid-
based excipients in oral solid dosage forms stems from their highly 
biocompatible, physically diverse, low cost and non-toxicity
2
. One of the most 
important property of lipids that is commonly exploited in drug delivery is 
their water insolubility. This renders them highly valuable in the development 
of oral dosage forms where they may be employed for encapsulating and 
protecting moisture-sensitive drugs
3





, enhancing drug absorption and 
bioavailability
6




The term ―lipid‖ describes a family of materials with diverse 
physicochemical properties, including fatty acids, fatty alcohols, waxes, 
hydrogenated vegetable oils and glycerides
9
. Most fatty acids and fatty 
alcohols of pharmaceutical grade are listed as GRAS (generally recognized as 
safe) excipients by the FDA
10,11
. They are frequently employed in food, 
3 
 
cosmetics and personal care products, partly due to their well-documented 
non-toxic nature. In the pharmaceutical industry, they are mainly employed as 
the vehicle or emulsifiers for creams, lotions and ointments
12-14
. Waxes are 
esters of fatty acids with long chain monohydric alcohols. Naturally occurring 
waxes are often found as mixtures of such esters, with the occasional presence 
of long chain hydrocarbons. Waxes, such as beeswax and carnauba wax, are 
commonly used as coating agents due to their toughness and high water 
resistance
15,16
. Glycerides, which are esters of glycerol and fatty acids 
(triacylglycerols) exist in a myriad of fatty acid chain lengths and degrees of 
saturation. Based on their extent of esterification, they can form mono-, di- or 
tri-glycerides. Glycerides with short-chain or unsaturated long-chain fatty 
acids exist as liquids or semisolids at room temperature and are frequently 
used to formulate ointments, creams and emulsions. On the other hand, 
glycerides with long-chain saturated fatty acids exist as solids at room 
temperature and may be employed as lubricants in the manufacture of solid 
oral dosage forms, among other uses in formulations.  
 
Modified forms of naturally occurring lipids have been used to develop 
various drug delivery systems. There are two major groups of lipid types. The 
first group consists of mixtures of naturally occurring triglycerides and these 
are standardized by established formulas in their compositions. The second 
group consists of novel lipid excipients which are usually chemically modified 
fatty acids with attached functional groups such as glycerol, polyethylene 
glycol, polyglycerol or propylene glycol to confer different melting points and 
hydrophile-lipophile balance (HLB) values for the lipids to be used in specific 
applications
17
. For example, to improve the retention of water-soluble drug 
4 
 
within the final dosage form, lipid excipients with higher melting points and 
lower HLB values (less polar) are desired and this can be achieved by 




Solid lipids, which refer to lipids that exist as solids at ambient 
temperature, are highly suitable for development into oral solid dosage forms 
but this potential remains relatively unrealized. Besides the applications 
mentioned above, solid lipids are increasingly employed as drug-carrying 
matrices. Suitable lipid matrix formers, in addition to being solids at room 
temperature, should ideally be thermally stable since most processes handling 
this class of materials employ some form of heating
19,20
. Typically, they 
possess melting points between 50°C and 85°C depending on their chemical 
structures and composition
21
. This melting point range confers versatility to 
solid lipid excipients such that they can be processed by compression (cold) or 
melt (hot) processes. Suitable processing techniques will be discussed in detail 
in the following section. 
 
A1.2.  Processing methods for lipids in the production of lipid matrix dosage 
forms 
 
A1.2.1. Direct compression 
 
Direct compression is a two-step production process, i.e. blending of 
powdered excipients and lubricants, followed by compaction of the mixture. 
The obvious advantage of direct compression lies in its simplicity and 
efficiency. One study compared the characteristics of directly-compressed 
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matrix tablets made up of solid lipid excipients versus other polymeric 
excipients
22
. It was found that all tablets exhibited satisfactory hardness, 
thickness, content uniformity and low friability. When the concentration of 
solid lipid excipient was increased in the tablet formulation, it retarded drug 
release. Among the lipid excipients discussed in literature, glyceryl behenate 
was shown to be capable of producing effective sustained drug release tablets. 
Notwithstanding their ability to sustain drug release, all lipid matrix tablets 
were found to have lower tensile strength than those produced using polymeric 
excipients. In a separate study using carnauba wax, beeswax, stearic acid, cetyl 
alcohol, cetostearyl alcohol and glyceryl monostearate as lipid matrix materials 
in tablets produced by direct compression, it was found that increasing the 
amount of lipid led to a significantly reduced burst release of theophylline. 
Cetostearyl alcohol retarded theophylline release most regardless of its 
concentration in the tablet
23
. Amaral et al. prepared hydrogenated castor oil 
matrix containing naproxen and a hydrophilic filler, lactose
24
. Without lactose, 
naproxen release was retarded and retardation increased with the concentration 
of the lipid in the tablet. Lactose acted as a channelling agent in the tablet, 
forming aqueous pathways when it dissolved to allow faster drug release. Drug 
release was further enhanced when microcrystalline cellulose was used in 
place of lactose
25
. The hydrophilic microcrystalline cellulose led to 
disintegration of the tablet during the dissolution test, exposing more drug 
surfaces for drug dissolution. Nanjwade et al. investigated the modification of 
metformin HCl release from stearic acid matrix tablets by adding a hydrophilic 
polymer, polyethylene glycol. Similarly, increasing stearic acid concentration 






Despite the convenience and efficiency of direct compression in the 
preparation of lipid matrix tablets as reported in various studies, this 
production process has several drawbacks. It is generally applicable only for 
lipids with higher melting points as low melting lipids may melt due to heat 
generated during tabletting. Additionally, control of drug release from a 
directly compressed lipid matrix tablet can be difficult to predict. Sometimes, 
the expected drug release profile may not be achieved and drug release rate 
tend to be slower than expected. Moreover, lipid matrix tablet formulation may 
not be suitable for a high dose drug as the flow and compression properties of 
the feed would depend more on the drug than the lipid excipient. Direct 
compression may also be unsuitable for sustaining the release of highly water-
soluble drugs as it often fails to fully encapsulate the drugs so as to impede 
their release. 
 
A1.2.2. Dry and wet granulation 
 
Dry granulation is a size enlargement process that converts powder into 
free flowing granules without utilizing water, organic solvents or binder 
solutions. In this process, the blend of excipient(s) and drug is roller 
compacted, and the compacted flakes obtained are milled to produce dense 
granules
27
. Lipid may be used as it can act as a dry binder by virtue of its 
inherently tacky nature. Unlike polymers which are frequently employed as 
dry binders in roller compaction, lipids are not hygroscopic and can aid in 
preserving the integrity of moisture-sensitive drugs. Hariharan et al. studied 
the roller compaction of various drug-polymer-lipid blends. Different ratios of 
polymer, microcrystalline cellulose or hydroxypropylmethylcellulose (HPMC), 
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and lipid, glyceryl behenate, were studied. The flakes produced were milled 
into granules, which were used to produce tablets. It was found that the lipid 
added was able to reduce the hydration rate of the polymers, thereby slowing 
down drug release. Different drug release profiles could be achieved by 
varying glyceryl behenate concentration in the tablet, imparting flexibility in 
formulation design
28
. Venkatesh et al. prepared roller compacted flakes of 
lithium carbonate with various lipids. The flakes were subsequently milled and 
the granules obtained were used to produce tablets. It was reported that lipid 
matrix tablets with a high drug load could be successfully prepared. 
 
Wet granulation is a powder agglomeration process which occurs in the 
presence of a liquid binder under shearing forces. The binder solution typically 
consists of various polymers is used as the granulating agent. Pulcini et al. 
investigated the production of glyceryl behenate-based tablets using an 
intermediate wet granulation step with binder solution comprising HPMC. It 
was reported that wet granulation is a viable alternative to dry granulation for 
the production of granules for compaction to form tablets
29
. A separate study 
by Zhang et al. showed that the drug release profiles of lipid-based tablets 
produced by wet granulation and by direct compression could be comparable
30
. 
Barakat et al. investigated carbamazepine release from granules and tablets 
made using wet granulation of glyceryl behenate and hydrophilic polymers, 
HPMC and microcrystalline cellulose. It was found that increasing the amount 




Both dry and wet granulations are viable processing methods in the 
production of lipid-based tablets, especially when direct compression is not 
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feasible. Most studies have demonstrated the concentration-dependent release 
retarding effect of lipids, making them suitable agents for sustaining drug 
release. 
 
A1.2.3. Melt pelletization/granulation 
 
Melt pelletization or melt granulation is a single step, one-pot and 
solvent-free process to obtain lipid matrix dosage forms. In this process, a 
meltable lipid binder is blended in a high shear mixer together with other 
ingredients. When the shear force is increased, heat and frictional forces 
generated by the impeller cause the melting of the lipid and it then acts as the 
granulating liquid
9
. Alternatively, molten lipid may be sprayed directly onto 
the agitated powder blend in the granulator. The molten lipid then binds 
various ingredients together to form agglomerates, sometimes highly spherical, 
which on cooling are flowable melt granules suitable for secondary processes 
such as tableting or capsule filling
32
. Tablets made from compaction of melt 
granules were found to have a more sustained drug release compared to melt 
granules alone or to tablets made from granules obtained from direct 
compression, dry or wet granulation
32
. This observation could be attributed to 
the encapsulation of the drug by the lipid in the melt granules. 
 
Despite the operational simplicity of melt granulation, it is not widely 
used for two main reasons. Firstly, the amount of lipid binder used should not 
exceed 20 %, w/w for successful granulation
33,34
. This limited amount of lipid 
binder may not be sufficient to impart the desired sustained release behaviour. 
Secondly, higher melting point materials such as high molecular weight lipids 
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are often preferred as they can better sustain drug release. However, such 
lipids usually have very narrow melting ranges, making it difficult to control 
the process and hence resulting in poor batch-to-batch reproducibility. 
Utilizing lower melting point lipids can be a viable solution to this problem, 
but such lipids were found to be unable to sustain the release of highly water-
soluble drugs
1
. In an attempt to address this problem, Hamdani et al. used a 
combination of two types of lipids – a high melting point, narrow melting 
range lipid (glyceryl behenate) and a lower melting point, large melting range 
lipid (glyceryl palmitostearate). Frictional forces generated by impeller shear 
were able to melt the lower melting point lipid and promoted granulation, 
while the higher melting point lipid remained unaffected but augmented the 
sustained release ability of the final product. This method was found to be 
useful for sustaining the release of ciprofloxacin, theophylline and ketoprofen 
from melt pellets
35




Moulding can be considered as one of the simplest and yet more 
effective methods to produce lipid matrix dosage forms. Briefly, the lipid is 
first melted and the drug dissolved or dispersed in it. The molten mixture is 
then filled into a casting mould with a predefined shape and size. The product, 
referred to as lipid mould, is obtained upon solidification of the drug-loaded 
lipid
36
. The moulding process is suitable for highly water-soluble drugs as a 
sufficient ‗shielding‘ effect is conferred by the total encapsulation of the drug 
within the lipid matrix. Using this method, Adnan et al. produced lipid moulds 
composed of diltiazem HCl and stearoyl polyoxylglyceride, which exhibited 
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good sustained release behaviour
37
. In order to ensure drug homogeneity 
within the solid lipid mould, lipids used in this process should solidify rapidly 
upon cooling to avoid sedimentation of the dispersed drug particles. A 
potential drawback of the moulding method for lipid mould production is that 
when highly compact, pore-free and water impervious hydrophobic moulds are 
produced, they will not wet well and drug release may be much slower than 
desired. A possible strategy to overcome this problem is to add hydrophilic 
additives such as mannitol, HPMC, polyethylene glycol or poloxamers to 




A1.2.5. Melt and mix methods 
 
The melt and mix method is relatively similar to the moulding method. 
The solid lipid is first melted and the drug dissolved or dispersed in the molten 
lipid. Instead of pouring the molten mixture into a designated mould, it is 
allowed to cool to solidify into a mass which is then ground to form granules 
or fine powder. The granules or powder obtained may be filled into capsules or 
compacted into tablets. Suitable lipids amenable for this method should fulfil 
the same requirements as that of the moulding method described earlier. 
Similar to the moulding method, drug release from granules prepared using the 
melt and mix method have been shown to be slow
41,42
 The drug is well 
encapsulated by a lipophilic ‗barrier‘ and has minimal contact with the 
surrounding fluid. This method can potentially be exploited for some other 
biopharmaceutical advantages, such as taste masking of bitter medicaments or 






A more advanced version of melt and mix method that is gaining 
considerable interest in recent years is hot melt extrusion. The latter is an 
easily scalable continuous manufacturing process and it allows for precise 
adjustments and control of processing parameters. Lipids with low melt 
viscosities are desirable in this production process as they can accommodate a 
higher drug load and ensure drug homogeneity in the resultant melt 
extrudates
44
. In one study, the type of extruder used, torque values applied 
during extrusion as well as the amounts of drug and filler in the formulation to 
produce satisfactory melt extrudates were determined
42
. It was found that the 
lipid concentration of the formulation had the greatest impact on drug release. 
Compared to polymers which is the mainstay of hot melt extrusion currently, 
lipids can be extruded with drug below the melting point of the lipids. Hence, 
drug-lipid mixtures generally require lower processing temperatures compared 
to drug-polymer mixtures. On top of the significant cost and energy savings, 
this also makes the process amenable to thermolabile drugs. The use of lipids 
in place of polymers can also eliminate the need for unnecessary additives 




A1.2.6. Hot melt coating 
 
As the name suggests, hot melt coating is a process whereby molten lipid 
is sprayed onto the drug particle surface to form a lipid ‗coat‘. The coated drug 
particles can then be filled into capsules or compacted as tablets. The use of 
lipids in place of polymers for coating has several advantages. For example, 
the amount of lipid required to achieve specific drug release behaviour is 
generally much lower compared to that of hydrophilic polymers. The 
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formulation can be simplified as usually only one type of lipid is sufficient. 
Moreover, lipids are relatively inexpensive compared to polymers
46
. Coating 
with lipid excipients opens up a multitude of potential applications, such as 
taste masking of bitter medicaments
47,48
, improving physical and chemical 
stability of drugs
49-51




A1.2.7. Spray congealing/chilling 
  
 Spray congealing, which is the process of interest in the present study, 
is discussed in greater detail in the subsequent section. It is a process in which 
a hot molten mixture is atomized into a cooled chamber where the molten 
droplets congeal (or solidify) to form solid particles, usually upon contact with 
cooling air. Spray congealing is emerging as a promising technology for 
handling meltable pharmaceutical excipients. 
 
A1.3. Production of solid lipid microparticles as a lipid matrix dosage form 
 
Solid lipid microparticles (SLMs) are one of the examples of lipid matrix 
dosage form. Various studies have highlighted the production of SLMs using a 







 and homogenization methods
68,69
. In the solvent evaporation 
method, the lipid and drug are first dissolved in a suitable organic solvent 
(usually chlorinated solvents) and the resultant mixture dispersed in an 
aqueous solution containing an emulsifying agent. The oil-in-water emulsion 
thus produced is stirred continuously for several hours at room temperature to 
allow evaporation of the organic solvent, leading to the formation of lipid 
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microparticles. In the melt dispersion technique, the drug is first dissolved or 
dispersed in the molten lipid and the hot molten mixture is then dispersed in an 
aqueous surfactant solution (heated above the melting point of the lipid). The 
emulsification process can be aided by a high shear device. The emulsion is 
then allowed to cool at room temperature or placed in an ice bath to obtain the 
microparticles. The major limitation of both the solvent evaporation and melt 
dispersion methods is the requirement of an organic solvent used in the process 
and it may be incompletely removed
70
. As many organic solvents are toxic in 
nature, this may give rise to safety issues. In addition, undesirable drug 
partitioning to the external aqueous phase is possible in these methods, often 
resulting in poor drug encapsulation efficiency
19
. In the homogenization 
method, an emulsion consisting of a drug-loaded lipid melt dispersed in a hot 
aqueous surfactant solution is first produced. High pressure homogenization is 
employed to break down this emulsion into fine droplets, which are then 
cooled to form microparticles. The use of high pressure in this process incurs 
higher energy consumption as well as added cost of the specialized equipment. 
During processing, the emulsion also heats up, which may affect the stability 
of the encapsulated drugs, especially those which are thermolabile. In the spray 
drying method, an emulsion with lipid and drug in the dispersed phase or an 
organic lipid solution with drug is prepared and sprayed into a hot air 
chamber
71
. The heat rapidly volatilizes the water or organic solvent, leading to 
the formation of microparticles. Besides incurring considerable equipment 
cost, the spray drying method will require considerable time to set up and 
clean after use
20,72
. Furthermore, sophisticated solvent recovery system must 
be in place to recover toxic organic solvents when used.  In light of the 
limitations associated with the above-mentioned methods of producing SLMs, 
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spray congealing could also be utilized as a rapid, one-step microencapsulation 
process to produce drug-loaded SLMs and it was applied in this study. 
 
A2. Introduction to spray congealing 
 
Spray congealing, also known as spray cooling, chilling or prilling, is a 
process in which a hot molten mixture is atomized into a chamber where the 
molten droplets congeal to form solid particles. The molten mixture may 
consist of one or more drugs which may be melted, suspended or dissolved in a 
matrix melt. The spray congealing process typically transforms molten 
droplets from a liquid to a solid state with the removal of heat from the 
droplets by the cooling air in the spray congealer chamber. Congealing can 
also be achieved by spraying the molten mixture into chilled solvents, 
desolvating liquid or sorptive particles. 
 
Spray congealing is widely accepted as a method of 
microencapsulation
73
. Drugs are encapsulated by matrix material during the 
stage of atomization where the drug particles served as solid seeds for the 
molten matrix material to coat or during the stage of solidification where the 
dissolved drug recrystallizes out and becomes embedded in the matrix 
material
40,74-78
. As a method of microencapsulation, spray congealing can be 
adapted for the production of specialized drug delivery systems. Since spray-
congealed particles consist of drug(s) embedded in or surrounded by a matrix 
material, they may be employed to enhance the stability
58,71
, mask unpleasant 
taste
77,79-81
 and reduce gastrointestinal irritation
82






The most common application of spray congealing is in the production 
of modified-release dosage forms
84
. Drug release rates can be altered by 
judicious choice of matrix materials and additives. By employing lipophilic 











 and microcrystalline wax
85
, 
microparticles with sustained-release properties can be produced. Drugs with 





 have been formulated in this manner. On the other hand, 







 have been investigated as potential matrix 











Spray congealing is also employed for the production of solid 
dispersions, mainly to enhance the dissolution of poorly water-soluble 
drugs
19,79,87,92,94,96,97
. Solid dispersions are systems consisting of a dispersion of 
discrete particles of drug in a matrix material. They may be produced by the 
melting, solvent or melting-solvent methods
84,87
. It is well known that the rate 
of cooling can affect the crystallinity of either the incorporated drug or the 
matrix material, which in turn affects the properties of product obtained. Spray 
congealing enables the control of cooling rate
98
, which may be employed to 
produce solid dispersions in the form of granules and microparticles. Spray 
congealing has been reported to be a useful technique to produce granules with 







A2.1. Principle of spray congealing 
 
In spray congealing, the matrix material is first heated up to a 
temperature of about 10 to 20°C above its melting point. The drug and/or 
additive(s) is/are added into the molten matrix material with constant stirring 
to form a homogeneous mixture. The resultant mixture may be a clear solution 
or a suspension where the drug and/or additives are dispersed as discrete 
particles in the molten liquid. The mixture is then conveyed by a peristaltic or 
piston pump to the spray nozzle where it is discharged as fine spray droplets 
into the cooling chamber. The sprayed droplets are subsequently cooled to 
temperatures below the melting point of the matrix material by the cooling air 
flow in the chamber and congeal to form solid particles (< 1 mm in diameter). 
The spray-congealed particles are collected by a vessel below the chamber and 
they are designated as the useful fraction. Very fine particles (generally < 10 
µm) are entrained from the chamber with the exhaust air and collected in a 
separate vessel in the cyclone. The entire process is rapid, with the residence 
time of the spray droplets a mere few seconds. A schematic diagram of the 
entire set-up of a laboratory scale spray congealer is shown in Figure A1. 
 
A2.2. Factors influencing spray congealing 
 
In spray congealing, optimization of process parameters is crucial in 
order to produce good quality spray-congealed products. Specific product 
attributes, such as sprayed particle morphology, size and size span, drug 
entrapment efficiency and drug release behaviour are highly dependent on 
process parameters such as atomization air temperature, atomization air 
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pressure, nozzle tip size and feed delivery rate. There are different types of 
spray nozzles, such as the pressure, two-fluid, rotary and ultrasonic nozzles. 
They utilize different principles to effect spray dispersion. The choice of spray 




Figure A1. A schematic diagram of a laboratory scale spray congealer 
(counter-current set up). 
 
A2.2.1. Equipment and process variables 
 
Atomization of the melt is achieved via the use of air flow, ultrasound or 
mechanical means. Briefly, two-fluid nozzle utilizes a high velocity heated gas 
flow concentric to the melt flow to disperse the molten feed stream into 
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droplets and propels them into the chamber for subsequent 
congealing
20,67,79,83,101
. Pressure atomizers simply consist of the melt being 
forced through a narrow orifice under high applied pressure to achieve 
atomization
67,102
. Rotary atomizers involve channelling of the melt onto a 
cylindrical wheel which rotates at high speed and disperses droplets through 
impact shear forces centrifugally
19,102,103
. Ultrasonic atomizers employ high 





After atomization, the discrete molten droplets suspended in the chamber 
undergo solidification or congeal upon contact with cooling air. Cooling air is 
supplied in one of two possible setups. It flows alongside the droplets in the 
co-current setup, while in the opposite direction, for the counter-current setup. 
The counter-current setup provides an advantage in that it increases the 
residence time of droplets in the chamber, thus allowing more complete 
solidification and potentially increasing the useful yield. The cooling air 
supplied is typically generated through conventional cooling systems or 
through the use of liquid nitrogen. Temperatures used for cooling can range 
from subzero temperatures to ambient room temperature, provided that the 
temperature difference is sufficient to allow for complete solidification. 
 
The choice of atomizer necessarily dictates the shape of the chamber, 
with the prime consideration that the sprayed droplets are allowed to 
sufficiently cool and solidify before contact with any surface. Pressure and 
two-fluid atomizers disperse droplets in a relatively narrow cone, and as a 
result, their corresponding chambers tend to be tall and narrow. If the cooling 
19 
 
air flows in a co-current manner, the atomizer and cooling air inlet would be 
situated at the top, whereas in the counter-current setup, the atomizer would be 
situated at the bottom, directing the droplets upwards towards the downward-
flowing cooling air. Rotary atomizers on the other hand generate droplets in a 





A final point of note pertains to the use of spray drying equipment for 
spray congealing. Due to the similarities in the mechanical principles of both 
techniques, it is possible to carry out spray congealing in a spray drying 





A2.2.1.1. Pressure atomizers 
 
Pressure atomizers utilize high pressure exerted on the molten feed when 
delivered through an orifice to form an expanding narrow conical liquid stream 
that breaks up into droplets, which congeal to produce microparticles. The 
droplet sizes are influenced by the physical properties of the feed (liquid) such 
as surface tension, density and viscosity, as well as frictional forces at the 
liquid-air interfaces
102
. It was found that increase in feed temperature and 
atomization pressure resulted in small microparticle size and higher product 
yield
71
. Additionally, feed temperature appeared to exert a greater influence 
than atomization pressure on microparticle size, but their effects on product 
yield were comparable. It was postulated that the lower viscosity of the feed at 
higher temperature facilitated breakup and dispersion of the liquid stream, thus 
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producing smaller particles. Lower melt viscosity also reduced the spray angle, 
and resulted in fewer particles adhering to the sides of the chamber before 
sufficiently congealing. Increase in atomization pressure imparted greater 
kinetic energy to the molten feed and produced smaller droplets. Nevertheless, 
increasing feed temperature and atomization pressure beyond optimal values 
could lead to loss of product yield as the increasingly light and buoyant 
droplets were more easily lost to the chamber wall. 
 
A2.2.1.2. Two-fluid atomizers 
 
Two-fluid atomizers utilize a high velocity gas flow adjacent to and 
encircling the molten feed flow. As the molten feed exits the nozzle orifice, the 
concentric high velocity gas flow generates strong shear forces on the liquid 
stream, thereby breaking it up into droplets
111
. The gas flow nozzle is often 
slightly angled to promote a spiral exiting gas flow that focuses on the liquid 
stream and narrows the spray angle. Nebulization of the molten feed is 
influenced by surface tension, density and viscosity of the feed, akin to 
pressure atomization. Higher viscosity of the molten feed was found to 
produce larger particles
79,112
, due to the greater ability of the liquid to resist 
shearing. Properties of the nebulizing gas, such as velocity and density, also 
play significant roles in influencing particle size and yields. Common gases 
used are air and nitrogen
102
. Greater nebulizing gas velocity and pressure were 
found to produce smaller particles as a consequence of the higher kinetic 
energy in the system, which resulted in greater atomization efficiency
20
. 
Additionally, lower useful yields may be obtained as more particles were lost 
to the chamber wall. Moreover, the particles produced were less spherical as 
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the surface tension could not overcome the kinetic energy to allow the droplet 
to assume a spherical shape
113
. Nozzle size for the molten feed was also found 
to be important
114
. With all other factors held constant, greater production rates 
and larger microparticle sizes were achieved with larger nozzle size. This was 
attributed to the lower backpressure with larger nozzle size, enabling higher 
feed rates which decreased atomization efficiency. Consequently, larger 
droplets and thus, larger microparticles were produced. These larger particles 
also possessed higher bulk density and better flowability. Drug dissolution 





A2.2.1.3. Rotary atomizers 
 
Rotary atomizers, also known as rotary centrifugal wheel atomizers, 
disperse the liquid feed by centrifugal forces conferred by a rapidly spinning 
wheel, disc or cup. The feed is introduced down the central axis of the 
atomizer via a feed tube, where the discharged feed spreads over the rotating 
surface as a thin film and is dispersed as droplets upon attaining sufficient 
energy
102
. Atomization efficiency is dependent on the rotational speed, feed 
rate, feed properties and design of the atomizer. In one study, stearic acid-ethyl 
cellulose microparticle mean size was found to increase directly with feed rate 
but inversely with rotational speed
19
. Increasing feed rate reduces atomization 
efficiency and gives rise to larger microparticles, while increasing rotational 
speed conveys a larger amount of kinetic energy to the feed and consequently, 
decreasing the product‘s particle size115. Rotational speed was deemed to have 
greater influence than feed rate on particle size. 
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A2.2.1.4. Ultrasonic atomizers 
 
Ultrasonic atomizers subject the molten feed to high frequency 
vibrations in order to break up the liquid stream into droplets. This atomizer 
type is particularly suitable for highly viscous feeds as well as abrasive and 
corrosive materials which are not suitable for other atomizer types
102
. 
Microparticle size was highly dependent on the frequency and amplitude of the 
ultrasound waves, which determine the atomization energy
104
. Limited studies 
also indicate that viscosity is not a major variable in influencing particle size. 
To date, investigations on the parameters influencing ultrasonic atomization 
are few and far between. 
 
A2.2.2. Formulation variables 
 
In spray congealing, a typical formulation consists of the matrix material, 
drug and additive. By utilizing matrix materials of different nature, specific 
aims such as taste masking of bitter medicaments, protection of moisture-
sensitive drugs as well as modified release of drug can be attained. Additives 
commonly used to modify microparticle characteristics include surfactants and 
hydrophilic polymers.  
 
A2.2.2.1.  Matrix materials 
 
The material that can be selected must satisfy a set of criteria in order to 
be amenable for spray congealing. Firstly, it must exist as a solid at room 
temperature and a liquid at a workable elevated temperature
21
.  The material 
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should also be thermo-stable such that it does not decompose or react upon 
heating, which is an essential part of the molten feed preparation step. The 
materials should ideally have melting points between 50 to 80°C and materials 
with melting points below 50°C may not be solidified sufficiently for 
collection while materials with melting points above 80°C necessitate high 
operating temperatures for feed delivery and feed atomization which can be 
detrimental to drug stability. 
 
The properties of the matrix material used would usually dictate those of 
the resultant microparticles, with some deviations depending on the additives 
and drug present
21
. Matrix materials can be classified into two main types – 
hydrophilic and lipophilic. The former is frequently used to enhance the 
release of poorly water-soluble drugs. As examples, the hydrophilic 
polyethylene glycol was used for indomethacin
92
, while stearoyl macrogol 









. Conversely, lipophilic matrix 
materials are excellent for retarding drug release. Hydrogenated soybean oil 
was used for sustained release of aspirin
101
 and the mixture of microcrystalline 
wax and stearyl alcohol was used to achieve the same effect for verapamil
85
. In 





Judicious choice of matrix materials allows the formulator to modulate 
the release characteristics of an encapsulated drug. The inherent 
physicochemical disadvantages of certain drugs such as those with poor water 
solubility can be overcome by the use of appropriate matrix materials. 
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Furthermore, matrix materials are able to confer additional benefits to the final 
product such as taste-masking, as a mixture of glyceryl monostearate and 




A2.2.2.2. Encapsulated active ingredients 
 
Spray congealing is commonly employed to encapsulate drugs for a 
variety of purposes as discussed previously. Besides conventional small 
molecule drugs, spray congealing can be utilized as a microencapsulation 
technique for other substances such as biologics, herbal extracts, vitamins and 
flavourings. The materials to be encapsulated may be dissolved or dispersed in 
the molten matrix. Maschke et al. reported the encapsulation of insulin in 
glyceryl tripalmitate lipid matrix and the resultant SLMs were able to sustain 
the release of bioactive insulin for up to 28 days
71
. In another study, bovine 
serum albumin was successfully encapsulated using glyceryl palmitostearate, 
tristearin and trimyristin lipid matrix without losing its structural integrity
119
. 
Passerini et al. demonstrated the efficient microencapsulation of Silybum 
marianum herbal extract using Gelucire 50/13, with the resultant 
microparticles exhibiting a favourable release profile and high oral 
bioavailability in rats
120
. Gamboa et al. observed that the microencapsulation 
efficiency of vitamin E in hydrogenated soybean oil was more than 90 % and 
both vitamin E and the lipid matrix were stable and did not undergo any 
polymorphic changes
70
. Sillick et al. used erythritol, an anhydrous sugar 
alcohol, to encapsulate liquid active ingredients such as limonene, nicotine, 






In general, release of the encapsulated substances is dependent on their 
respective solubility in water as well as the lipophilicity of the matrix 
used
85,104
. Polymorphism of encapsulated substances can also influence their 
release, with the amorphous form exhibiting faster release than the crystalline 
form
83
. Besides its water solubility, solubility of the encapsulated substance in 
the matrix itself can also impact drug release. For example, 5 and 10 %, w/w 
loading of praziquantel in a hydrophilic stearyl macrogol glyceride matrix 
showed greater drug release rates compared to the 20 and 30, % w/w drug 
loads. Praziquantel is poorly water-soluble. At low drug loads, praziquantel 
was fully dissolved in the hydrophilic matrix, which in turn facilitated its 
release as the matrix interacted with water. At higher drug loads, solubility of 
praziquantel in the matrix was exceeded and excess drug existed as discrete 
particles within the matrix and they were slow to dissolve
86
. Hence, the 
solubility of the drug in the matrix should be considered when determining the 




Additives can influence the properties of the resultant microparticles in 
several ways. Firstly, addition of additives can lead to changes in particle size, 
usually becoming larger. Amphiphilic surfactants, such as poloxamer 188, 
polyoxyethylene sorbitan monoleate and sorbitan monooleate were found to 
increase the size of microparticles produced when used with low melting 
triglyceride, Witepsol H15
122
. Similar observations were made for the addition 
of the hydrophobic polymer, ethyl cellulose, to stearic acid
19
 and silica gel 





Additives are also able to modify drug release properties. The addition of 
a surfactant, sorbitan monooleate, in concentrations of 1 and 4 %, w/w to 
various waxes hastened the release of sulphaethidole under acidic 
environment
114
. Conversely, drug release was impeded at the surfactant 
concentration of 10 %, w/w. The explanation given was that two factors were 
at play. At a low concentration, the surfactant aided the wetting of the drug-
loaded wax particles, thus facilitating the dissolution of the encapsulated drug. 
At a high concentration, the surfactant increased the tackiness of the particles, 
leading to clumping which significantly reduced the effective surface area 
exposed to the dissolution medium. The flow properties of the particles were 
also impaired by the addition of sorbitan monooleate at a high concentration. 
In other studies, addition of ethyl cellulose enhanced drug release from 
carnauba wax and other synthetic waxes. It is noteworthy that an additive may 
retard drug release as a consequence of increased particle size. In the above 
mentioned study where Aerosil was incorporated into cetostearyl alcohol or 
carnauba wax, the larger resultant particles had contributed to the slower drug 
release observed
91
. In a separate study, hydrophilic poloxamer was found to 
enhance econazole nitrate release
88
. Although it is apparent that surfactants and 
hydrophilic additives can often enhance drug release, the converse may also be 
the result and an additive included in a lipid formulation may have different 
effects on different matrix materials with respect to drug release. Confounding 
effects of additives, such as increase in tackiness and/or change to particle size, 
should be duly considered. 
 
Lastly, additives can impact polymorphic transformation of the matrix, 
especially if a lipid matrix when heat has to be employed. Lecithin, for 
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example, was found to impede the conversion of cetostearyl alcohol from its 
metastable form to its stable crystalline form
123
. The effect of polymorphic 
changes will be discussed in greater detail in section A4.3.  
 
A2.3. Advantages and disadvantages of spray congealing 
 
Spray congealing is a rapid, single-step operation suitable for batch or 
continuous production and can be easily scaled up to manufacture large 
quantities of a product
79,86,87,124
. Microparticles produced by spray congealing 
are generally non-aggregated, dense, spherical and highly flowable
20,120
. 
Compared to spray-dried particles, the surfaces of spray-congealed particles 
are relatively smooth. There are no internal evaporative effects which may 
cause surface protuberances as solvents are not used in formulations used to 
prepare spray-congealed particles
65,95,114
. The properties of spray-congealed 
particles which also include being denser and free flowing make them suitable 




Another advantage of spray congealing is that the particles can be 
prepared without including water and this makes the process attractive for 
processing moisture-sensitive drugs. In addition, the avoidance of organic 
solvents makes the manufacturing method an environmentally friendly process 
and there are no associated risks with residual organic solvents in the products. 







Spray congealing is a versatile technique as both hydrophilic and 
hydrophobic low melting point matrix materials can be used
72
. Selection of 
suitable matrix materials allows modification of dissolution behaviour, taste 
masking of drug and enhancement of drug stability as mentioned previously.  
Recently, this technology was employed to produce a delivery system with 
improved stability for insulin, a peptide drug
71
. It has also been used for the 
production of SLMs for parenteral administration
58
 and topical application
33
, 




Microparticles prepared by spray congealing generally have high 
encapsulation efficiencies of greater than 90 %
79,119,122,126
. This is in contrast to 
other techniques, such as the emulsification method
122
, where high 
encapsulation efficiency is difficult to attain. With high encapsulation 
efficiency, little drug lost will be encountered during processing, leading to 
significant cost savings especially for expensive drugs.  
 
One of the main drawbacks of spray congealing is that the rapid cooling 
process may induce polymorphic changes to the drugs and other components 
of the microparticles
72,87
. The transformation from the original stable 
crystalline form to a less stable polymorph or amorphous form
71,72,74
 can be 
affected by the composition of the lipid matrix material or the cooling rate
58
. 
These polymorphic changes may affect the physical stability and/or dissolution 
profile of the microparticles
20
. Another disadvantage of spray congealing is 
that the drug must be stable at the temperature required to melt the matrix 
material. This may limit the choice of suitable matrix materials for 
thermolabile drugs such as acyclovir, erythromycin and isotretinoin. 
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Furthermore, not all materials have melting points that are suitable for spray 
congealing. The process of spray congealing is also not favourable for highly 
viscous molten mixtures as they will not disperse well and may cause clogging 
of the feed tubes or atomizer, resulting in premature termination of the 
process
20
. Certain drugs increase the viscosity of the molten feed and it has 
been reported that it is generally difficult to achieve a drug loading exceeding 




A3. Importance of viscosity in spray congealing 
 
Viscosity is defined as the resistance of a liquid to flow. There are 
various types of viscometers, such as capillary viscometers, falling sphere 
viscometers and rotational viscometers, employed for the determination of 
viscosity
127
. In the determination of viscosity using the capillary viscometers, 
the time required for the test liquid to flow by gravity through the vertical 
capillary tube from one mark to another is measured and compared with the 
time required for a liquid of known viscosity. For the falling sphere 
viscometers, the time taken by a glass or steel ball to fall vertically from one 
point to another in the test liquid is measured. Both the capillary viscometers 
and falling sphere viscometers are single point viscometers in which shear rate 
of the test liquid cannot be varied. Hence, these viscometers are not suitable 
for determining the viscosity of non-Newtonian liquids, whose viscosity is 
affected by shear rate. For the rotational viscometer, the viscosity is 
determined from the viscous drag exerted on a body when it is rotated in the 
test liquid. The shear rate of the test liquid can be varied in this type of 
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viscometers, making it suitable for determining the viscosity of both 
Newtonian and non-Newtonian liquids. 
 
Historically, knowledge of viscosity was used mainly as a means of 
characterizing and classifying fluids and semi-solids
127
. However, in recent 
years, viscosity is increasingly recognized as a fundamental physicochemical 
property affecting many pharmaceutical processes, particularly melt processes
9
 
such as melt granulation
128-131
 and spray congealing
19,79,91,94,96
. In spray 
congealing, viscosity of the molten feed is affected by the atomization air 
temperature, physical properties of the meltable material as well as the amount 
of drug or additive added. Viscosity of the molten melt is one of the most 
important factors in determining the feasibility of the spray congealing process 
as well as the resultant product attributes. Specifically, melt viscosity will 
affect molten droplet size during the atomization process, which will 




A3.1. Limitation of viscosity as a parameter 
 
Despite the importance of melt viscosity in spray congealing, few studies 
have investigated its correlation with the final product attributes. Of these 
limited studies, conflicting findings were reported. In Passerini et al.‘s work 
using Gelucire 50/13 and carbamazepine
94
, it was reported that an increased 
melt viscosity (due to increased drug loading) produced smaller spray-
congealed microparticles. Albertini et al.‘s work using Precirol AT05 (mixture 
of mono-, di- and triglycerides of stearic and palmitic acid) as matrix material 





. However, in another reported work by Albertini et al., 
using cetostearyl alcohol and carnauba wax as matrix materials, higher melt 
viscosity was reported to result in bigger spray-congealed microparticles
79
. 
The effects of decreasing melt viscosity have been reported as inconclusive in 
some other studies. In the study of Maschke et al. employing glyceryl 
tripalmitate as matrix material and insulin as the additive, it was concluded that 
a lower melt viscosity resulted in smaller particles
96
 whereas Scott et al.‘s 
report on stearic acid as matrix material and ethyl celluose as viscosity-




The seemingly contradictory observations by these different research 
groups could be explained by the presence of possible confounders in the 
experiments. For example, introduction of additives such as drugs or various 
viscosity-modifying additives into the matrices could have caused unforeseen 
interactions that have larger impact on particle size than the melt viscosity. For 
instance, the use of different types of atomizing nozzles and/or high shearing 
forces during atomization could have caused the effects of viscosity to be 
undermined. Overall, there are still rather few studies that compare pure matrix 
materials of different viscosities and their resultant spray-congealed particle 
sizes. Such studies would ideally provide valuable insights on the actual effect 
of viscosity with fewer confounding variables. 
 
In general, the viscosity of a melt decreases with increased 
temperature
132
. This is often attributed to the molecules attaining higher kinetic 
energies and alongside a reduction of intermolecular cohesive forces 





. Although this relationship is seemingly obvious, research in 
this area has remained relatively limited since the days of Reynold and 
Arrhenius, when viscosity was proposed to be related to temperature by an 
exponential relationship
99
. Reynold‘s equation only applies within a limited 
temperature range which restricts its application in pharmaceutical processes 
when elevated temperatures are employed.                                              
 
This gap in knowledge relating to the exact viscosity-temperature 
relationship of materials makes fair comparison between studies employing the 
same material at different temperatures not possible and this somewhat impairs 
the integration of data from multiple sources. As the exact relationship 
between viscosity and temperature is not clearly established for most materials, 
citing the viscosity at a particular temperature may lead to some misguided 
assumptions about the characteristics of the materials. This could contribute to 
conflicting observations pertaining to the effects of viscosity on the size of 
spray-congealed particles. Furthermore, choosing a suitable temperature for 
the purpose of comparing the viscosities of different molten materials can be 
challenging when they intrinsically have markedly different melting points. 
Hence, studies investigating the effect of viscosities of molten liquids on 
processes needed to be carried out at many different temperatures, generating 
some degree of complexity in experiment design and analysis of acquired data. 
 
A3.2. Viscosity-temperature models 
 
Currently, there are not many proposed viscosity-temperature 
relationship models for molten liquids. Established models mainly originated 
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from the food industry and are widely used to describe the viscosity-
temperature relationships of food systems such as edible polymers, vegetable 
oils, honey and sugar solutions
136-140
. However, these models are found to be 
facing various restrictions and are often semi-empirical or empirical in 
nature
141
. Firstly, they are often derived from studies performed over varied 
temperature ranges, and it is inappropriate to apply them beyond the 
designated temperature ranges for which they were developed
132
. As an 
example, the Williams-Landel-Ferry (WLF) model is only applicable to 
amorphous, linear flexible homopolymers with distinct glass transition 
points
142
 and is therefore not suitable for lipid-based excipients. Other 
examples include the Andrade‘s and Power law models. The former applies to 





In conclusion, the literature findings suggested the need for an in-depth 
investigation into the viscosity-temperature relationships of molten materials. 
Within the scope of the present work, this investigation was largely limited to 
lipid-based excipients used in spray congealing. To expand the scope and 
applicability of the observations made, a wider range of lipoidal chemical 
classes – fatty alcohol, fatty acid, fatty ester, mono-, di- and tri-glycerides of 
lipids were curated and investigated. 
 





Spray congealing employs cold air to cause rapid congealing of the 
dispersed molten feed droplets into solid microparticles. This rapid 
solidification process leaves little time for molten lipids to reorganize and 
revert back to their most stable crystal form (polymorph), potentially giving 
rise to different polymorphs compared to their pre-processed state.  
 
A4.1. Solid state characteristics of lipid-based excipients 
 
It is now widely accepted that there are 3 major crystal forms of lipid-
based excipients; α-form (hexagonal subcell packing), β‘-form (orthorhombic 
subcell packing) or β-form (triclinic subcell packing)144. These 3 crystal forms 
are also known as polymorphs. Whether a lipid exists in the α, β‘ or β 
polymorphic form is largely dependent on a few factors, notably the 
manufacturing or storage conditions
1
. The various crystal forms of lipids have 
different physical properties. The α-polymorph, being the least stable, has the 
lowest melting point whereas the most stable β- polymorph has the highest 
melting point. In terms of density, the α-polymorph is the least dense with 
relatively loose molecular packing while the β-polymorph has the highest 
density with compact, organized molecular packing. The β‘-polymorph has 
intermediate stability, melting point and density
145-148
. Figure A2 shows a 
schematic diagram of the different polymorphic forms of lipids. In the α-
polymorph, molecules (represented by rectangles) are oriented randomly to 
each other and the 3 representative crystal planes. For the β‘- and β- 
polymorphs, there is greater order of their molecules to each other and to the 
crystal planes. This gives rise to the hexagonal, orthorhombic and triclinic 
subcell packing respectively. 
35 
 
From Figure A2, it can be seen that the alkyl chain axes of the α-form 
are in a random order, with the crystal assuming a hexagonal shape. This type 
of molecular structural arrangement is said to approximate best to the liquid 
phase
145. For the β‘-polymorph which has intermediate properties, alternate 
rows of the chain axes are arrange in opposite directions and the resultant β‘-
polymorph has an orthorhombic shape. For the β-polymorph, the rows are 
uniformly arranged in the same direction and presenting a triclinic shape. X-
ray diffraction (XRD) and thermal analyses are techniques frequently 
employed to determine the polymorphic form of the lipids. The former 
technique enables the elucidation of the short and long spacings of the unit cell 
of lipid crystals and definition of the unit cell is critical for distinguishing the 
various polymorphs. The latter technique provides information in the form of 
melting points and melting enthalpies of particular lipids to support 




Figure A2. Structures of α-, β‘- and β- polymorphs of lipids. 
 
A4.2. Factors affecting solid state characteristics of lipid-based excipients 
 
Polymorphism refers to the existence of a material in more than one 
crystal form due to variations in its molecular packing. This phenomenon is 
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common in lipids, especially complex lipids with long chain lengths
144
. As 
mentioned previously, lipids can exist in 3 polymorphic forms, i.e. α, β‘ and β 
polymorphs. When a lipid is melted and rapidly cooled, it often re-crystallizes 
into the lower melting unstable (α-polymorph) or metastable (β‘-polymorph) 
forms first. These forms will gradually revert to the more thermodynamically 
stable β-form during storage146. This process is monotropic, always proceeding 
from the less stable to the most stable form with the lowest free energy, as in 




There are a few critical factors which can determine the polymorphic 
form attained after processing. Manufacturing and storage temperatures were 
found to be predominant factors in various studies. Using twin-screw 
extrusion, Windbergs et al. made lipid extrudates from tristearin at two 
different temperatures. The products extruded at a lower temperature existed as 
mixtures of α- and β-polymorphs, whereas a higher processing temperature 
produced only the stable β-polymorph151. However, in another study, a higher 
processing temperature resulted in glyceryl trimyristate crystallizing in its 
unstable α-polymorph152. The rate and extent of cooling employed during 
processing can also impact the resultant polymorphic form. Brubach et al., 
Pivette et al. and Sutananta et al. had all collectively demonstrated that a slow 
cooling rate promoted the formation of unstable polymorphs with glycerides 
whereas rapid cooling favoured the formation of stable polymorph
153-155
. It was 
rationalized that rapid cooling facilitated quick rearrangement of the lipid 
crystals into its most stable conformation. Eldem et al. stored spray-dried 
glyceryl tristearate micropellets at different temperatures for 6 months. At 
higher storage temperatures, conversion of the unstable α-polymorph to the 
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stable β polymorph was accelerated. Thus, it was postulated that higher storage 
temperatures facilitated the rearrangement of the lipid crystal structure, to 




Additives are frequently incorporated into lipid matrices to modulate 
product characteristics, particularly for the drug release behaviour. Additives 
such as hydrophilic polymers and surfactants were found to influence lipid 
polymorphism. Some additives have been used to preserve the metastable form 
of the lipid, preventing reorganization into the stable form after processing.  
The metastable state of matrix is sometimes desirable as it can be associated 
with enhanced drug release due to its loose crystal packing, and this can be 
beneficial for drugs with poor wettability and solubility. Eldem et al. reported 
that the addition of lecithin conferred a stabilizing effect on the metastable 
polymorph of tristearin, such that tristearin conversion to the stable 
polymorphic form was significantly delayed. The effect of lecithin on glyceryl 
behenate was even more pronounced as it was able to permanently preserve 
glyceryl behenate‘s metastable state123. Hydrophilic polymers, which are 
commonly added to solid dosage forms for the purpose of modifying drug 
release, can also affect lipid polymorphism. The addition of poloxamer to 
glyceryl palmitostearate was found to stabilize the lipid from further 
polymorphic changes
38
. This could be explained by the presence of long 
polymeric chains interspersing between the shorter and loosely packed alkyl 
chains of the lipids, thereby impeding molecular movement and reorganization 
of the lipid molecules. However, additives have also been shown to be able to 
hasten the reorganization of the lipid into its most stable form immediately 
after the production process. Herrmann et al. added medium chain triglycerides 
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to tristearin and observed an instantaneous crystallization of the latter in its 
stable β-polymorph156. The same phenomenon was observed in the preparation 
of suppositories using lipid base Witepsol H-15, where the addition of 
lipophilic liquids such as isopropyl myristate and lauryl alcohol accelerated the 




Manufacturing temperature, storage temperature and additives are major 
factors affecting the polymorphic form of the final lipid product. Other minor 
factors include the presence and nature of solvents, as well as the type and 




A4.3. Consequences of solid state modifications in spray congealing 
 
 In spray congealing, drastic temperature changes due to rapid cooling 
and high shear forces encountered in the process are known to induce 
polymorphic transitions in the lipid matrix and/or encapsulated drug
87,96
. 
Transition of drug from one polymorph to another or to an amorphous state 
can have profound effects on drug stability and solubility, the latter being more 
critical for poorly water-soluble drugs. Drugs in the amorphous state may be 
less stable, and any subsequent reversion to the more stable polymorph during 
storage can lead to changes in drug release properties
83,159
. For the lipid matrix, 
studies have shown that spray congealing of complex lipids, such as 
glycerides, tend to cause polymorphic changes in the resultant SLMs, with the 
worst case scenario being the eventual expulsion of the drug from the lipid 
matrix during storage
70,160,161
. Thus, it is important to ascertain the 
susceptibility of lipids used to polymorphic transitions as well as the time 
39 
 
frame required for its conversion to its stable form during the preformulation 
stage. Such knowledge on the solid state characteristics of lipids should be 
integrated into formulation design and development for processes involving 
heating and/or cooling of lipid-based excipients.  
 
A5. Drug release from lipid matrices 
 
Swellable or erodible cellulose-based polymeric matrix materials were 
frequently used to achieve modified release of drug
162,163
. Compared to 
polymeric systems, drug release from lipid-based dosage forms is relatively 
less understood. The hydrophobic, water-insoluble nature of lipids allows them 
to act as a barrier to restrict liquid penetration, which delays drug dissolution 
and diffusion out of the dosage form. A thorough understanding of the 
underlying drug release mechanisms as well as factors influencing drug release 
from lipid dosage forms can facilitate formulation development and aid in 
modifying drug release behaviour of lipid-based dosage forms. 
 
A5.1. Factors affecting drug release from lipid matrices 
 
Drug release from lipid dosage forms can be influenced by several 
factors. For lipid microparticles, the molecular weight of lipid, drug content, 
particle size, crystallinity of the lipid and drug, and presence of other 
excipients can affect drug release
164
. Higher molecular weight lipids are 
generally more lipophilic and can retard drug release to a greater extent. 
Higher drug content results in a potentially higher diffusion gradient and 
hence, enable a more rapid drug release. Furthermore, smaller particles have a 
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larger surface area to volume ratio and therefore, become more ‗exposed‘ to 
the surrounding fluid, leading to a faster rate of drug release. The solid state 
characteristics of the entrapped drug can also impact the drug release 
behaviour. Lower drug crystallinity generally results in a higher drug release 
rate, as drug molecules dissociate less easily from a compact organized crystal 
lattice than an amorphous state. The presence of additives, especially 
hydrophilic polymers or surfactants, can improve wettability and thereby 
accelerate drug release. All the aforementioned factors influence drug release 
from SLMs to varying degrees. It was reported that the most important factor 
impacting drug release is the physical properties and chemical composition of 
the lipophilic matrix itself
76,77
. Drug release rate of more lipophilic matrices is 
generally lower. 
 
A5.2. Drug release adjustments 
 
Alterations to the drug release behaviour of lipid matrix dosage forms 
mainly involve modifying the lipid‘s water permeability, which can govern the 
dissolution and diffusion of drug out of the matrix. The permeability of the 
lipid matrix to water is influenced by the production method, the 





Manufacturing processes, such as spray congealing, moulding and blend-
melt methods, utilizing water-insoluble lipids, result in the production of 
water-resistant systems, where the lipid can form a ‗barrier‘ around drug 
particles to hinder wetting or even the entry of water into the matrix. Such 
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systems usually exhibit delayed release of a freely water soluble drug. On the 
other hand, lipid matrix dosage forms produced by direct compaction of the 
powdered excipients into tablets tend to exhibit relatively faster drug release. 
In the latter case, without melting, the drug may fail to be adequately encased 
by the lipid component and when wetted, water will have easy access to the 
unshielded drug surfaces for dissolution. The influence of the physicochemical 
properties of the lipid matrix on the drug release behaviour of lipid matrix 
dosage forms was previously discussed. Drug release rates from bulkier and 
more lipophilic matrices are generally lower. 
 
One of the approaches to modulate drug release from lipid matrices is by 
the incorporation of additives. Drug release can be hastened with the addition 
of highly wettable, water-soluble additives. Upon contact with the dissolution 
medium, these additives rapidly dissolve to create multiple pathways and 
aqueous channels, facilitating the entry of the medium into the lipid matrix 
structure. Consequently, the medium was able to access and dissolve the 
entrapped drug, with the dissolved drug exiting the matrix by diffusion through 
the channels. This formulation approach has been widely adopted. For 
instance, lactose was dispersed as a hydrophilic additive in hydrogenated 
cottonseed oil to modulate theophylline release from the resultant spray-
congealed SLMs
77
. HPMC, a swellable hydrophilic excipient, has also been 
used to modify drug release from glyceryl palmitostearate lipid matrix
39
. The 
hydrophilicity of microcrystalline cellulose associated with water conduit by 
capillary channels was also found to enhance lipid matrix tablet disintegration 
and drug release
42,167
. Modification of drug release from lipid casts, moulds or 
coated dosage forms may also be carried out by adopting the same concept as 
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previously discussed by the inclusion of a pore former. Pore formers are 
essentially channel forming agents and are typically hydrophilic polymers, 
surfactants or other highly water-soluble excipients such as lactose and 
mannitol. When a lipid matrix containing pore forming additive comes into 
contact with the dissolution medium, the pore former will either form the 
aqueous conduit or dissolve and leach out of the lipid matrix, creating aqueous 
pores for drug release. Jannin et al. investigated the addition of poloxamers to 
glyceryl distearate lipid mould and found that the addition of poloxamer had a 
concentration-dependent effect in accelerating drug release
38
. The addition of 
hydroxypropyl-beta-cyclodextrin and polyethylene glycol as pore formers in 
tristearin matrix also yielded similar results
168,169
.  Non-ionic surfactants such 
as sorbitan monooleate were also found to be good pore formers when added 





A5.3. Drug release mechanisms of lipid matrices  
 
Drug release from lipid matrices can be a complex system governed by 
different mechanisms that may occur singly or concurrently
171
. Precise control 
of the rate and extent of drug release from lipid matrix systems is difficult to 
attain. Three drug release mechanisms have commonly been described
89,171
: (a) 
initial penetration of fluid into the system, dissolution of the drug particles and 
diffusion of the drug molecules through the fluid-filled pores and out of the 
matrix, (b) surface erosion of the lipid matrix and gradually releasing the drug 




Most lipid matrix dosage forms were observed to remain intact at the end 
of dissolution runs with little evidence of gelation or surface erosion, 
suggesting that Fickian diffusion process accounts for a bulk of drug 
released
172,173
. Therefore, drug release often occurs with the penetration of the 
medium into the lipid matrix, followed by dissolution of the drug within and 
diffusion of the dissolved drug out through the fluid-filled pores. Since 
aqueous diffusion into the matrix and dissolved drug out, the critical 
parameters governing drug release would clearly be the wettability or 
hydrophilicity of the matrix and drug. Kreye et al. investigated the water 
uptake from a variety of lipid-encapsulated drugs of different water solubility 
and found that the rate of water uptake correlated well with the eventual rate of 
drug release
174
. Highly wettable lipid matrix invariably accelerated water entry 
by diffusion (higher rate of water uptake) and faster diffusion of the dissolved 
drug out of the lipid matrix.  The study further explored the impact of the 
applied compression force on lipid matrix dosage form on the drug release 
rate. It was found that a higher compression force produced denser compacts 
with lower porosity, thus hindering the permeation of water and resulting in a 
lower rate of drug release.   
 
Since the rate of diffusion within the lipid matrix is the main determinant 
of drug release rate, the dimensional attributes of the final dosage form should 
be given due consideration. Three separate studies found that increasing size of 
lipid implants resulted in decreased drug release rates
175-177
.  It was postulated 
that larger dimensions gave rise to longer diffusional path lengths, resulting in 
the dissolution medium requiring a longer path length to reach the embedded 
drug. This increased barrier to water diffusion will in turn slow drug 
44 
 
dissolution, pore creation and the diffusion of drug solution out of the lipid 
matrix. Compared to conventional tablets, mini-tablets (diameter ≤ 2 mm) are 
much smaller in size. In addition to their significantly larger surface area to 
volume ratio, mini-tablets also have shorter diffusion path lengths. Thus, mini-
tablets show more rapid water penetration, drug diffusion and drug release
178
. 
However, the importance of dosage form dimensions may be diminished when 
the drug involved is highly water-soluble. 
 
Besides diffusion being the key factor accounting for drug release from 
most lipid matrix dosage forms, drug release can also occur by gradual surface 
erosion of the lipid. This is especially true for simple lipids such as stearic acid 
and cetostearyl alcohol, where prolonged exposure to the dissolution medium 
causes slow erosion of the lipid surface
179,180
. Coupled with the diffusion 
mechanism occurring concurrently, this can potentially lead to an enhanced 
drug release rate. 
 
A5.4. Comparison of drug release between solid dispersion system and solid 
solution system 
 
In the preparation of lipid matrix dosage forms using melt methods such 
as moulding, melt and mix method and spray congealing, drug(s) are dissolved 
or suspended in the molten lipid. Upon solidification of the lipid, the 
miscibility of the drug with the solid lipid matrix can impact the drug release 
behaviour. Whether the drug exists as a solution or dispersion in the solid lipid 
matrix can be differentiated based on the molecular state of the drug. A solid 
solution is formed if the drug is molecularly dissolved and forms a one-phase 
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system with the solid matrix. On the other hand, a solid dispersion is formed if 
the drug is dispersed as discrete crystalline or amorphous particles and forms a 
two-phase system with the solid matrix. Theoretically, the drug can be 
miscible with the matrix over the whole composition range but in reality, most 




Whether the drug exists as a dispersion or solution within the solid 
matrix can have significant ramifications on the drug release profiles. Solid 
solutions have been reported to sustain drug release with a low burst effect
183
 
as drug release takes place by slow diffusion of the drug from deep within the 
matrix or by gradual erosion of the insoluble and hydrophobic lipid matrix. 
Additionally, molecularly dispersed drugs in solid solutions have been 
described before to have limited mobility
184
. This can severely impede the 
passage of drug molecules out of the matrix and into the dissolution medium. 
Conversely, the discrete drug particles in a solid dispersion can directly 
interact with the dissolution medium more easily and thus, release rate is 
usually higher. Nonetheless, the influence of the solid solution or solid 
dispersion systems on drug release from solid lipid matrix system is currently 














B.  HYPOTHESIS AND OBJECTIVES 
 
The following are the hypothesis statements that form the basis for this 
research study: 
 
 The viscosity-temperature relationship of lipid-based excipients used in 
spray congealing can be described by a more accurate and 
representative model than the current ones available. 
 
 Polymeric additives can be employed as viscosity-modifying agents for 
lipid matrix materials. 
 
 Spray congealing and presence of additives can influence the solid state 
characteristics of solid lipid microparticles produced. 
 
 Lipid matrix type, polymeric additive type and concentration, 
microparticle size, drug-matrix miscibility and matrix polymorphism 
can influence the drug release behaviour of solid lipid microparticles. 
 
The objectives of this study can be summarized by the following statements: 
 
 Investigations into the viscosity-temperature relationship of 
hydrophobic matrix materials amenable for spray congealing by using 
lipid-based excipients encompassing a wide range of chemical classes 
and properties – fatty alcohol, fatty acid, fatty ester, mono-, di- and tri-
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glycerides. The study was also aimed at developing a more universal 
model to better describe the viscosity-temperature relationship of the 
selected lipid-based materials, and to compare the devised model with 
existing models described in literature.   
 
 Investigate the effects of a model drug and matrix-modifying polymeric 
additives (PVP/VA and EC) on lipid-based formulation viscosity and 
resultant spray-congealed SLMs characteristics. Intermolecular 
interactions between the lipid-based matrix material and polymeric 
additive, as well as application of the developed model (Tp parameter) 
to binary and ternary formulations would also be studied. 
 
 Investigate drug-matrix miscibility and influence of spray congealing, 
as well as additives , on the solid state characteristics of the model drug 
(IBU) and lipid matrix materials (CA, SA and GB) using a combination 
of calorimetric and spectroscopic techniques. 
 
 Investigate drug release from IBU-loaded SLMs produced by spray 
congealing using CA, SA or GB as lipid matrix material and PVP/VA 
or EC as matrix- and release-modifying agents. The effects of lipid 
matrix type, polymeric additive type and concentration, microparticle 
size, drug-matrix miscibility and matrix polymorphism on the drug 
release behaviour of IBU-loaded SLMs would be analyzed. A 
combination of drug release modelling and post-dissolution SEM 
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images would be employed to provide complementary insights on the 
drug release mechanisms of the different lipid matrices. 
 
This study consists of 4 parts. For each part, the results of the relevant 






















C1.1.  Drug 
 
Pure Ibuprofen (IBU, Beacon Pharmaceutical, Singapore), a white 
crystalline powder with melting range of 75-77°C was used as the model drug. 
Degradation of IBU occurs between 120°C to 280°C, far beyond the 
temperatures employed in spray congealing in the present work
185
. IBU is 
classified under Group II in the Biopharmaceutics Classification System 
(BCS), i.e. IBU has high permeability and low solubility. As IBU is a weak 
acid with pKa of 4.54, it has very poor solubility in acidic medium but high 
solubility in neutral to alkaline media
95,186
. The solubility of ibuprofen is very 
low (about 0.058 mg mL
-1
) in the pH range of 1.2-4.0. Beyond pH 6.0, the 
solubility of ibuprofen increases drastically. The solubility of ibuprofen is 
about 0.9 mg mL
-1
 at neutral pH and more than 3.8 mg mL
-1
 at alkaline pH.   
IBU is a non-steroidal anti-inflammatory drug with a short elimination half-life 
of 1.8 to 2 hours
187
, making it a suitable model drug for sustained and modified 
release applications. 
 






Cetyl alcohol (CA; Crodacol C90, Croda, Singapore), myristyl myristate 
(MM; Crodamol MM, Croda, Singapore), triple pressed stearic acid (SA; 
Timur Oleochemicals, Malaysia), glyceryl dibehenate (GB; Compritol 888 
ATO, Gattefosse, France), hydrogenated soybean oil (HSO; Sterotex HM, 
Abitec, USA), hydrogenated vegetable oils (HVO; mixture of hydrogenated 
castor oil and hydrogenated soybean oil, Sterotex K, Abitec, USA), 
hydrogenated cottonseed oil (HCO; Sterotex NF, Abitec, USA) and glyceryl 
monostearate (GMS; Lipo Chemicals Co., Shanghai) were used as 




Stearoyl macrogol-32 glycerides EP (GE; Gelucire 50/13, Gattefosse, 
France), poloxamer 188 (P188; Lutrol F68, BASF, Germany), polyethylene 
glycol 1500 (PEG 1500; BASF, Germany) and polyethylene glycol 3350 (PEG 





Polyvinyl-2-pyrrolidone-vinyl-acetate (PVP/VA; Plasdone S630, 
Ashland, USA) and ethyl cellulose (EC; BDH Chemicals, UK) were employed 
as matrix- and release-modifying agents. 
 




Potassium dihydrogen phosphate, sodium hydroxide (Merck, Darmstadt, 




C2.1. Preparation of blank CA, SA and GB melts for spray congealing 
 
Individual lipid matrix material was accurately weighed into a 250 mL 
beaker and transferred into a pre-heated oven (UL 40, Memmert, Schwabach, 
Germany) set at 10°C above its melting point (Table D1) to produce a clear 
molten liquid. The molten liquid was removed from the oven and maintained 
at about 15°C above its melting point in a thermostated container while 
waiting for it to be spray-congealed. 
 
C2.2. Preparation of CA-, SA- and GB-based binary lipid-polymer and 
ternary lipid-polymer-drug molten mixtures for temperature ramping 
tests and spray congealing 
 
The binary lipid-polymer formulations were prepared by adding 
appropriate amounts of PVP/VA or EC to CA, SA or GB in a 250 mL beaker, 
as previously described (Table C1). The binary lipid-polymer formulation was 
referred to as a drug carrier. Ternary lipid-polymer-drug formulations were 
also prepared, by adding 2 parts of IBU to 8 parts of the respective drug 
carrier. The formulations with CA or SA (CA or SA formulations) were heated 
to 70°C while those containing GB (GB formulations) were heated to 80°C for 
30 min and stirred to form homogenous molten mixtures. 
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Table C1. Composition of binary formulations (drug carrier) for spray congealing. 
 




M100 A0 100 0 
M97.5 A2.5 97.5 2.5 
M95 A5 95 5 
M92.5 A7.5 92.5 7.5 
M90 A10 90 10 
*M refers to matrix material, A refers to additive, and the suffix numerals refer to the  
percentage by weight. 
 
C2.3. Preparation of CA-, SA- and GB-based physical mixtures 
 
Two grams of IBU and 8.0 g of CA, SA or GB were accurately weighed 
and geometrically mixed using a spatula. The mixture was further subjected to 
continuous shaking in a plastic bag for 10 min. It was then hermetically sealed 
in the plastic bag and stored at 25°C in a desiccator until further use. 
 
C2.4. Preparation of CA-, SA- and GB-based binary drug-lipid casts 
 
The matrix materials, CA and SA were supplied as waxy, white granules 
and flakes respectively. They were individually ground using a mortar and 
pestle and the resultant powders stored overnight in a desiccator before use. 
GB was a fine white powder and used as supplied. Various amounts of IBU 
and the powdered CA, SA or GB were accurately weighed into beakers to give 
mixtures of 10 g each. The mixtures consisting of CA, SA or GB were melted 
in a pre-heated oven at 60°C, 69°C or 86°C, respectively. The molten mixtures 
were periodically removed from the oven and stirred until homogeneous. The 
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molten mixtures were then placed in a refrigerator set at 4°C and allowed to 
solidify over about 5 min. The solidified mixtures (casts) obtained were gently 
ground using a mortar and pestle and the resultant powders used for thermal 
analyses. 
 
C2.5. Preparation of solid lipid microparticles by spray congealing 
 
The microparticles were prepared using a laboratory scale spray 
congealer (Mobile Minor 2000, GEA-Niro, Denmark) with a cylindrical 
chamber (internal diameter: 0.8 m, height: 0.86 m) and conical base. A 
pneumatic fountain two-fluid nozzle equipped with a 2.0 mm nozzle tip was 
used for the atomization of the molten feed at an atomizing pressure of 0.2 bar 
into the cooling chamber maintained at 5-10°C. Atomization air temperature 
was set and maintained at 10°C above the melting points of the respective lipid 
matrix materials. Air was extracted from the chamber by an exhaust fan. The 
molten feed was maintained at 5°C above the atomization air temperature by a 
heated jacket while it was being delivered from the feed reservoir to the spray 
nozzle using a peristaltic pump (Masterflex, Cole-Parmer, USA) at a rate of 50 
mL/min. The sprayed droplets, upon contact with cold air in the chamber, 
congealed to form lipid microparticles which were collected by a collecting 
vessel at the bottom of the chamber and designated as the useful yield. Fines (< 






C2.6. Characterization of molten mixtures, physical mixtures, drug-lipid casts 
and microparticles 
 
C2.6.1. Continuous ramping tests 
 
Continuous ramping tests were performed using a rheometer (AR-G2, 
TA Instruments, USA) with a parallel plate system (20 mm diameter, gap 200 
μm) to determine the viscosity of the molten formulations at different shear 
stress. Briefly, samples were heated to a temperature of 10ºC above their 
respective peak melting temperatures (Table D1) and held at that particular 
temperature for an equilibration time of 5 min. The samples were then sheared 
at an increasing shear stress from 0 to 10 Pa over time duration of 5 min to 
obtain the rheograms. The viscosities of the formulations were determined 
from the slope of the rheograms. The measurements were carried out in 
triplicates and the results averaged. 
 
C2.6.2. Temperature ramping tests 
 
Temperature ramping tests were performed using a rheometer (AR-G2, 
TA Instruments, USA) to investigate the viscosity-temperature relationship of 
the lipid matrix materials, polymeric matrix materials, binary lipid-polymer 
formulations and ternary lipid-polymer-drug formulations. It involved the 
application of a constant shear stress while ramping the temperature at a user 
defined rate. Briefly, samples were heated from their respective peak melting 
temperatures (Table D1) to 100°C at a constant shear stress of 5 Pa over time 
duration of 5 min. Viscosity values were recorded at different temperatures. 
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Temperature ramping curves of viscosity against temperature were plotted for 
each data set. All experiments were performed in triplicates. Best-fit 
mathematical models were derived for these curves using Matlab R2010b (The 
Mathworks Inc, Natick, MA, USA) program.  
 
C2.6.3. Differential scanning calorimetry (DSC) 
 
The thermal characteristics of the unprocessed materials, drug-lipid 
physical mixtures, drug-lipid casts and spray-congealed SLMs of various 
formulations were determined using a differential scanning calorimeter (DSC-
60, Shimadzu, Japan). A hermetically sealed aluminium pan loaded with 
approximately 5 mg of sample was placed in a DSC furnace and heated from 
25-100°C at a rate of 10°C/min. An empty sealed aluminium pan was used as a 
reference. The measurements were carried out in triplicates and results 
averaged. 
 
C2.6.4. Determination of useful yield and total yield of spray-congealed solid 
lipid microparticles 
 
The product was obtained from two collection points, namely the 
collection vessel at the base of the chamber (useful fraction), and the other at 
the cyclone (fines). 
 




Useful yield (%) = 
                         
                          
 X 100 ……………....Equation (1) 
 
Total yield (%) = 
                                         
                          
 X 100....Equation (2) 
 
The weight of the starting material was determined from the difference in the 
weight of the container of molten mixture before and after the spray 
congealing process. 
 
C2.6.5. Surface examination of spray-congealed solid lipid microparticles 
 
The morphology of unprocessed IBU crystals and spray-congealed 
SLMs was examined using a scanning electron microscope (JSM-6010LV, 
Jeol, Japan). SLMs were mounted on aluminum studs using conductive carbon 
tape and observed at 1.0 kV under high vacuum. 
 
C2.6.6. Particle size analysis of spray-congealed solid lipid microparticles 
 
Particle size measurement of the useful fraction was carried out using a 
laser diffractometer (LS230, Coulter, USA) with a dry powder module. The 
cumulative undersize distribution plot by volume was constructed and the 
median particle size determined. The size span, Sx, was calculated as follows: 
 
Sx = (d90–d10)/d50……………………………………………...…....Equation (3) 






 percentiles of the 
cumulative particle size distribution respectively. The median particle size is 
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indicated by d50 value. The size span represents the spread of the size 
distribution of the particles, where a higher value indicates a broader size 
distribution. Size measurements were carried out in triplicates for each batch 
and the results averaged. 
 
C2.6.7. Fourier transform-infrared (FTIR) spectroscopy 
 
Interactions between lipids and IBU as well as polymeric additives 
(PVP/VA and EC) were investigated using Fourier transform-infrared (FTIR) 
spectroscopy (Spectrum 100, Perkin Elmer, USA). The attenuated total 
reflection (ATR) method was employed. The prism surface was first cleaned 
with 90 % ethanol and dried using lint-free tissue. A background reading was 
first taken, followed by samples of approximately 20 mg, placed on the clean 
prism surface and compressed. Infrared spectra of the samples were obtained 
and analyzed. The prism surface was cleaned using 90 % ethanol in between 
samples. 
 
C2.6.8.  Nuclear magnetic resonance (NMR) spectroscopy 
 
Interactions between lipids and polymeric additives (PVP/VA and EC) 
were further elucidated using NMR spectroscopy. About 10 mg each of the 
individual components and their physical mixtures were accurately weighed 
and dissolved in 0.5 mL of deuterated chloroform. 
1
H NMR spectra were 





C2.6.9. Hot stage microscopy 
 
IBU-loaded (20 %, w/w) spray-congealed SLM samples were examined 
using a hot-stage microscope (BX51, Olympus Optical, Japan) with a heating 
unit (THMS 600, Linkam Scientific Instruments, UK). A small amount of 
spray-congealed SLMs were scattered on a glass slide and heated at 5°C/min. 
Changes in the SLMs with temperature were monitored by capturing timed 
images detailing the entire melting process. 
 
C2.6.10. Powder X-ray diffraction (XRD) analysis 
 
The polymorphic profiles of the unprocessed materials, physical 
mixtures and spray-congealed SLMs were obtained using the X-ray powder 
diffractometer (XRD-6000, Shimadzu, Japan) with Cu Kα radiation 
(λ=1.5406Å). The voltage and current were 40 kV and 30 mA respectively. 
The scanning angle ranged from 10 to 50° (2θ) with a scanning rate of 2° (2θ) 
/min. 
 
C2.6.11. Determination of drug content and encapsulation efficiency of spray-
congealed solid lipid microparticles 
 
The drug-loaded SLMs were accurately weighed and transferred into a 
100 mL volumetric flask. Phosphate buffer (pH 6.8) was added to the mark 
and the flask was placed in a shaker bath (M20S, MT/2, Lauda, Germany) at 
60°C (for CA-based SLMs), 69°C (for SA-based SLMs) or 86°C (for GB-
based SLMs) and agitated at 110 oscillations/min for 30 min. The test mixture 
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was cooled to room temperature before an aliquot sample was removed 
through a 0.45 μm filter membrane (RC, Sartorius, Germany).  
Spectrophotometric analysis (UV 1201, Shimadzu, Japan) was carried out at 
221 nm (λmax)
188
. Drug content was expressed as the amount of drug 
encapsulated per unit weight of SLMs. The drug content of SLMs was 
determined in triplicates and the results averaged. From the drug content 
results, the encapsulation efficiencies (%) were calculated as follows: 
 
EE (%) = 
  
  
 X 100……….……………………………………......Equation (4) 
 
where Wa and Wt are the assayed and theoretical drug contents, respectively. 
 
C2.6.12. Drug release study of spray-congealed solid lipid microparticles 
 
Drug dissolution profiles for spray-congealed SLMs in phosphate buffer 
(pH 6.8) were determined using the USP dissolution test method (Apparatus 2) 
with a paddle speed of 50 rpm. A dissolution test unit (9ST, Caleva, England) 
with an autosampler (Datacheck, Caleva, England) was used. The volume of 
dissolution medium used was 900 mL, maintained at 37°C. 99.0 g of IBU-
loaded spray-congealed microparticles/physical mixtures or 19.8 g of pure IBU 
powder were added respectively to the dissolution vessels. Samples of 3 mL 
were withdrawn at specific time points: 5, 10, 15, 30, 45, 60, 90, 120, 150, 
180, 240 and 300 min. The samples were then assayed for IBU by ultraviolet 
(UV) spectrophotometry at 221 nm (λmax)
188
. Dissolution test for each 
formulation was carried out in triplicates and the values were averaged. Both 
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the unsieved and sieved (180-250 μm) fractions were used for this part of the 
study. The unsieved fraction provides insights on the performance of the 
formulation, whereas the sieved fraction eliminates effects due to differences 
in particle size. 
 
C2.6.13. Drug release modelling 
 
Drug release was analyzed using T50 %, T75 % and T90 %, representing the 
time taken in minutes to achieve 50 %, 75 % and 90 % drug release 
respectively. These values were derived by fitting the averaged (n=3) 
dissolution profiles of the respective formulations to appropriate mathematical 
models (Equations 5-10) using the KinetDS 3.0 Rev. 2010 software 
189
. T50 %, 
T75 % and T90 % values were then obtained by substituting 0.5, 0.75 or 0.9 into 
the respective equations.  
 
Zero order release model 
Q = kt + Q0………………………………………………...….…....Equation (5) 
 
First order equation 
 
 





Hixson-Crowell cube root equation 
Q
1/3 
= kt + Q0










Q = 100 [1 – exp (
 ( )  
 






where Q is the amount (%) of drug substance released at the time t, Q0 is the 
initial value of Q, t is the time, k is the rate constant, and a, b are arbitrary 
constants. 
 
C2.6.14. Statistical analysis of data 
 
The results were analyzed using one-way analysis of variance (ANOVA) 
at 5 % level of significance with the aid of statistical analysis software (SPSS, 





























Part D1: Viscosity-temperature relationship of meltable matrix materials 
for spray congealing and its impact on solid lipid microparticles produced 
 
The objective of this part of the study was to investigate the viscosity-
temperature relationship of hydrophobic lipid matrix materials amenable for 
spray congealing. Lipid-based excipients encompassing a wide range of 
chemical classes and properties – fatty alcohol, fatty acid, fatty ester, mono-, 
di- and tri-glycerides were employed. The viscosity-temperature relationship 




D1.1. Melting points of materials 
 
Materials used in this study for spray congealing were primarily lipid-
based, including representatives of fatty alcohol (CA), fatty acid (SA), fatty 
ester (MM), mono- (GMS), di- (GB) and triglycerides (hydrogenated oils). A 
wide range of chemical classes and properties was employed to examine if the 
range of lipids, especially the more hydrophobic lipid-based materials, were 
amenable for spray congealing.  
 
The peak melting points of the materials were generally low, ranging 





Table D1.  Melting points and flow characteristics of various lipid-based materials at 
different temperature. 
 













CA 3988 ± 75 50.4 ± 0.3 60 65 17.10 ± 0.39 8.61 ± 0.20 
SA 4216 ± 73 59.0 ± 0.1 69 74 19.13 ± 1.69 15.09 ± 0.14 
GB 1243 ± 193 75.9 ± 0.5 86 91 48.35 ± 1.66 101.79 ± 18.71 
GMS 1430 ± 65 66.8 ± 0.4 77 82 35.88 ± 2.61 38.55 ± 3.35 
MM 5556 ± 69 50.2 ± 1.2 60 65 9.18 ± 0.12 6.63 ± 0.10 
HSO 3638 ± 28 70.3 ± 0.3 80 85 21.43 ± 0.92 23.06 ± 4.23 
HVO 2085 ± 212 63.9 ± 0.3 74 79 58.51 ± 3.85 55.23 ± 7.49 
HCO 3227 ± 10 65.2 ± 0.4 75 80 22.59 ± 0.33 24.06 ± 2.59 
± standard deviation; 
*Spraying temperature (ST) is the atomization air temperature used. It was set and 
maintained at 10°C above the melting point of the material. 
**Delivery temperature(DT) is the temperature at which the molten feed was maintained (5°C 
above the atomization air temperature) using a heated water bath while it was delivered to the 
spray nozzle using a peristaltic pump. 
 
D1.2. Flow properties of materials 
 
The flow properties of materials were investigated at 10°C above their 
respective peak melting points. The rheograms of all the molten samples 
showed a straight line passing through the origin (Figure D1), indicating 
Newtonian flow. The Newtonian flow behaviour of the triglycerides was also 
observed in other studies
190
. Viscosity, which reflects the resistance of the 
sample to flow when stress is applied, is indicated by the gradient of the 
rheogram. The viscosity was constant despite different shear stresses applied. 




(A)            (B) 
 
(C)            (D) 
 
(E)            (F) 
 
(G)            (H) 
 
 
Figure D1. Rheograms of molten (A) cetyl alcohol; (B) stearic acid; (C) glyceryl 
dibehenate; (D) glyceryl monostearate; (E) myristyl myristate; (F) hydrogenated 
soybean oil; (G) hydrogenated vegetable oils and (H) hydrogenated cottonseed oil at a 
temperature of 10ºC above their respective peak melting points. All experiments were 















































































































































Shear stress (Pa) 
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D1.3. Relationship of viscosity with temperature 
 
Temperature ramping plots for the various lipid-based materials 
generally showed a biphasic relationship between viscosity and temperature 
(Figure D2). At lower temperatures, a relatively rapid decrease in viscosity 
with increasing temperature in an approximately linear fashion was observed. 
This phase gradually transited to the next which was characterized by another 
linear relationship but with a gentler gradient. The sharpness of the transition 
point appeared to be related to the lipid type. For pure and relatively small 
lipid-based materials such as CA, SA and MM, the transition point was 
significantly sharper than molecularly larger GB, which is a mixture of 
behenic acid glycerides.  
 
Rheograms of the polymeric materials GE, PEG 1500, PEG3350 and 
P188 were also obtained for comparison (Figure D3). Unlike the lipid-based 
materials, these polymers did not exhibit any clear biphasic viscosity-







Figure D2. Temperature ramping curves of (A) cetyl alcohol; (B) stearic acid; (C) 
glyceryl dibehenate; (D) glyceryl monostearate; (E) myristyl myristate; (F) hydrogenated 
soybean oil; (G) hydrogenated vegetable oil and (H) hydrogenated cottonseed oil. All 
experiments were performed in triplicates. Rheograms were plotted using the Matlab 
software. 


























































































































































































Figure D3. Representative temperature ramping curves of (A) Gelucire 50/13; (B) 
polyethylene glycol 1500; (C) polyethylene glycol 3350 and (D) poloxamer 188. All 
experiments were performed in triplicates. Rheograms were plotted using the Matlab 
software. 
 
The temperature ramping curves of the lipid-based materials were fitted 
to existing viscosity-temperature models, such as the Andrade‘s model and the 
Power law model, in order to investigate their suitability in modelling the 
viscosity-temperature profiles of the lipid-based materials.  
 
Andrade‘s equation:  
η = Ae(B/T) ……………………………………………...........…....Equation (11) 
 
Power law: 
η = ATn ……………………………………………………..…....Equation (12) 
where η = viscosity in Pa.s, T = temperature in °C and n, A, B are constants. 

































































































The coefficients of determination (goodness-of-fit, R
2
) for both models 
were mostly in the range of 0.80 to 0.97 (Table D2), indicating moderate fits. 
The biphasic nature of their rheograms when fitted to linearly transformed 
Andrade‘s model and Power law model further substantiated the above 
(Figures D4A and D4B). Conversely, the rheograms of the polymers GE, PEG 
1500, PEG3350 and P188 were well described by the two models (Figures 
D4C and D4D). 
 
Table D2.  Values of constants A, B, C and D of the biexponential temperature 
ramping curves of the lipid-based materials; coefficients of determination (R
2
) in the 
fitting of the biexponential model, Andrade‘s model and the Power Law model to the 
temperature ramping curves of lipid-based materials and polymers. 
 











CA 2.37 x 10
5
 -0.301 0.0536 -0.0237 0.998 0.929 0.882 
SA 2.63 x 10
12
 -0.522 0.149 -0.0288 0.993 0.936 0.908 
GB 1.23 x 10
4
 -0.113 0.0314 0.0455 0.998 0.978 0.966 
GMS 5.60 x 10
3
 -0.170 0.111 -0.0170 0.998 0.963 0.936 
MM 1.47 x 10
9
 -0.487 0.0221 -0.0157 0.999 0.854 0.803 
HSO 1.10 x 10
12
 -0.452 0.0586 -0.0132 0.960 0.880 0.863 
HVO 4.23 x 10
12
 -0.419 0.913 -0.0359 0.953 0.973 0.973 
HCO 9.38 x 10
11
 -0.521 0.0845 -0.0177 0.993 0.963 0.953 
GE ---------------------------N/A---------------------------- 0.999 0.998 
PEG 1500 ---------------------------N/A---------------------------- 0.985 0.999 
PEG 3350 ---------------------------N/A---------------------------- 0.993 1.000 





(A)                (B) 
 
(C)                (D) 
 
 
Figure D4. Viscosity-temperature relationship of MM, which is representative of the other 
lipid-based materials, fitted to linearly transformed (A) Andrade‘s model, and (B) Power law 
model. Viscosity-temperature relationship of GE, which is representative of the other 
polymers, fitted to linearly transformed (C) Andrade‘s model and (D) Power law model. 
 
In pursuit of a simple mathematical model that could adequately 
represent the viscosity-temperature relationship of the lipid-based materials, 
curve fitting of the data sets using the Matlab program was performed. It was 







 …………………………………………...…....Equation (13) 




The values of the coefficients A-D as well as the coefficients of 
determination (goodness-of-fit, R
2
) for data fitting to Equation 13 are shown in 
Table D2. 
 
D1.4. Elucidation of Transition Point (Tp) 
 
The temperature ramping curves of the lipid-based material showed that 
their viscosity varied with temperature in a biexponential manner, typically 
characterized by a distinct transition point (Figure D2). Noting that this 
transition point is characteristic of each material, attempts were made to 
determine its coordinates by manipulation of the curves using MatLab. 
Mathematically, rotation of the biexponential curve by an angle of 45° 
anticlockwise will produce a curve having a minimum point corresponding to 
the transition point. Determination of this minimum point by differentiation of 
the rotated curve will yield the coordinates of the transition point. 
 
The derivation of the transition point is further illustrated below. Firstly, 
the biexponential equation derived for each material was transformed by 
scaling the x and y values to between 0 and 1 using equations (14) and (15): 
 
   
       (  )
   (  )     (  )
………………………………………….…....Equation (14) 
 
where x0 and x represent arbitrary untransformed and transformed values 




   
       (  )
   (  )     (  )
………………………………...……….…....Equation (15) 
 
where y0 and y represent arbitrary untransformed and transformed values 
respectively for viscosity. 
 
After scaling, the arbitrary values of x and y were then rotated 
anticlockwise by θ = 45° about the origin using equations (16) and (17): 
 
             .……………………………………....…....Equation (16) 
             .……….……………………………….......Equation (17) 
 




              ……….……………………………….......Equation (18) 
 
               ……….………………………………....Equation (19) 
 
Substitution of equations (18) and (19) into equation (13) gives: 
 
                 (           )      (           )…..Equation (20) 
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    )    (           )......................................Equation (21) 
 
The transition point desired in the biexponential curve, equation (13), is 




   ……………………………………………...……….…....Equation (22) 
 
Substituting equation (22) into equation (21) gives: 
 
           (           )        (           )….…....Equation (23) 
 
Solving equations (20) and (23) simultaneously with known constants 
(A, B, C, D) generates the values of X and Y at the minimum point. 
 
Finally, substitution of X and Y into equations (18) and (19) generates 
the scaled x and y values of the transition point. 
 
Undoing the scaling by using equations (24) and (25) gives the viscosity 
and temperature values of the transition point. 
 
     (   (  )     (  ))      (  )………………….…....Equation (24) 




In order to express the transition point as a single value, its x-coordinate 
(i.e. temperature) was divided by its y-coordinate (i.e. viscosity) to produce the 
Tp value, which is a temperature-independent rheological parameter. The Tp 
values determined for the lipid-based materials are shown in Table D1. 
 
It was of interest to investigate the relationship of Tp with melt viscosity. 
The melt viscosities of the lipid-based materials were determined 
experimentally at 76°C, 80°C, 85°C and 90°C, which were the temperatures at 
which the various materials existed in molten state. Correlation analyses of the 
Tp values with corresponding melt viscosity values at a particular temperature 
were conducted (Table D3, H1). Tp was found to have an inverse relationship 
with melt viscosity at all 4 temperatures, whereby material of higher melt 
viscosity showed lower Tp value. Tp values had relatively good correlation 
with melt viscosity at all 4 temperatures (absolute r > 0.8), supporting Tp as a 
parameter that can be used to represent viscosity.  
 
Table D3. Correlation analyses of Tp with melt viscosities. 
 
Correlation of Tp with melt viscosity (r value) 
Melt viscosity at 
76°C 
Melt viscosity at 
80°C 
Melt viscosity at 
85°C 
Melt viscosity at 
90°C 
-0.836* -0.858* -0.917** -0.922** 
*p<0.01; **p<0.001 
 
D1.5. Production of microparticles by spray congealing 
 
Microparticles were successfully produced by spray congealing all of the 
lipid-based materials attempted. The total yields and useful yields obtained for 
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all formulations were greater than 88 % and 77 % respectively (Table D4). The 
spray congealing process is known in literature to be capable of achieving high 
total yields, of 90 % or higher
79,96
. The loss in total yield was mainly due to 
adherence of the microparticles to the chamber wall while a lower useful yield 
was due to losses through the generation of fines (< 10 µm) which were 
collected in the cyclone from the exhausting airflow. The fines, albeit still a 
―yield‖, were not considered useful yield as they were outside the targeted size 
range.  
 
Table D4.  Yields and particle size characteristics of microparticles produced from 
different materials spray-congealed under similar conditions (0.2 bar pressure, 28 
% airflow, atomizing air temperature 10°C above materials peak melting 
temperature). 
 









CA 88.7 ± 6.0 78.3 ± 2.3 10.3 ± 5.0 113.3 ± 3.5 1.7 ± 0.0 
SA 92.5 ± 2.9 80.0 ± 6.8 12.5 ± 5.4 112.0 ± 12.1 1.5 ± 0.2 
GB 90.3 ± 3.0 85.8 ± 3.8 4.5 ± 1.0 191.0 ± 23.5 3.6 ± 0.2 
GMS 97.7 ± 2.5 89.2 ± 3.5 8.5 ± 2.2 185.5 ± 10.9 3.5 ± 0.5 
MM 93.8 ± 2.7 77.5 ± 2.7 16.3 ± 0.2 95.9 ± 2.1 1.3 ± 0.2 
HSO 91.8 ± 5.5 80.0 ± 1.8 11.8 ± 4.2 126.3 ± 3.9 1.7 ± 0.0 
HVO 88.6 ± 2.3 78.7 ± 2.5 9.9 ± 0.2 174.6 ± 3.6 2.1 ± 0.4 
HCO 94.7 ± 2.3 83.5 ± 1.3 11.1 ± 1.9 144.0 ± 4.1 2.2 ± 0.2 
± standard deviation 
 
D1.6. Characterization of spray-congealed solid lipid microparticles 
 
D1.6.1. Surface morphology of spray-congealed microparticles 
 
The microparticles produced generally appeared discrete, filled and 
highly spherical (Figure D5). The spherical shape was attributed to the 
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minimization of surface energy after atomization of the molten feed. The 
particles produced appeared as dense spheroids unlike spray dried particles as 
there were no internal evaporative effects on the microparticles and congealing 





Figure D5. Representative SEM images of microparticles produced from (A) cetyl 
alcohol; (B) stearic acid; (C) myristyl myristate; (D) hydrogenated soybean oil; (E) 
hydrogenated vegetable oils; (F) hydrogenated cottonseed oil; (G) glyceryl 
monostearate and (H) glyceryl dibehenate. [Note: Images were captured at different 
magnifications to better depict the surface morphologies]. 
 
D1.6.2.  Median size and size span of spray-congealed microparticles 
 
Median sizes of microparticles were reported due to the non-parametric 
nature of the size profiles (Figure D6). The median size and span of 
microparticles are shown in Table D4. The span increased concurrently with 
(C) 





the median size of the microparticles with a correlation coefficient of 0.909 (p 
<0.01). Graphs of size span against Tp and melt viscosities are presented in 
Figure H4. Median microparticle sizes were correlated with Tp as well as melt 
viscosity at 76°C, 80°C, 85°C and 90°C (Table D5, H2). Unlike melt viscosity, 
Tp showed an inverse relationship with median microparticle size. The 
correlation between Tp and microparticle size (absolute r value of 0.983) was 
significantly stronger than that between melt viscosity and microparticle size 
(absolute r value of 0.849-0.933). From Figure D7A, it can be clearly seen that 
the relationship between Tp and microparticle size is a nearly perfect linear 
trend, compared to the more scattered plots of melt viscosity versus 
microparticle size (Figures D7B, C, D, E and F). 
 
Table D5. Correlation of median microparticle size with Tp and melt viscosities. 
 
Correlation of microparticle size with Tp and melt viscosity (r values) 













Figure D6. Size distribution of spray-congealed microparticles of CA,  
SA, GB, HSO, HCO, HVO, GMS and MM. 
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(A)               (B) 
 
(C)               (D) 
    
(E)               (F) 
   
Figure D7. Graphs of median size of spray-congealed microparticles against (A) Tp; 
(B) melt viscosity at spraying temperature; (C) melt viscosity at 76°C; (D) melt 






D1.7.1.  Relationship of viscosity with temperature 
 
Temperature ramping experiments performed on the variety of lipid-
based materials (CA, SA, GB, GMS, MM, HSO, HVO and HCO) revealed 
biexponential relationship between their viscosities and temperature. These 
materials are composed of simple, albeit relatively large molecules (Table D6). 
All of these materials possess long alkyl chains in their molecular structures, 
and are hydrophobic in nature. 
 
Although the phenomenon of decreasing viscosity with increasing 
temperature is well known
190-192
, the biexponential viscosity-temperature 
relationship for lipid-based materials presented in this study is new. Through 
fitting of the viscosity-temperature rheograms to Andrade‘s model and Power 
law model, it was also shown that the viscosity-temperature relationship of 
lipid-based materials could not be adequately described by these ‗monophasic‘ 
models. Conversely, the rheology of GE, PEG 1500, PEG3350 and P188 were 
well described by these models, especially the Power law model. The 
viscosity-temperature curve of the lipid-based materials typically consisted of 
2 distinct phases, which is suggestive of complex phenomena occurring at the 
molecular level. As with all substances, an increasing temperature generally 
leads to increased kinetic energy in the component molecules and a 
corresponding attenuation of weak intermolecular attractions (London 
dispersion forces)
193
. This may explain the steep decrease of viscosity with 
temperature in the first phase. Subsequently, the transition to a very gentle 
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decline in viscosity suggests that attractions between the molecules have 
weakened to a point where the alignment of their long alkyl chains towards the 
direction of shear and parallel to one another is largely completed at the 
transition point. At this stage, viscosity seems to have reached a ‗minimum‘ 
with further increases in temperature no longer producing significant viscosity 
changes. As for the ‗monophasic‘ viscosity-temperature relationships seen for 
GE, PEGs and poloxamer, these are due to a simple process of gradual 
attenuation of intermolecular attractions between polymeric chains of variable 
lengths as temperature increases. This results in the alignment of polymer 
chains to the shear direction proceeding continuously without any significant 
transition point. 
 
D1.7.2. Application of Tp as a parameter to represent rheological 
characteristics of lipid-based materials 
 
The rheograms of the lipid-based materials typically showed a distinct 
transition point. Using a Matlab transformation, the coordinates of the 
transition point could be determined and transformed into a single numerical 
value, Tp. Tp values, which were found to be characteristic of the materials, 
showed a good inverse relationship with viscosity at various temperatures. It is 
thus proposed that Tp is a suitable temperature-independent parameter that can 
be used to compare the rheological characteristic of lipid-based materials. 
 
Tp value appears to relate to the molecular structure of the lipid-based 
material and type of intermolecular attractive forces involved (Table D6). 
Larger molecules capable of hydrogen bonding tend to have lower Tp values. 
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MM, which has the highest Tp value (5556), has molecular structure composed 
of two 14-carbon chains connected by an ester linkage. MM is thus relatively 
non-polar with weak intermolecular forces of attraction. SA, which has the 
second highest Tp value (4216), is an 18-carbon fatty acid with the ability to 
form dimers via hydrogen bonding
194
. These SA dimers interact with each 
other via weak dispersion forces as the carboxyl moiety is no longer available 
for hydrogen bonding. CA, which has a lower Tp value (3988) than SA, is a 
16-carbon fatty alcohol with the ability to form hydrogen bonds with other CA 
molecules via its hydroxyl moiety. Unlike SA, CA does not form dimers but a 




Despite the lack of hydrogen bonding, HSO and HCO do not have 
markedly different Tp values (3638 and 3227) from CA (3988). This is 
probably due to their much larger molecular size, leading to larger dispersion 
forces between the triglyceride molecules
196
. HSO has slightly higher Tp value 
than HCO, which may be due to the higher degree of unsaturation of the fatty 
acid moieties in HSO. Unsaturation gives rise to ‗kinks‘ in the long alkyl 
chains, which results in a more globular molecular surface, lower surface area 
and hence slightly weaker dispersion forces due to poorer packing and lateral 
interactions
197
. HVO, which is composed of a mixture of hydrogenated castor 
and soybean oils, has comparable molecular weight to HSO and HCO. 
However, the fatty acid moieties of HVO have an additional hydroxyl group, 
which imparts a small degree of hydrogen bonding that contributes to its lower 






Among the lipid-based materials, GB and GMS have the lowest Tp 
values (1243 and 1430, respectively). Even though GB is much larger in 
molecular size than GMS, their Tp values are not markedly different. This is 
probably because GMS has an additional hydroxyl group which enables more 
extensive intermolecular hydrogen bonding. 
 
D1.7.3. Application of Tp as a predictor of spray-congealed microparticle 
median size and a parameter for formulation optimization and 
product design 
 
The various lipid-based materials were spray-congealed to produce 
microparticles. A linear relationship (R
2
 = 0.967) was observed between Tp 
values and the resultant microparticle size. Viscosities of the lipid-based 
materials at spraying temperature, as well as, 76°C, 80°C, 85°C and 90°C were 
also correlated with the microparticle size. Compared to Tp, viscosity 
exhibited a weaker linear relationship with microparticle size (R
2
 = 0.720-
0.871). Therefore, Tp was found to be a better predictor of microparticle size 
than viscosity. 
 
Viscosity of the molten feed is of paramount importance in assessing the 
suitability of the feed for spray congealing. It is a fundamental 
physicochemical property of the liquid that governs liquid flow and 
atomization, which in turn determine the molten droplet size and consequently, 
spray-congealed microparticle size. As discussed earlier, Tp values were found 
to have a stronger linear relationship with the spray-congealed microparticle 
size than viscosity. This establishes Tp as a potentially useful material attribute 
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capable of predicting the spray-congealed microparticle size of lipid-based 
formulations. The ability to predict the size of spray-congealed microparticles 
produced has wide implications. In the preparation of particulate delivery 
systems, particle size can influence bulk properties, such as flow, weight 
uniformity of final dosage form and consequently, the dissolution rate of the 
dosage form. Therefore, the determination of the Tp value can be applied for 
accurately predicting the spray-congealed microparticle size and this can be 
exploited during formulation optimization, leading to significant cost and time 
savings. It is foreseeable that Tp may be useful as a guide for the production of 
microparticles of a desired median size. 
 
Additionally, the conventional use of viscosity at a fixed temperature to 
correlate to process variables has several disadvantages. With reference to 
Figure D8, it is apparent that the viscosity-temperature profiles of materials 
may be markedly different from one another. For instance, at a temperature of 
65°C, the viscosity of GMS lies within the first phase of the curve, where 
viscosity decreases rapidly with increasing temperature. In contrast, the 
viscosity of CA and MM lie in the relatively flat second phase. The weaker 
correlation between microparticle size and melt viscosity might be attributed to 
the complex phenomena proposed. Furthermore, at the same temperature, 
materials with low melting points are in liquid state while those with high 
melting points such as GB and HVO are in solid state, making comparison of 
their viscosity impossible. With the different temperature and temperature 
ranges employed in different processes, it is also difficult to select the most 
‗representative‘ temperature of which to quote the viscosity. Prior work done 
to compare different materials had had to resort to the comparison of 
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viscosities between materials at a few temperatures, giving rise to large 
amounts of data
191,192,198
. In some cases, viscosity between two materials may 
be similar at a lower temperature but differ significantly at a higher 
temperature or vice versa. 
 
Tp effectively circumvents these problems as it is a unique constant for 
each material, and does not require specification of a particular temperature 
when reported. In a sense, Tp can be regarded as an invariant rheological 
parameter that is independent of temperature. 
 
 
Figure D8.  Representative temperature ramping curves of lipid-based materials. 
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Table D6.  Tp values, chemical classes, hydrogen bonding ability, molecular weight 
and structures of (1) myristyl myristate; (2) stearic acid; (3) cetyl alcohol; (4) 
hydrogenated soybean oil; (5) hydrogenated cottonseed oil; (6) hydrogenated vegetable 
oils (mixture of hydrogenated castor oil and hydrogenated soybean oil); (7) glyceryl 
monostearate and (8) glyceryl dibehenate. 
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D1.8. Conclusion of Part D1 
 
In Part D1, it is shown that lipid-based materials have viscosity-
temperature profiles that follow a biexponential model more closely than 
existing models. Utilizing this biexponential model, a novel parameter (Tp) 
was derived to describe the rheological characteristics of the materials. Tp 
values had good correlation with viscosities at various temperatures. Larger 
molecules capable of hydrogen bonding tend to have lower Tp values. 
Additionally, Tp values showed a strong linear relationship with the median 
size of the spray-congealed microparticles. This correlation was found to be 
stronger than that of viscosity with microparticle size, making Tp a better 
predictor of microparticle size than viscosity. 
 
In conclusion, this part provided insight into the biexponential 
relationship between viscosity and temperature for the small library of lipid-
based materials tested. Tp, a new parameter that emerged in the process of 
analyzing the above relationship, is a viable parameter of the rheology of 
materials in relevant applications. Tp has potentially wide application in 
formulation optimization, particularly for melt processes where viscosity is 
known to play a significant role in influencing product attributes. These 
processes include melt granulation, melt extrusion and hot melt coating where 







Part D2: Effects of polymeric additives and model drug on viscosity of 
lipid-based formulations for spray congealing and impact on solid lipid 
microparticles produced 
 
In Part D1, a new biexponential model was developed from the biphasic nature 
of the viscosity-temperature relationship of lipid-based materials. This 
culminated in the derivation of the parameter Tp, which showed good 
correlation with viscosity and median particle size of resultant spray-congealed 
SLMs. Additives may be employed to modify the properties of SLMs. 
 
The objective of Part D2 of this study was to investigate the effects of a model 
drug IBU and matrix-modifying polymeric additives (PVP/VA and EC) on 
selected lipid matrix viscosity and resultant spray-congealed SLMs 
characteristics. Intermolecular interactions between the matrix material and 
additive, as well as the application of Tp to binary and ternary formulations 
were also studied.  
 
D2.  Results 
 
D2.1.  Selection of lipid matrix materials 
 
CA, SA and GB lipid matrix materials were selected for Part D2 of the 
study from among the 8 lipids studied in Part D1. The selection was based on 
the results of preformulation observations where these 3 materials were found 
to form clear molten mixtures with the polymeric additives and model drug 
IBU (Figures D9A, B). All mixtures appeared homogeneous and existed as 
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single liquid phase systems. They were also stable with no evidence of phase 
separation from the time of preparation till they were spray-congealed. The 
other molten lipids were able to dissolve IBU but not the chosen additives, 
with the additives found suspended or floating on the surface of the molten 
lipids. In spray congealing, melt solutions are preferred over melt suspensions 
as the former ensure good drug or additive homogeneity in the molten matrix 
by preventing phase separation. Additionally, the absence of suspended 
particles can minimize clogging of the feeding tube and atomizer, hence 
obviating premature termination of the spray congealing process when flow 
stops.  Moreover, these three lipids represent a sampling of materials from 
both ends of the range of Tp values obtained in Part D1, and also represent 3 
different chemical classes of lipids. 
 
        (A)          (B) 
     
 
 






D2.2.   Effect of IBU and polymeric additive type and concentration on the 
viscosity-temperature relationship of the lipid systems 
 
In order to investigate the influence of PVP/VA and EC on the viscosity 
and Tp of the binary formulations, various concentrations (0 to 20 %, w/w) of 
the individual polymeric additive were added to the respective lipid-based 
materials and heated to form molten mixtures. The latter were then subjected 
to temperature ramping tests to determine their viscosity-temperature 
rheograms as shown in Figure D10. The rheograms consisted typically of 
biphasic curves showing transition points. Such biphasic curves were also 
observed for a range of different lipid-based materials, without additives, as 
seen in Part D1. At higher concentrations (>10 %, w/w) of PVP/VA or EC in 
the binary mixtures, the transition point became less distinct. Nevertheless, the 
Tp values could still be determined with the aid of the Matlab R2010b (The 
Mathworks Inc, Natick, MA, USA) program. For the ternary formulations 
containing 20 %, w/w IBU, the rheograms obtained displayed no overt 
difference from their corresponding binary rheograms (Figure D11). 
 
 
The Tp values of the binary lipid-polymer and ternary lipid-polymer-
drug formulations are shown in Table D7. With increasing concentration of 
PVP/VA from 0 to 20 %, w/w, the Tp value of the binary CA formulation 
decreased from 3988 to 370, corresponding to a concentration-dependent 
increase in viscosity. The same trend was observed for EC, where the Tp value 
was reduced from 3988 to 13.73 with 20 %, w/w EC. For both polymers, Tp 
decreased in an exponential manner with increasing polymer concentration 
(Figure D12).  
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(A)              (B) 
 
 
(C)               (D) 
  
 
(E)               (F) 
  
Figure D10. Representative viscosity-temperature rheograms of binary molten 
mixtures with 10 %, w/w polymeric additive: (A) CA-PVP/VA; (B) CA-EC; (C) 
SA-PVP/VA; (D) SA-EC; (E) GB-PVP/VA and (F) GB-EC. All experiments were 









































































































































 (A)              (B) 
 
  (C)              (D) 
 
  (E)                         (F) 
  
 
Figure D11. Representative viscosity-temperature rheograms of ternary molten 
mixtures with 20 %, w/w IBU and 10 %, w/w polymeric additive: (A) CA-PVP/VA-
IBU; (B) CA-EC-IBU; (C) SA-PVP/VA-IBU; (D) SA-EC-IBU; (E) GB-PVP/VA-
IBU and (F) GB-EC-IBU. All experiments were performed in triplicates. 
Rheograms were plotted using the Matlab software. 
 
The relationship was described by the equation y = 3046e-0.109x for PVP/VA 
whereas it was y = 2845.4e-0.277x for EC (x = concentration of polymeric 
additive; y = Tp). From these equations, it is evident that EC has a greater 
effect on Tp of the formulations than PVP/VA. The equations and coefficients 












































































































































) are listed in Table D8.  In the presence of 20, % w/w 
IBU, the formulations had consistently higher Tp values for the each 
corresponding polymer concentration. IBU thus appeared to reduce the 
viscosities of the formulations when added. 
 























0 3988±75 5173±27 4216±73 5382±44 1243±193 2664±4 
2.5 2191±50 3848±66 3458±47 3873±42 851.1±84.6 1590±331 
5 1450±32 3073±57 2432±24 3008±2 568.1±18.4 1183±264 
7.5 1205±65 2379±165 1658±51 2218±134 454.0±42.1 792.8±136.4 
10 1003±55 1937±35 874.6±43.0 1592±15 311.2±18.9 683.2±169.2 
12.5 762.0±56.8 1291±29 658.4±98.4 1086±5 241.2±38.1 512.8±113.8 
15 643.0±24.5 1030±97 439.4±35.9 764.7±14.8 209.6±5.1 392.7±83.2 
20 370.0±7.0 540.6±1.5 132.4±2.5 315.5±125.2 96.72±5.38 170.0±56.1 
EC 
2.5 1100±63 2768±158 2778±15 2989±32 946.0±42.6 1352±262 
5 805.8±1.1 1418±52 1755±88 1642±68 725.7±59.0 861.5±51.0 
7.5 351.2±10.2 783.2±40.5 812.8±50.4 1069±22 425.7±38.0 499.9±45.0 
10 112.5±14.4 381.5±0.8 382.0±16.8 576.2±12.5 241.1±52.0 293.5±60.6 
12.5 103.5±4.0 243.6±19.0 240.0±11.1 325.6±19.2 196.5±33.0 123.9±1.6 
15 41.31±15.12 143.1±3.4 122.4±2.5 175.6±13.9 94.88±16.00 77.17±1.91 
20 13.73±4.43 57.35±0.20 67.56±2.76 76.91±7.76 26.42±1.00 49.47±16.16 
± standard deviation 
 
For SA and GB formulations, similar trends were obtained with the 
addition of both polymeric additives (Table D7). Figures D12A and D12B 
show a ―crossing over‖ of SA and CA trend lines in the presence of PVP/VA. 
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This pattern was observed regardless if IBU was included or not, indicating 
that PVP/VA caused a rise in the viscosity of SA to a greater degree per 
concentration increase. The reverse trend was true for formulations with EC as 
the slopes for CA formulations with or without IBU were now steeper than for 
SA formulations. 
 
Tp values for GB formulations were consistently lower than those for 
CA and SA formulations when compared across similar polymer 
concentrations and in the presence of IBU. This reflects the higher viscosity of 
GB and its formulations compared to CA or SA formulations.  
 
Table D8. Equations and coefficients of determination (R
2
) of the binary and 
ternary systems. 
 




CA + PVP/VA y = 3046e
-0.109x
 0.964 
CA + EC y = 2845.4e
-0.277x
 0.980 
SA + PVP/VA y = 4712.4e
-0.154x
 0.990 
SA + EC y = 4363.1e
-0.223x
 0.984 
GB + PVP/VA y = 1146.6e
-0.123x
 0.991 
GB + EC y = 1611.1e
-0.191x
 0.977 




CA + PVP/VA y = 5328.4e
-0.111x
 0.995 
CA + EC y = 4562.1e
-0.228x
 0.994 
SA + PVP/VA y = 5857.7e
-0.139x
 0.992 
SA + EC y = 5090.9e
-0.216x
 0.997 
GB + PVP/VA y = 2365.5e
-0.128x
 0.987 






(A)         (B) 
 
 
(C)          (D) 
 
 
Figure D12. Graph of Tp values against concentration of (A) PVP/VA only; (B) 
PVP/VA with 20 %, w/w IBU; (C) EC only and (D) EC with 20 %, w/w IBU for CA, SA 










20 %, w/w IBU 
20 %, w/w IBU 
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D2.3.  Intermolecular interaction between lipid and additive 
 
D2.3.1.  Nuclear magnetic resonance  spectroscopy 
 





















































































































































































































































































H NMR spectra of (A) pure CA; (B) CA with 10 %, w/w PVP/VA; 
(C) CA with 10 %, w/w EC; (D) GB; (E) GB with 10 %, w/w PVP/VA and (F) GB 




































































The NMR spectra of CA and its mixtures with 10 %, w/w PVP/VA or 
EC are shown in Figures D13A, B and C. For pure CA, the large multiplet at 
δ1.254 corresponded to the methylene protons of the long carbon chain of CA. 
The triplet at δ0.877 and the pentet at δ1.563 corresponded to the protons of 
the γ-carbon and the β-carbon respectively. The poorly resolved quartet at 
δ3.636 may be assigned to the protons of the α-carbon, to which was also 
bonded the hydroxyl group. Due to the labile nature of the hydroxyl proton, 
coupling of the α-carbon protons to the hydroxyl proton was relatively poor, 
leading to broadening of the quartet peaks. Interestingly, in the presence of 
PVP/VA or EC, this quartet transformed into a triplet and alongside, there was 
significant sharpening of the peaks. This signified a loss of coupling with the 
hydroxyl proton due to its increased labile nature, which was brought about by 
significant hydrogen bonding between CA and the two additives. Additionally, 
it appeared to be more pronounced in EC, suggesting that more extensive 
hydrogen bonding between CA and EC existed. In conclusion, hydrogen 
bonding between CA and polymeric additives PVP/VA or EC was the primary 
reason for the elevation in viscosity of CA obtained with increasing 
concentrations of either additive.  
 
NMR studies were not performed on SA as the carboxyl proton is too 
labile to be detected by conventional NMR techniques.  
 
The NMR spectra of GB and its mixtures with PVP/VA or EC are shown 
in Figures D13D, E and F. The NMR spectrum of GB consisted of distinct 
groups of peaks. The set of intense multiplets from δ0.50 to δ2.50 could be 
attributed to the protons of the long behenate carbon chains. The set of less 
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intense multiplets from δ3.50 to δ4.40 aptly corresponded to the protons of 
carbons adjacent to the ester moieties, where they were more deshielded due to 
the electronegativity of the carbonyl groups. The small multiplets in the region 
of δ4.90 to δ5.30 could be attributed to the protons attached to the glycerol 
moiety while the broad singlet at δ6.133 corresponded to the hydroxyl protons. 
In the presence of PVP/VA, it totally disappeared and in the presence of EC, it 
was significantly depressed and shifted upfield to δ6.803. These changes were 
due to the formation of hydrogen bonding between the hydroxyl groups of GB 
and the two polymeric additives, leading to a deshielding effect on the 
hydroxyl proton and a concurrent increase in its labile nature. The NMR 
spectra revealed that GB was capable of hydrogen bonding with PVP/VA and 
EC, akin to the situation with CA. Hydrogen bonding between the functional 
groups of GB matrix and additives was thus believed to have contributed to the 
elevation of viscosity of molten GB with increasing concentrations of either 
additive.  
 
D2.3.2.  Fourier transform-infrared spectroscopy 
 
In addition to the observations derived from NMR spectroscopy with 
regards to hydrogen bonding, FTIR spectroscopic studies were also performed 
on the unprocessed lipids, IBU, polymers and spray-congealed SLMs. From 
Figure D14A, it was evident that after spray congealing with PVP/VA, the O-
H stretches of the hydroxyl group of CA had melded into a single broad band 
centred at 3280.28 cm
-1
 from the original 2 peaks at 3323.06 cm
-1
 and 3220.25 
cm
-1
. Concurrently, the C=O stretches of PVP/VA ester groups had shifted 











along with a change in peak intensity and shape. These changes suggested 
significant interactions between the hydroxyl groups of CA and the carbonyl 
groups of PVP/VA, likely due to hydrogen bonding. When spray-congealed 
with EC, the two O-H stretches of CA also exhibited the same phenomenon as 
with PVP/VA due to hydrogen bonding with EC. The appearance of a small 
absorption peak at ca. 1120 cm
-1
 also indicated the formation of hydrogen 
bonds between the hydroxyl moiety of CA and the ether oxygens of EC 
(Figure D14B). 
 
The physical mixture of SA with PVP/VA and the spray-congealed 
SLMs produced identical spectra (Figure D14C). This was also the case for SA 
and EC (Figure D14D). Evidently, there appeared to be no hydrogen bonding 
between SA and either additive.  
 
The O-H stretch band of GB at 3420.85 cm
-1
 showed relatively minor 
changes after spray congealing with PVP/VA or EC. It is not unexpected that 
the hydrogen bonding between GB and PVP/VA was limited as GB is a very 
large diglyceride, with a sole hydroxyl group nested between two long and 
bulky behenate chains. This caused severe steric hindrance, preventing the 
formation of extensive hydrogen bonding with the carbonyl groups of PVP/VA 
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Figure D14. FTIR spectra of (A) unprocessed CA, PVP/VA, their physical mixture 
and spray-congealed CA-PVP/VA SLMs; (B) unprocessed CA, EC, their physical 
mixture and spray-congealed CA-EC SLMs; (C) unprocessed SA, PVP/VA, their 
physical mixture and spray-congealed SA-PVP/VA SLMs; (D) unprocessed SA, EC, 
their physical mixture and spray-congealed SA-EC SLMs; (E) unprocessed GB, 
PVP/VA, their physical mixture and spray-congealed GB-PVP/VA SLMs and (F) 
unprocessed GB, EC, their physical mixture and spray-congealed GB-EC SLMs. 
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D2.4.   Characteristics of the spray-congealed microparticles produced 
from the binary and ternary formulations 
 
The binary and ternary formulations were spray-congealed to obtain 
SLMs. These SLMs were then subjected to a series of characterization studies. 
 
D2.4.1.  Total yields and useful yields 
 
The yields of all the formulations were generally high, with useful yields 
greater than 70 % while total yields exceeded 80 % (Table D9). The product 
losses were mainly attributed to adherence of the microparticles to the chamber 
wall and generation of fines (< 10 µm) which were collected in the cyclone at 
the air exhaust system. Various concentrations of the polymeric additive, 
ranging from 0 to 10 %, w/w, were combined with the respective lipid-based 
materials. Not all formulations were successfully spray-congealed; for the 
binary systems, PVP/VA could only be incorporated up to 7.5 %, w/w and 2.5 
%, w/w in SA and GB respectively, and EC up to 5 %, w/w for CA and SA 
and 2.5 %, w/w for GB; For the ternary systems containing drug, PVP/VA 
could be incorporated up to 7.5 %, w/w in GB, and EC up to 7.5 %, w/w in CA 
or SA and 2.5 %, w/w in GB. Beyond the stated concentrations for either 
polymeric additive, the molten mixtures became too viscous for the purpose of 
spray congealing. The high viscosities hindered feed delivery to the atomizer 
and may cause gradual congelation of the feed in the tubing and clog the spray 




For the binary system, the addition of PVP/VA had little effect on 
changing the total yields of the formulations for all three lipids (p>0.05). 
However, it significantly increased the useful yields of CA formulations 
(p<0.05) but not of SA- (p>0.05) and GB (p>0.05) formulations. EC had 
similar effects as PVP/VA on both the total yields and useful yields of all three 
lipid systems. For the ternary system, the addition of PVP/VA did not impact 
significantly on the total yields of SA-based SLMs (p>0.05). It reduced the 
total yields of CA-based SLMs (p=0.01) but increased the total yields of GB-
based SLMs (p<0.01). With regards to the useful yields, the addition of 
PVP/VA led to an increase for the GB-based SLMs (p<0.01) but had no effect 
on the other two lipids. On the other hand, EC had no significant effects on 
either the total or useful yields of any of the three lipid matrix materials.  
 
D2.4.2.  Median particle size 
 
Particle size distribution of the useful yield fraction was determined and 
found to be non-parametric in nature for all the formulations. Therefore, 
median sizes of the microparticles were reported (Table D9). For the binary 
systems, increasing PVP/VA or EC concentration significantly increased the 
median particle size of the CA (p<0.05) and SA (p<0.01) but not the GB 
(p>0.05) formulations. For CA, when the concentration of PVP/VA was 
increased from 0 to 5 %, w/w, there was about 50 % increase in microparticle 
size from 113 to 170 μm. The effect of EC was similar to that of PVP/VA, 
increasing microparticle size by 45 % at 5 %, w/w, EC. For SA, PVP/VA only 
caused a 22 % size enlargement at 5 %, w/w, while EC resulted in a 56 % 
enlargement at the same concentration. Due to the limited number of 
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formulations that could be successfully spray-congealed, the size effect of the 
polymeric additives on GB formulations could not be conclusively determined. 
Nevertheless, there was slight decrease in size with 2.5 %, w/w EC although 
the decrease in size was not found to be statistically significant. 
 
The ternary systems showed broadly similar trends as the binary systems 
(Table D9). For CA- and SA-based formulations of the ternary systems, 
increasing polymeric additive concentrations invariably led to larger SLM 
median sizes (p<0.01). This is attributed to the viscosity-enhancing ability of 
both PVP/VA and EC polymeric additives in the melts, which was 
concentration dependent and is shown in Table D10. This concentration-
dependent viscosity enhancing behaviour of polymeric additives is equally 
applicable for the above-mentioned binary lipid-polymer systems. For the 
ternary systems, 10 %, w/w of PVP/VA raised the viscosity of CA- or SA-
based formulations by more than 4-folds while 7.5 %, w/w of EC increased it 
by 7-folds or more. GB-based formulations experienced a statistically 
significant increase in size with the addition of PVP/VA (p<0.01) although the 
absolute increase in median size was small (Table D9). Additionally, the sole 
formulation containing EC did not show any significant size increase (p=0.50). 
This was likely due to the fact that either of the two polymeric additives was 
unable to enhance the viscosity of GB-based formulations to as large an extent 
as compared to the former two lipids. A possible reason for this was the 





Table D9. Useful yield, total yield and median particle size of binary and ternary spray-congealed 
formulations. 
 
















CA 100 (control) 78.3 ± 2.3 88.7 ± 6.0 113.3 ± 3.5 76.5 ± 2.5 91.2 ± 3.0 93.6 ± 1.5 
CA 97.5 PVP/VA 2.5 74.1 ± 8.6 91.2 ± 5.5 125.5 ± 3.0 77.6 ± 0.8 84.6 ± 0.4 120.8 ± 2.7 
CA 95 PVP/VA 5 77.4 ± 4.0 85.9 ± 5.1 170.0 ± 15.1 78.6 ± 0.3 84.3 ± 0.6 128.5 ± 2.6 
CA 92.5 PVP/VA 7.5 80.5 ± 2.3 87.0 ± 2.6 176.3 ± 13.2 78.8 ± 1.9 81.4 ± 2.7 139.7 ± 1.7 
CA 90 PVP/VA 10 88.7 ± 0.7 93.6 ± 0.7 187.6 ± 6.0 80.0 ± 0.6 82.6 ±  1.6 158.6 ± 4.4 
CA 97.5 EC 2.5 81.8 ± 1.1 92.2 ± 1.5 152.8 ± 26.9 71.5 ± 3.4 91.2 ± 8.0 122.7 ± 0.3 
CA 95 EC 5 88.1 ± 5.2 93.5 ± 4.2 163.8 ± 4.1 77.6 ± 3.4 87.0 ± 0.9 146.7 ± 1.9 
CA 92.5 EC 7.5** ---------------------N/A------------------- 78.5 ± 0.9 86.5± 1.3 170.1 ± 2.8 
SA 100 (control) 80.0 ± 6.8 92.5 ± 2.9 112.0 ± 12.9 83.3 ± 2.1 94.8 ± 4.8 120.8 ± 2.3 
SA 97.5 PVP/VA 2.5 78.3 ± 0.1 92.3 ± 3.9 125.4 ± 5.6 85.0 ± 1.6 96.3 ± 2.4 128.8 ± 1.3 
SA 95 PVP/VA 5 80.1 ± 2.1 94.6 ± 1.3 136.8 ± 4.5 82.5 ± 6.7 92.1 ± 4.1 136.3 ± 6.2 
SA 92.5 PVP/VA 7.5 82.2 ± 1.3 94.2 ± 2.6 150.0 ± 1.9 85.1 ± 0.3 95.3 ± 1.6 144.6 ± 6.3 
SA 90 PVP/VA 10** ---------------------N/A------------------- 82.6 ± 1.9 93.5 ± 1.3 154.5 ± 4.4 
SA 97.5 EC 2.5 75.7 ± 2.4 90.0 ± 6.8 137.6 ± 1.6 78.4 ± 1.5 89.8 ± 1.6 131.8 ± 9.5 
SA 95 EC 5 81.2 ± 1.8 92.7 ± 1.8 174.9 ± 9.2 81.3 ± 2.2 92.5 ± 2.3 155.2 ± 3.5 
SA 92.5 EC 7.5** ---------------------N/A------------------- 81.3 ± 1.4 90.7 ± 1.3 163.3 ± 1.7 
GB 100 (control) 85.8 ± 3.8 90.3 ± 3.0 191.0 ± 23.5 77.3 ± 3.9 85.3 ± 3.8 159.6 ± 3.2 
GB 97.5 PVP/VA 2.5 82.6 ± 2.6 88.3 ± 1.8 193.5 ± 10.7 88.1 ± 1.1 95.2 ± 0.8 163.5 ± 0.3 
GB 95 PVP/VA 5 ---------------------N/A------------------- 92.6 ± 1.6 96.4 ± 2.3 163.6 ± 2.5 
GB 92.5 PVP/VA 7.5 ---------------------N/A------------------- 91.7 ± 5.5 96.1 ± 2.2 169.6 ± 3.0 
GB 97.5 EC 2.5 82.8 ± 4.0 90.7 ± 2.2 179.5 ± 3.5 81.3 ± 1.7 88.4 ± 3.0 156.6 ± 2.7 
± standard deviation; 
* Suffix numerals refer to the percentages by weight; 
**Formulations could not be spray congealed 
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Table D10. Viscosity values of ternary mixtures at their spraying temperatures of 
60°C (CA), 69°C (SA) and 86°C (GB) respectively. 
 
*Drug carrier 







14.28 ± 0.03 
CA 97.5 PVP/VA 2.5 21.03 ± 0.40 
CA 90 PVP/VA 10 56.52 ± 0.01 
CA 97.5 EC 2.5 35.04 ± 0.35 
CA 92.5 EC 7.5 148.5 ± 0.4 
   
SA 100 
69 
13.87 ± 0.09 
SA 97.5 PVP/VA 2.5 20.39 ± 0.02 
SA 90 PVP/VA 10 59.94 ± 1.53 
SA 97.5 EC 2.5 31.56 ± 0.10 
SA 97.5 EC 7.5 109.3 ± 0.7 
   
GB 100 
86 
31.56 ± 0.17 
GB 97.5 PVP/VA 2.5 44.70 ± 0.46 
GB 92.5 PVP/VA 7.5 84.58 ± 0.86 
GB 97.5 EC 2.5 57.98 ± 0.49 
* Suffix numerals refer to the percentages by weight; ± standard deviations 
 
D2.5. Correlation of Tp and viscosity with median particle size 
 
For the binary and ternary formulations of CA or SA, good linear 
relationships were obtained between Tp and median particle size (Figures 
D15A-B, R
2
 = 0.833-0.992). Within each series of formulations, lower Tp 
values corresponded to larger particle sizes. As the number of GB formulations 
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successfully spray-congealed was limited, no conclusive correlation could be 
elicited. 
 
It was of interest to determine if the above correlations were independent 
of the formulation type. Hence, the Tp values of all the formulations were 
plotted against the corresponding resultant SLMs‘ median particle sizes. A 
clear linear relationship was observed with a correlation coefficient of 0.853, 
indicating a good correlation which was independent of the formulations 
(Figure D16). This is notable, considering that the formulations ranged from 
pure lipids to binary lipid-polymer and ternary lipid-polymer-drug systems. 
 
Viscosity values of all formulations at 90°C were also plotted against the 
spray-congealed products‘ corresponding median sizes. It is challenging to 
choose a representative temperature for the viscosity values as the 3 series of 
formulations had vastly different melting points (CA, 50°C; SA, 59°C; GB, 
76°C). The temperature of 90°C was chosen because at this particular 
temperature, the rheograms of all formulations were already in the second 
phase as reflected in Figures D10 and D11. Comparing the plot of median size 
against Tp (Figure D16, R = 0.853) with the plot of median size against 
viscosity (Figure D17, R = 0.754), it is clear that Tp showed better correlation 
with the microparticle size. Furthermore, the use of Tp avoided the difficulty 


































Figure D15. Relationship of microparticle size with Tp value for (A) binary formulations and 
(B) ternary formulations. Data for GB formulations were not presented as there were only 2 data 
points (Table D9). 
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Figure D17. Graph of median size of microparticles against viscosity values at 90°C 
for all formulations. 
 
y = -0.0172x + 188.94 
R² = 0.727; R = 0.853 
 
y = 1142.8x + 118.45 




D2.6.  Discussion 
 
D2.6.1.  Effect of polymeric additives on Tp values of lipid formulations 
 
A biexponential relationship between viscosity and temperature was 
exhibited by all the formulations composed of lipid-based material and 
polymeric additive, with or without drug. This observation substantiated earlier 
findings that the rheograms of lipid-based formulations were characterized by 
2 phases connected by a transition point. Consequently, Tp values were 
obtainable for all of the formulations studied. 
 
Addition of PVP/VA or EC invariably resulted in the lowering of Tp 
values in a concentration-dependent manner for both binary and ternary 
systems. Hence, these polymeric additives may be employed to adjust the Tp 
values of lipid-based formulations. The lowering of Tp was especially marked 
for CA and SA, and less so for GB. This is probably due to the lower intrinsic 
viscosity of CA and SA compared to GB. Additionally, the effect of EC in 
lowering Tp was larger than that of PVP/VA. NMR spectroscopy revealed that 
CA and GB could interact with the two polymeric additives via hydrogen 
bonding. It also showed that EC formed more extensive hydrogen bonds with 
the above lipids, which corroborated with the rheological findings. FTIR 
spectroscopy generally supported the NMR data, except that in the case of GB, 
the hydrogen bonding with both polymeric additives was found to be less 
significant compared to that of CA, highlighting that hydrogen bonding was 
unlikely to account for most of the viscosity enhancement brought about by the 
polymeric additives. Notwithstanding, the increase in viscosity brought about 
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by both polymeric additives can be attributed in part to an increase in hydrogen 
bonding, in addition to basic van der Waals‘ forces of attraction. 
 
In the case of SA, no evidence of hydrogen bonding with PVP/VA or EC 
could be detected. This was not surprising, considering that SA had been 
widely reported to exist as hydrogen-bonded dimers
194,199
. As such, the 
interaction between the two polymeric additives and SA is believed to be 
predominantly by van der Waals‘ forces of attraction.   
 
The findings discussed had focused on the rheological attributes of the 
formulations when molten but of great relevance too were the solid state 
characteristics of the spray-congealed products. These will be further 
elaborated in Part D3. 
 
D2.6.2.  Production of spray-congealed solid lipid microparticles from 
binary and ternary formulations 
 
High yields of spray-congealed microparticles were obtained for all the 
lipid-based formulations studied. For spray congealation, the drug and/or 
additives may be dissolved or dispersed in the molten lipid matrix material to 
form a molten mixture of suitable viscosity for atomization into a cold 
chamber. The spray congealing process was relatively easy to carry out and 
high production yields were achieved. Additionally, the microparticles 
produced were discrete, dense, highly spherical and possessed good flow 
properties, rendering them ideal for secondary blending into feeds for tableting 
or capsule filling. However, one limitation encountered pertains to the 
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relatively low concentration (≤ 10 %, w/w) of PVP/VA or EC that could be 
incorporated with the various lipids to prevent increase in viscosity to levels 
that render the molten liquid unsuitable for atomization. Interestingly, the 
addition of IBU countered the viscosity-enhancing effect of the polymeric 
additives, thereby allowed higher concentrations of the additives to be used. 
 
D2.6.3.  Application of Tp as a predictor of spray-congealed microparticle 
size produced from lipid-based formulations with/without 
polymeric additive and drug 
 
From the studies in Part D1, it was found that Tp values could be used to 
predict the median size of spray-congealed microparticles produced from lipid-
based materials of diverse chemical classes and properties. The results of Part 
D2 further show this application of Tp to lipid-based formulations comprising 
PVP/VA or EC with/without IBU. Tp showed better correlation with 
microparticle size than viscosity for all the formulations studied. Tp is 
therefore useful as a rheological physicochemical parameter for prediction of 
resultant spray-congealed microparticle size. 
 
D2.7.  Conclusion of Part D2 
 
Both IBU and polymeric additives, PVP/VA and EC, were found 
amenable as additives to form molten lipid-based formulations of CA, SA or 
GB. Both components formed clear mixtures with the lipid-based materials. 
Addition of PVP/VA or EC increased viscosity but lowered Tp value in a 
concentration-dependent manner, with EC exerting greater effects. This 
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outcome was likely due to increased intermolecular interactions such as 
hydrogen bonding as in the case of CA and a lesser extent for GB. The 
addition of IBU produced opposite effects on viscosity, thus enabling higher 
concentrations of the polymeric additives to be used without elevating the 
viscosity to levels unsuitable for spray-congealation. It was likely that IBU had 
disrupted the lipid-lipid and lipid-polymer intermolecular interactions via a 
‗lubricating‘ effect. IBU was also determined to have minimal interaction with 
either additive. When the binary and ternary formulations were spray-
congealed, high yields of good quality microparticles were obtained. Tp 
showed better correlation with spray-congealed microparticle size than 
viscosity, establishing Tp as a useful rheological parameter for predicting 















Part D3. Drug-matrix miscibility and solid state characteristics of 
unprocessed materials and spray-congealed lipid matrix 
 
The drastic temperature change that occurs during the spray congealing 
process can lead to polymorphic transitions of the drug and/or lipid matrix 
material. This is a great concern in drug formulation as it can affect the 
stability and drug release profile of the product. 
 
The objective of Part D3 was to investigate drug-matrix miscibility and the 
influence of spray congealing, as well as additives , on the solid state 
characteristics of the model drug (IBU) and lipid matrix materials (CA, SA and 
GB) using a combination of calorimetric and spectroscopic techniques. 
 
D3.  Results 
 
D3.1.  Determination of drug-matrix miscibility 
 
D3.1.1.  Thermal analysis of drug lipid casts 
 
The presence of solute in a matrix is able to depress the melting point of 
the matrix in a colligative manner, i.e. the degree of depression is proportional 
to the concentration of solute. When a molecularly dispersed solute in a solid 
matrix exceeds its solubility limit in the matrix, it will precipitate or crystallize 
out as discrete particles or crystals, forming a solid dispersion. Determining the 
solubility of IBU within solid lipid by observing the melting point depression 
of the solid lipid caused by the solubilized IBU and thereafter determining the 
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solubility limit of IBU in the solid matrix by the preparation of drug-lipid casts 
could provide the means to interpret results obtained from other techniques. 
The melting points of binary drug-lipid casts containing IBU in increasing 
concentrations were assessed by DSC, through which the melting point 
depression of the lipid and solubility limit of IBU in CA, SA and GB solid 
lipid matrices were derived.  
 
Representative DSC thermograms of the various drug-lipid casts are 
shown in the appendix (Figures H1 – H3). For CA, with 0 to 50 %, w/w of 
IBU, only one melting endotherm was observed (Figure H1). It corresponded 
to the melting of the matrix. A depression from 51.4°C to 44.7°C was observed 
when 10 % IBU was present (Figure D18). However, increasing IBU 
concentration further did not bring about any additional depression in the 
melting point of CA, indicating that IBU had a solubility of less than 10 % in 
solid CA and existed as a dispersion within solid CA above this concentration. 
When the CA melted at about 46°C (onset of melting), the dispersed IBU 
dissolved in the molten CA, accounting for the absence of the IBU melting 
peak (Figure H1). At 60 %, w/w of IBU, an additional melting peak was 
observed at 60.8°C. This peak is attributed to the melting of IBU and indicates 
that at this concentration of IBU (i.e. 60 %) the solubility of IBU in the molten 
CA had been exceeded. This higher melting peak increased with decreasing 
CA concentration, indicating a reciprocal colligative effect of CA on IBU, 
which was now acting as the solvent. However, the melting peak of CA was 
still observable at 90 %, w/w IBU, suggesting that IBU was unable to fully 




Similarly, only one melting endotherm was observed for SA with IBU 
concentrations from 0 to 50 %, w/w. It corresponded to the melting of the 
matrix. However, the melting point of SA continued to be depressed at IBU 
concentrations above 10 %, w/w and levelled off around 48°C at 30 %, w/w of 
IBU (Figure D18). This demonstrates the greater solubility of IBU in SA 
compared to CA. Similarly, the concentration of IBU at 60 %, w/w exceeded 
the solubility of IBU in the molten SA and the melting peak of IBU appeared. 
Interestingly, the melting peak of SA disappeared with 90 %, w/w of IBU, 
suggesting that IBU was able to fully solubilize 10 %, w/w SA.  
 
For GB, the findings were similar to those of SA. Melting point 
depression of GB progressed to 30 %, w/w of IBU and levelled off thereafter 
at about 60°C. IBU was soluble in solid GB up to 30 %, w/w, similar to SA. 
Beyond 30 %, w/w of IBU, the melting temperature of GB remained relatively 
constant (Figure D18). The melting peak of IBU was not observed until it 
accounted for 70 %, w/w where it appeared after the melting of GB was 
completed, resulting in thermograms with two melting peaks for 70 %, 80 % 
and 90 %, w/w of IBU (Figure H3, Appendix). The melting peak of GB was 
observed even at 90 %, w/w IBU, indicating that IBU was not able to dissolve 
even 10 %, w/w GB.  
 
In light of the above results, 20 %, w/w IBU was chosen as the 
concentration to be used in the subsequent investigations, where the CA-IBU 
mixture would exist as a solid dispersion whereas the SA-IBU and GB-IBU 




Figure D18. Plot of mean melting temperatures of lipid-drug casts with increasing 
concentrations of IBU. 
 
D3.1.2.  Scanning electron microscopy 
 
SEM was utilized to study the surface morphology of drug crystals, 
spray-congealed blank SLMs and drug-loaded SLMs. As shown in Figure 
D19A, IBU existed as elongated, prismatic plate-shaped crystals of various 
sizes as reported elsewhere
200
. Spray-congealed SLMs produced from all the 
formulations were generally spherical, non-aggregated and dense. SLMs 
composed of only pure lipid matrix material (blank SLMs) had generally 
smooth surfaces, especially for SA (Figure D19C). Blank CA-based SLMs 
(Figure D19B) exhibited a slightly undulating surface morphology, whereas 
those of GB (Figure D19D) presented with some evidence of plate-like 
structures on the surface. 
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The addition of 20 %, w/w IBU produced significant changes on the 
surface of CA and GB-based SLMs. Specifically, numerous rough 
outcroppings appeared on the surface of CA-based SLMs (Figure D19E) while 
the surface of GB SLMs smoothened considerably (Figure D19G). SA-based 
SLMs exhibited no significant changes (Figure D19F). The outcroppings 
suggest that IBU had not dissolved but precipitated out upon the congealing of 
CA to form a dispersion of IBU in the solid CA matrix. This finding was 
supported by the earlier thermal analysis of the drug-lipid casts which showed 
that 20 %, w/w IBU had exceeded the solubility of IBU in solid CA matrix 
(Figure D18). Conversely, the surface smoothness and lack of surface outcrops 
or precipitates suggests that IBU was efficiently entrapped as solute within the 
SA and GB-based SLMs. This observation was consistent with the earlier 
thermal analysis, which showed that 20 %, w/w of IBU existed as a solid 




The addition of PVP/VA or EC produced a small but observable 
smoothening of the CA microparticle surface (Figures D19H, I). Interestingly, 
no aggregates of polymer were observed and the presence of polymer appeared 
to slightly decrease the size of the IBU precipitates as well. For SA, the 
characteristic smooth surface was lost when either PVP/VA or EC was added 
(Figures D19J, K). Intuitively, this phenomenon suggests that the additives 
were not dissolved within the solid microparticles but rather, dispersed within 
it. The surface morphology of GB microparticles did not appear to change 
much with the addition of PVP/VA or EC (Figures D19L, M), except for the 
presence of small flossy strands. In Part D2 of this study, the melts with 
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PVP/VA or EC were found to be more viscous and had accounted for the 




Figure D19. SEM images of (A) IBU; (B) blank CA-based SLM; (C) blank SA-
based SLM; (D) blank GB-based SLM; 20 %, w/w IBU-loaded spray-congealed 
(E) CA-based SLM; (F) SA-based SLM; (G) GB-based SLM; (H) CA-based 
SLM with 5 %, w/w PVP/VA; (I) CA-based SLM with 5 %, w/w EC; (J) SA-
based SLM with 5 %, w/w PVP/VA; (K) SA-based SLM with 5 %, w/w EC; (L) 
GB-based SLM with 5 %, w/w PVP/VA and (M) GB-based SLM with 2.5 %, 
w/w EC. [Note: Images were captured at different magnifications to better depict 
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D3.1.3.  Fourier transform-infrared spectroscopy 
 
Figure D20 showed the FTIR spectra of unprocessed IBU, lipid matrix 
materials (CA, SA and GB), their physical mixtures and spray-congealed IBU-
loaded SLMs. 
 
The prominent C=O stretch of the carboxylic acid moiety of IBU was 
located at 1708.14 cm
-1 
(Figure D20A). A few weak absorption peaks were 
observed at the 3000-2600 cm
-1
 region corresponding to C-H stretches and also 
contained a very wide absorption band superimposed on the C-H stretches. 
This is characteristic of hydrogen-bonded dimers of carboxylic acids, therefore 





      
 
 























     
 
 











     
 
 














Figure D20. FTIR spectra of unprocessed IBU, lipid matrix materials (CA, SA and 




Spray-congealed CA, SA and GB products all exhibited strong 
absorptions in the 2960-2840 cm
-1
 range corresponding to C-H stretches of 
their long carbon chains. Additionally, the spectrum of CA contained O-H 
stretches at 3323.06 cm
-1
 and 3225.31 cm
-1 
(Figure D20A), while those of GB 
(Figure D20C) may be found as a wide absorption centred at 3420.85 cm
-1
. SA 
exhibited a strong C=O stretch absorption at 1697.96 cm
-1
 (Figure D20B), 
while that of GB is centred at 1736.00 cm
-1 
(Figure D20C). Additionally, SA 
showed a similar broad O-H band as IBU, indicating that SA also exists as 
hydrogen-bonded dimers. The FTIR spectrum of spray-congealed CA 
containing IBU greatly resembled that of its physical mixture, suggesting that 
hydrogen bonding between CA and IBU is minimal. The spectrum of spray-
congealed SA with IBU was superimposable on that of its physical mixture, 
and as such also indicated the absence of hydrogen bond formation between 
IBU and SA. Lastly, the spectrum of spray-congealed GB with ibuprofen 
showed a significant change in the C=O absorption band with a shift from 
1736.00 to 1719.59 cm
-1
. At the same time, the O-H stretch of GB showed a 
shift to 3444.05 cm
-1
. These observations suggest a small degree of hydrogen 
bonding of GB with ibuprofen. 
 





, corresponding to the acetate and pyrrolidone groups respectively 
(Figure D20D). The broad peak at 3444.61 cm
-1
 was due to residual water as 
PVP/VA is slightly hygroscopic. Unlike the case of IBU and CA, the spectrum 
of spray-congealed CA microparticles containing 10 %, w/w PVP/VA showed 
significant differences from its corresponding physical mixture (Figure D20D). 





. Concurrently, the C=O stretches of PVP/VA had shifted to 
1719.38 cm
-1
 and 1663.81 cm
-1
 along with a change in peak intensity and 
shape. These changes suggest significant interactions between the hydroxyl 
groups of CA and the carbonyl groups of PVP/VA due to extensive hydrogen 
bonding. 
 
The spectrum of EC was dominated by a broad complex band between 
1200 cm
-1
 to 900 cm
-1
, likely composing of the overlapping of several C-O 
bending absorptions (Figure D20E). When spray-congealed with CA, the two 
O-H stretches of CA also exhibited the same phenomenon as with PVP/VA 
due to hydrogen bonding with EC. The appearance of a small absorption at ca. 
1120 cm
-1
 also indicates the formation of hydrogen bonds between the 
hydroxyl moiety of CA and the ether oxygens of EC. 
 
It was noted that the spectra for the physical mixture of SA with 
PVP/VA and the spray-congealed SLMs were identical (Figure D20F). This 
was also the case for SA and EC (Figure D20G). Evidently, there appeared to 
be no hydrogen bonding between SA and either additive. Since SA exists as 
homodimers, the hydrogen bonding moieties of SA are locked in hydrogen 
bonds with itself, restricting the availability of hydrogen bonds to form 
between SA and PVP/VA or EC. 
 
The pyrrolidone C=O stretch of PVP/VA was poorly resolved from the 
C=O stretch of GB at 1735.92 cm
-1
 in the physical mixture, appearing as a 
minor distortion on the right side of the peak (Figure D20H). This is due to the 





the spectrum of the corresponding microparticles indicates hydrogen bond 
formation between GB and PVP/VA. For spray-congealed microparticles 
composed of GB and either polymeric additive, the broad O-H stretch band of 
GB showed relatively minor changes. It is not unexpected that the hydrogen 
bonding between GB and PVP/VA is limited as GB is a very large diglyceride, 
with a sole hydroxyl group nested between two long and bulky behenate 
chains. This results in severe steric hindrance, preventing the formation of 
strong hydrogen bonding with the carbonyl groups of PVP/VA or the ether and 
hydroxyl moieties of EC (Figure D20I).  
 
D3.1.4.  Hot stage light microscopy 
 
Hot stage light microscopy was carried out to optically examine the 
melting processes of 20 %, w/w IBU-loaded CA, SA and GB SLMs. A series 
of light microscope images was captured during the heating of spray-
congealed CA microparticles containing IBU (Figure D21). It was observed 
that upon the melting of CA, which started at 45°C, small reflective 
particulates were suspended in the molten matrix. These particulates rapidly 
dissolved into the molten matrix to form a clear homogeneous melt at about 
53°C. One such particulate can be clearly seen on the CA microparticle surface 
at 45°C (circled with broken line, Figure D21). Since it had been earlier 
established that IBU was not fully dissolved in solid CA at 20 %, w/w, it is 
reasonable to believe that these particulates were IBU precipitates. The melting 
of the lipid matrix began at 47°C for SA, with the molten matrix not showing 
any evidence of suspended IBU particulates. From the series of light 
microscope images captured from the video recording of the heating of spray-
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congealed GB microparticles containing 20 %, w/w IBU, two distinct melting 
events were observed. The microparticles showed the first sign of melting at 
60°C (circled with continuous line, Figure D21). This was complete by around 
62°C. Subsequently, the next melting event occurred at 70°C, eventually 
forming a clear liquid with no suspended particulates by 71°C. These two 
melting events coincided with the two melting temperatures observed in the 
analysis of GB microparticles with 20 %, w/w of IBU. These findings agree 
well with the DSC results, substantiating that IBU existed as a dispersion 
within solid CA and as a solution within solid SA or GB at a concentration of 




Figure D21. Hot stage microscopy images captured at different phases of melting of 20 %, w/w 








D3.2. Characterization of solid state of IBU and IBU-loaded solid lipid 
microparticles and the influence of PVP/VA and EC 
 
D3.2.1.  Thermal analysis 
 
Figure D22 and Table D11 showed the melting endotherms and melting 
points of the lipid matrix materials (CA, SA and GB), spray-congealed blank 
SLMs, physical mixtures of matrix materials and IBU and 20 %, w/w IBU-
loaded spray-congealed SLMs. The melting endotherm of IBU (m.p. ca. 76°C) 
was absent from the DSC thermograms of all spray-congealed formulations 
with 20 %, w/w IBU (Figures D22A, B, C). Although it is possible that this is 
due to the amorphization of IBU in the lipid matrices, the melting endotherm 
of IBU was not observed in the DSC curves of the corresponding physical 
mixtures either. This suggests that IBU could have dissolved in the molten 





Spray congealing CA together with IBU led to a depression in the 
melting point of CA from 50.9°C to 46.2°C (Figure D22A, Table D11). This is 
in agreement with the results from thermal analyses of the binary drug-lipid 
casts (Figure D18). The physical mixture showed some distortion in the 
melting endotherm of the matrix, and this may be explained as a partial 




Spray-congealed SA-based SLMs containing IBU also showed a 
depression of the melting point of SA from 56.8°C to 53.8°C (Figure D22B, 
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Table D11). Similarly, the physical mixture exhibited a distortion in the 
melting endotherm due to the partial dissolution of IBU in the melting SA
204
. 
With 7.5 % PVP/VA or EC, the melting endotherm of both CA and SA 
remained relatively unchanged (Figures D22D, E). Only thermograms of 
formulations containing the highest possible concentrations of either polymer 
were presented as these would represent the greatest possible influence on the 
melting point of the unprocessed lipids. 
 
The melting peak of GB was broad (compared to CA and SA) and 
aligned with the composition of the Compritol 888 ATO brand of GB, which 
consisted of mono-, di- and tri-glycerides in a mixture dominated by the 
diglyceride
153
. The melting point centred at 75.8°C, which corresponded to the 
stable β‘-polymorph of GB as indicated by XRD studies. The physical mixture 
of GB and IBU showed a broad melting peak with some degree of melting 
point depression that could be attributed to the partial dissolution of IBU in GB 
during the heating process. In contrast, the melting endotherm of the IBU-
loaded spray-congealed GB microparticles showed two poorly resolved peaks 
centred at 60.4°C and 66.9°C (Figure D22C, Table D11). The presence of two 
melting points for the microparticles suggests the possibility of two coexisting 
polymorphs of GB
205
, which is highly possible when a lipid of large molecular 
weight is spray-congealed
206-209
. Notably, both melting points were 
significantly depressed compared to that of unprocessed GB (75.8°C) owing to 
the presence of 20 %, w/w of IBU. The higher melting point also corresponded 





No distinct melting peaks were observed for PVP/VA and EC. 
Comparison of the thermograms of spray-congealed GB with and without 
these polymeric additives revealed that the two melting peaks centred at 
60.4°C and 66.9°C had not shifted despite significant changes in their relative 
intensities (Figure D22F). This implies that PVP/VA and EC had formed solid 
dispersions with GB, which would have minimal effects on depressing the 
melting points of GB. PVP/VA appeared to favor the formation of the higher 
melting point polymorph than EC since the intensity of the higher melting 
polymorph was greater than the lower melting polymorph. Moreover, the 
higher melting peak was more pronounced in intensity for the GB-IBU-
PVP/VA formulation whereas the relative intensities of the two melting peaks 
were similar for the GB-IBU-EC and the GB-IBU formulations. 
 
Table D11. Melting points of unprocessed lipid matrix materials, spray-congealed 
blank SLMs, physical mixtures (matrix: drug; 80:20) and 20 %, w/w IBU-loaded 
spray-congealed SLMs. 
 
Formulations Melting point (°C) 
CA SA GB 
Unprocessed lipid matrix materials 51.3 57.0 76.3 
Spray-congealed blank SLMs 50.9 56.8 75.8 
Physical mixture (matrix: drug; 80:20) 50.4 56.0 68.6 



















































Figure D22. DSC thermograms of 1(A) CA; (B) SA and (C) GB unprocessed 
matrix, blank spray-congealed SLMs, 20 %, w/w IBU-loaded SLMs and 
physical mixture comprising 20 %, w/w IBU. IBU-loaded spray-congealed 




D3.2.2.  Powder X-ray diffraction studies 
 
CA exhibited the same Bragg peaks before and after spray congealing 
(Figure D23A). The intense Bragg peak at 21.8° and a weaker one at 24.8° 
corresponded to d-spacings of 4.07Å and 3.59 Å respectively, indicating that 
CA existed as monoclinic crystals of the γ-polymorph210,211. CA is a relatively 
small lipid consisting of only 16 carbons, which explains the lack of 
polymorphism induced by rapid cooling when spray-congealed
212
. This also 
applied to SA, which produced nearly superimposable diffractograms before 
and after spray congealing (Figure D23B). In this case, an intense Bragg peak 
was found at 21.5° and a weaker one at 24.0°, with d-spacings of 4.13Å and 
3.70Å respectively corresponding to the stable B-polymorph of SA, which has 




Unprocessed GB exhibited broad Bragg peaks at 21.3° and 23.5°, with d-
spacings of 4.17Å and 3.78Å respectively (Figure D23C). These spacings 
alluded to the existence of β‘-polymorph, which is organized in an 
orthorhombic crystal subcell structure
145,153,161
. Upon spray congealing, the 
rapid cooling caused the rapid crystallization of GB into an unstable α-
polymorph, characterized by a single broad Bragg peak at 21.4° (d-spacing of 
4.15Å). This unstable α-polymorph reverted to the more stable β‘- polymorph 
over the course of a year. 
 
IBU crystals exhibited multiple sharp peaks typical of highly crystalline 
substances (Figure D23G). Intense Bragg peaks were observed at 12.2°, 16.5°, 
16.8°, 17.6°, 19.1°, 20.2°, and 22.4°. Spray congealing of CA with IBU 
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produced some changes in the crystal structure of IBU but not in the CA 
matrix itself. The Bragg peaks assigned to spray-congealed CA were 
superimposable over those of its physical mixture and did not exhibit any 
changes over the course of one year. However, the Bragg peaks of IBU as seen 
in the X-ray diffractogram of 20 %, w/w IBU-loaded CA-based SLMs 
underwent a large change. Specifically, the sharp Bragg peaks had given way 
to broader peaks at 16.6°, 17.7° and 20.2° (Figure D23D). The disappearance 
of sharp peaks and appearance of fewer, broader peaks suggest a significant 
loss of crystallinity in IBU to a partially amorphous state
204,215
, with the 
presence of drug-matrix interactions
216
. This state was highly stable within the 
matrix as it persisted without any further changes for up to a year of storage. 
 
Spray congealing of SA with IBU showed similar changes in the crystal 
structure of IBU, with the same 3 broad Bragg peaks appearing in the X-ray 
diffractograms of the SLMs. The lipid matrix itself showed negligible 
difference from the physical mixture and was stable for up to a year (Figure 
D23E). Spray congealing GB with IBU led to congealing of GB into the α-
polymorph as it did when sprayed by itself with the appearance of the 3 broad 
peaks as with SA. The unstable α-polymorph of GB rapidly reverted to the 
more stable β‘-polymorph within 1 month of storage. While the lipid matrix 
converted to the more stable β‘ polymorph, IBU did not recover its 
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Figure D23. XRD diffraction patterns of (A) unprocessed CA and freshly spray-
congealed CA blank SLMs; (B) unprocessed SA and freshly spray-congealed SA 
blank SLMs; (C) unprocessed GB, freshly spray-congealed GB blank SLMs and 
GB blank SLMs after storage for 1 year at 25°C; (D) 20 %, w/w IBU-loaded CA-
based SLMs; (E) 20 %, w/w IBU-loaded SA-based SLMs; (F) 20 %, w/w IBU-
loaded GB SLMs and the effect of aging (day zero, 1 week, 1 month, 3 months 
and 1 year) upon storage at 25°C and (G) unprocessed IBU. 
 
In the presence of both 2.5 %, w/w (Figure D24A) and 10 %, w/w of 
PVP/VA (Figure D24B), CA appeared to exhibit a peak shift with peaks at 
21.4° and 24.2° (d-spacings of 4.15Å and 3.67Å). These observations suggest 
a small expansion of the unit cell dimensions from the original d-spacings of 
4.07Å and 3.59Å instead of a true polymorphism
217
. Regardless, the CA 
crystals reorganized to the original dimensions as the peaks at 21.4° and 24.2° 
gave way to peaks at 21.8° and 24.8°, respectively. With a higher amount of 
PVP/VA, this reorganization was accelerated and completed in a month 
(Figure D24B). On the other hand, 2.5 %, w/w of PVP/VA slowed it to a year 
(Figure D24A). The expansion of unit cell dimensions caused by PVP/VA may 
be attributed to the formation of extensive H-bonds between CA and PVP/VA 
145 
 
during the rapid congealing process. Spray congealing of CA with 2.5 %, w/w 
(Figure D24C) or 7.5 %, w/w of EC (Figure D24D) produced Bragg peaks at 
21.4° and 24.2° as with PVP/VA. In the case of high EC content, the presence 
of the polymer retarded the contraction of the CA unit cells, as reorganization 
was incomplete even after a year (Figure D24D). Lower concentration of EC 
had a smaller effect as the stable unit cell dimensions were completely adopted 
within a year (Figure D24C). CA has been shown by NMR and FTIR to have 
extensive H-bonding capabilities with EC, similarly with PVP/VA. In both 
cases, the extensive H-bonding with the additives seemed to restrict molecular 
movements and reorganization capabilities. In stark contrast however, it was 
observed that higher EC concentration slowed down the contraction, while the 
reverse was true for PVP/VA. 
 
When SA was spray-congealed with either additive, strong Bragg peaks 
at 21.5° and 23.8° were observed, similar to those of spray-congealed blank 
SA. Essentially, SA did not undergo any form of change to its physical state in 
the presence of the additives, regardless of their concentrations used. The 
reason underlying this may be the relatively low degree of interaction between 
SA and the two additives, which is supported by FTIR findings earlier (Figures 
D24E, F, G, H).  
 
Spray congealing GB with 2.5 %, w/w (Figure D24I) or 7.5 %, w/w 
PVP/VA (Figure D24J) also resulted in the α-polymorph which reverted to the 
β‘-polymorph within 1 month for the lower PVP/VA concentration and 1 week 
for the higher PVP/VA concentration. This observation suggests that a higher 
concentration of PVP/VA accelerated the conversion of the unstable α-
146 
 
polymorph to the stable β‘-polymorph. The underlying cause is at present 
unknown. Conversely, in the presence of 2.5 %, w/w EC, the conversion of the 
α-polymorph to the stable β‘-polymorph was complete only at the end of 1 
year (Figure D24K). EC exerted a stabilizing effect on the α-polymorph, 
possibly by means of its large size which hindered the molecular 
rearrangement of GB. 
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Figure D24. XRD diffraction patterns of 20 %, w/w IBU-loaded (A, B, C, D) 
CA-based SLMs; (E, F, G, H) SA-based SLMs and (I, J, K) GB-based SLMs 
with various concentrations of PVP/VA and EC and the effect of aging (day zero, 
1 week, 1 month, 3 months and 1 year) with storage at 25°C. 
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D3.3.  Discussion 
 
In Part D3, three lipid matrix materials, CA, SA and GB and a model 
drug IBU were characterized for their solid state properties when spray-
congealed as SLMs. Properties studied included intermolecular interactions 
and the nature of the IBU-lipid solid mixtures, with and without the inclusion 
of polymeric additives, PVP/VA or EC. Polymorphic changes were also 
tracked for up to a year. 
 
Solid miscibility of IBU within CA, SA or GB matrix was investigated 
by conducting thermal analyses on drug-lipid casts. Given that the melting 
point depression of SA and GB continued until 30 %, w/w IBU whereas it 
levelled off beyond 10 %, w/w IBU in CA, it was inferred that both SA and 
GB could dissolve IBU to a greater extent. Through the plots, it was also 
possible to determine the cryoscopic constants of IBU in CA, SA and GB 
(gradient of the declining slope), with values of -0.679°C/ (%, w/w), -0.284°C/ 
(%, w/w) and -0.515 (%, w/w) respectively, representing the degree of 
depression of melting point for every increase in %, w/w of additive. IBU at 20 
%, w/w was chosen as the concentration to be incorporated into CA, SA and 
GB-based SLMs, as CA would be expected to form a two-phase solid 
dispersion with IBU while SA and GB would form one-phase solid solutions.  
 
All three lipids existed in their most stable polymorphic states before 
spray congealing. CA existed as the γ-polymorph, which is the stable 
monoclinic form for fatty alcohols with an even number of carbon atoms
212
; 
SA existed as the monoclinic B-polymorph
213,214
 and GB as the orthorhombic 
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β‘-polymorph145,153,161. Due to the heterogeneous nature of GB, it exhibited 
relatively broad Bragg peaks in the X-ray diffractogram as compared to CA 
and SA. It is prudent to note here that although the polymorphs are termed as 
α, β‘ and β, different symbols have been assigned to polymorphs of different 
lipids. The γ-polymorph of CA and the B-polymorph of SA are analogous to β. 
To reiterate, the most stable polymorph of GB is the β‘-polymorph and not the 
conventional β, due to its relative hetereogeneity. 
 
Upon spray congealing, CA and SA, being relatively smaller-sized lipid 
molecules, were able to rapidly reorganize back to their stable monoclinic 
polymorphs, bypassing the unstable polymorphic forms that usually resulted 
after very rapid cooling. The orthorhombic β‘-polymorph of GB invariably 
congealed first as the hexagonal α-polymorph, which was identified by means 
of its X-ray diffractogram showing a very broad single Bragg peak. This less 
stable polymorphic form rearranged itself into the more stable orthorhombic 
β‘-polymorph over the course of a month. GB consists of very large 
glycerides, with an average of 47 carbons per molecule (based on the major 
dibehenate component) and is therefore expected to require more time in its 
conversion to the stable polymorph unlike smaller molecular weight lipids
218
. 
The above findings underline an important concern when formulations 
employed contain complex lipids. Significant polymorphic changes in lipids 
may occur during processing, which may impact upon the physical stability of 
the formulation over time and the release profile of the encapsulated drug 
could be affected. GB, being a glyceride, has been widely used in sustained 
release formulations
219,220
. It has inherent problems associated with 
polymorphism
153,161,207
, the impact of which on drug release from spray-
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congealed solid lipid microparticles is not clear. On the other hand, CA and SA 
emerged as lipid carriers which exited the process as their stable polymorphs, 
thus avoiding potential concerns arising from product instability issues during 
storage or secondary processing, and represents a significant advantage over 
complex lipids for the production of SLMs. The diffractogram of unprocessed 
IBU showed multiple sharp and clearly defined peaks, which is typical of a 
crystalline material. However, these peaks were largely lost upon spray 
congealing with all 3 lipids, and the crystallinity of IBU did not recover over 
the course of a year, highlighting the ability of the lipid matrix materials in 
stabilizing the amorphous form of IBU.  
 
IBU was shown to form a solid dispersion when spray-congealed with 
CA, whereas it formed solid solutions with SA and GB. Numerous IBU 
precipitates were found on the surface of the CA microparticles. The IBU 
particles would likely be found dispersed within the microparticle interior as 
well. Solid dispersions exhibiting similar outcroppings of drug on the surfaces 
of microparticles had been observed with poloxamer 188 and Gelucire
203,221
. 
XRD analysis showed a significant loss of crystallinity of IBU after spray 
congealing with CA and notably even after 1 year of storage, this amorphous 
state of IBU was maintained by CA even as it existed as precipitates and was 
not molecularly dispersed within CA. 
 
While the surfaces of the IBU-loaded CA-based SLMs were rough, those 
of SA and GB exhibited very smooth surfaces, with no evidence of IBU 
precipitates. This observation is typical of a solid solution of drug within its 
matrix
95,201
 and is confirmative that in this case, IBU formed solid solutions 
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with SA and GB. Through XRD analyses, the major Bragg peaks exhibited by 
crystalline IBU disappeared upon spray congealing with SA and GB as well. In 
addition, significant melting-point depression caused by IBU also indicated 
that IBU had dissolved within the SA or GB matrices
222
. Importantly, these 
solid solutions of IBU with SA or GB did not experience phase separation, 
indicating the high stability of these two systems. As both SA and GB and IBU 
are generally hydrophobic (IBU exists as non-polar dimers), the compatible 
intermolecular forces of attraction are believed to be the driving forces behind 
the formation of such homogeneous mixtures. A similar solid solution 
formulation had been reported previously, comprising ketoprofen dissolved 




Despite the similarities between CA and SA in terms of molecular 
weight, molecular shape as well as the presence of a polar moiety, their 
behaviour towards spray congealing with IBU was greatly dissimilar. This may 
be attributed to the conventional knowledge that organic acids tend to exist as 
homodimers
223,224
, and was further evidenced by the broad acid O-H stretches 
in the FTIR spectra of SA and IBU. In fact, dimer formation between SA 
molecules had been shown to impair hydrogen bonding with felodipine as the 
carboxyl groups of SA were no longer free
83
. Since the polar groups of IBU 
and SA were engaged in homodimer hydrogen bonding, the homodimers 
essentially became non-polar. IBU and SA thus interacted mainly via van der 
Waals‘ forces of attraction between homodimers, and this similar magnitude of 
the ―inter-dimer‖ forces of attraction allowed a like-like interaction, resulting 
in the formation of a solid solution. CA, on the other hand, has a free hydroxyl 
group which forms hydrogen bonds in a loose molecular network. The 
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relatively strong and exothermic hydrogen bonds will be exclusive towards 
non-polar entities such as IBU dimers. This lack of interaction between CA 
and IBU was once again evident in the FTIR spectra recorded, and as such, 
IBU existed as a dispersion within spray-congealed CA microparticles at 20 %, 
w/w and had a lower solubility limit within CA as compared to SA. The 
interaction between IBU and the large non-polar GB molecules is believed to 
be analogous to that with SA dimers, consisting mainly of van der Waals‘ 
forces. IBU was thus also able to form a solid solution with GB. 
 
The addition of polymeric additives can have profound effects on the 
polymorphism of the lipid matrix materials. For example, the addition of the 
poloxamer to glyceryl palmitostearate was found to stabilize the lipid from 
further polymorphic changes
38
. The effects of PVP/VA and EC are however, 
currently not clearly understood. In this study, PVP/VA and EC were shown to 
expand the unit cell dimensions of CA when spray-congealed together, 
possibly due to extensive hydrogen bonding between CA and both additives as 
shown by FTIR and NMR studies. There were however no polymorphic 
changes found. Overall, EC was able to retard the reorganization of CA to its 
stable unit cell dimensions more than PVP/VA, and this may be attributed to a 
larger degree of hydrogen bonding with CA, but may also be in part due to the 
larger size of EC polymer chains compared to PVP/VA chains which impeded 
movement at the molecular level. 
  
The interaction of SA with the two additives proved to be unremarkable 
as SA immediately congealed into the most stable B-polymorph regardless of 
the concentration and type of additive. As mentioned earlier, SA exists as 
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dimers, which have lost the ability to form hydrogen bonds with either of the 
additives. The relatively poor degree of interaction between SA with either of 
the two polymeric additives may explain the lack of polymorphic changes.  
 
Despite the formation of solid dispersions of PVP/VA and EC with GB, 
the stability of GB polymorphs was profoundly affected by the presence of 
PVP/VA or EC as revealed by XRD. PVP/VA, at 7.5 %, w/w, accelerated the 
conversion of the unstable α-polymorph to the stable β‘-polymorph in less than 
a week. On the other hand, EC at 2.5 %, w/w stabilized the α-polymorph such 
that its conversion to the stable polymorph was complete only after one year. 
This stabilizing effect may be attributed to a partial embedding of the 
polymeric additive into the matrix
225
 or an interaction with the matrix via the 
small extent of hydrogen bonding as shown by NMR studies or van der Waals‘ 
interactions
226
. Notwithstanding, the effect of polymeric additives on the 
stability of lipid polymorphs is not clear and the contrasting findings here, 
albeit preliminary, highlight that there may be no straightforward 
generalization of their effects. As a final note, the addition of either additive 
had no bearing on the polymorphism of the encapsulated IBU. IBU remained 
in its amorphous state with no signs of recovery of its crystalline form for up to 
a year. 
 
D3.4.  Conclusion of Part D3 
 
The effects of spray congealing and polymeric additives on the solid 
state characteristics of CA, SA and GB were investigated by a combination of 
calorimetric and spectroscopic techniques. CA and SA are useful when a lipid 
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matrix that does not exhibit polymorphic changes in the product after spray 
congealing is desired. On the other hand, spray congealing resulted in GB 
polymorphic changes, which reverted back to the stable polymorphic form 
within a month. CA was found to incorporate 20 %, w/w IBU as a solid 
dispersion, while SA and GB formed solid solutions with IBU. Presence of 
polymeric additives expanded the unit cell dimensions of CA but has 
negligible effect on SA. Additives can also either speed up or slow down the 
polymorphic conversions in GB. Such additives may be useful as agents to 
either stabilize an unstable polymorph or to hasten its conversion to the stable 
polymorph. It would be interesting to investigate if polymorphism of GB 














Part D4: Drug release and other properties of spray-congealed IBU-
loaded solid lipid microparticles 
 
The hydrophobic nature of lipids can be exploited as lipid matrix systems to 
produce SLMs with the ultimate goal of achieving sustained drug delivery for 
drugs with short elimination half-lives. Despite the widespread and longtime 
use of lipids in various products and production processes by the food and 
pharmaceutical industries, there is still some gaps in knowledge about drug 
delivery from lipid-based formulations
1
. Thus, better understanding of the 
underlying drug release mechanisms of SLMs can facilitate improved 
formulation development and aid in achieving the desired drug release 
behaviour. 
 
The objective of Part D4 of the study was to investigate drug release from 
IBU-loaded SLMs produced by spray congealing using CA, SA or GB as lipid 
matrix material and PVP/VA or EC as matrix- and release-modifying agents. 
The SLMs produced were further characterized. The effects of lipid matrix 
type, polymeric additive type and concentration, microparticle size, drug-
matrix miscibility and matrix polymorphism on the drug release behaviour of 
IBU-loaded SLMs were analyzed. A combination of drug release modelling 
and post-dissolution SEM images were critically evaluated to provide 
complementary insights on the drug release mechanisms of the different types 






D4.  Results 
 
D4.1.   Characterization of spray-congealed IBU-loaded solid lipid 
microparticles produced from different lipids 
 
D4.1.1.  Drug content and drug entrapment efficiencies 
 
From Table D12, the assayed drug contents were found comparable to 
the theoretical drug content (20 %, w/w of SLMs) for all formulations. The 
encapsulation efficiency exceeded 90 %, with the exception of CA formulation 
with 2.5 %, w/w EC which was slightly lower, at 88 %. Generally, 
formulations containing PVP/VA showed slight increases in their respective 
EE (p<0.01), whereas those containing EC showed slight decreases (p<0.05). 
Nevertheless, it must be stressed that although the above variations were 
statistically significant, the EEs achieved in this study were still remarkably 
high. In the spray congealing process, the molten drug was dispersed or 
dissolved in the molten matrix material and the resultant mixture atomized to 
produce droplets that congealed to form SLMs. In this method, there was 
theoretically no loss of drug to the surrounding through partitioning. In 
addition, molten IBU was readily miscible with the molten lipid matrix 
materials. It has been reported that drug and matrix compatibility is the key to 
high encapsulation efficiencies
85
. Therefore, the miscibility of IBU with CA, 






D4.1.2.  Drug release study (unsieved) 
 
From Figure D25, both pure drug and physical mixtures (of CA, SA or 
GB with 20 %, w/w IBU) showed fast and large extent (>90 %) of IBU release 
(within 5 min). IBU is highly soluble at neutral to high pH as it is a carboxylic 
acid which would be ionized under those conditions. Combining IBU with 
milled CA, SA or GB powder to form a physical mixture (IBU : CA = 20 : 80) 
was not able to retard the dissolution process and allowed an almost immediate 
and rapid release of the drug content. This shows that physical mixing of drug 
with the lipid-based excipients was incapable of imparting any sustained-





Figure D25. Drug release profiles of pure drug and physical mixtures 







Table D12. Drug content and encapsulation efficiency of spray-congealed SLMs  
produced from the various formulations of drug carrier. 
 
Drug carrier* 





CA 100 2.16 ± 0.02 98.27 ± 0.71 
CA 97.5 PVP/VA 2.5 2.20 ± 0.11 100.00 ± 5.03 
CA 95 PVP/VA 5 2.18 ± 0.04 98.95 ± 1.71 
CA 92.5 PVP/VA 7.5 2.10 ± 0.04 95.68 ± 1.74 
CA 90 PVP/VA 10 2.09 ± 0.02 95.21 ± 1.00 
CA 97.5 EC 2.5 1.94 ± 0.04 88.40 ± 1.76 
CA 95 EC 5 2.03 ± 0.07 92.46 ± 3.03 
CA 92.5 EC 7.5 1.98 ± 0.01 90.16 ± 0.09 
   
SA 100 2.17 ± 0.03 98.56 ± 1.29 
SA 97.5 PVP/VA 2.5 2.18 ± 0.02 99.58 ± 0.84 
SA 95 PVP/VA 5 2.20 ± 0.05 100.00 ± 2.18 
SA 92.5 PVP/VA 7.5 2.20 ± 0.01 100.00 ± 0.67 
SA 90 PVP/VA 10 2.20 ± 0.12 100.00 ± 5.28 
SA 97.5 EC 2.5 2.09 ± 0.01 95.58 ± 0.45 
SA 95 EC 5 2.20 ± 0.03 100.00 ± 1.38 
SA 92.5 EC 7.5 2.08 ± 0.02 96.09 ± 0.71 
   
GB 100 2.06 ± 0.05 93.77 ± 2.41 
GB 97.5 PVP/VA 2.5 2.20 ± 0.02 100.00 ± 0.96 
GB 95 PVP/VA 5 2.20 ± 0.06 100.00 ± 2.65 
GB 92.5 PVP/VA 7.5 2.20 ± 0.04 100.00 ± 1.97 
GB 97.5 EC 2.5 1.99 ± 0.02 90.34 ± 0.89 




In order to provide insights on the overall characteristics of the 
formulations, dissolution studies were performed on the unprocessed SLMs 
(unsieved). With reference to Figure D26A and Table D13 which compares the 
ability of the three lipid matrix materials to sustain the release of IBU, it was 
evident that CA had the poorest performance, reaching maximum drug release 
of about 95 % relatively quickly (< 30 min). SA and GB were able to 
adequately sustain drug release, with 50 % drug release only after 21.8 and 
35.2 min respectively. Despite its better release sustaining ability and high 
encapsulation efficiency, GB was unable to fully release the drug in 5 h, with 
the amount of drug release levelling off around 80 %.  
 
For the CA system (Figures D26B, C), the effects of adding PVP/VA in 
increasing concentrations cannot be easily generalized. The release of IBU was 
increasingly retarded up to 5 %, w/w PVP/VA. The sustaining effect conferred 
by 5 %, w/w PVP/VA was marked enough to slow down 90 % drug release 
from 25.7 min to 88.6 min. Thereafter, the trend reversed, with 7.5 %, w/w 
PVP/VA performing slightly poorer than 5 %, w/w PVP/VA and the release 
profile with 10 %, w/w PVP/VA overlapping that of the only CA matrix. On 
the other hand, the trend with increasing concentration of EC was relatively 
straightforward, with increasing concentration of EC conferring better 
sustaining ability. For instance, 90 % drug release was only achieved at 54.1 
min for 7.5 %, w/w EC. Interestingly, drug release with 7.5 %, w/w EC was 
faster compared to that of 5 %, w/w PVP/VA despite the relatively more 




For the SA system (Figures D26D, E), addition of PVP/VA in increasing 
concentrations decreased the sustaining ability of SA. Time required for 90 % 
drug release decreased from 188 min to 51.3 min as the PVP/VA content 
increased from 0 % to 10 %, w/w (Table D13). Modification of the drug 
release profiles by EC was more complex. With 2.5 %, w/w of EC, the rate of 
drug release at the beginning was faster, with 50 % drug release achieved in 
less than half the duration needed for only SA. However, as EC content 
increased further, drug release started to slow down such that by 7.5 %, w/w of 
EC, the dissolution profile was generally superimposable on that of only SA. 
 
Similar to the case with SA, increasing concentrations of PVP/VA with 
GB hastened the release of IBU such that with 7.5 %, w/w of PVP/VA, time 
taken for 50 % drug release was almost six times shorter than that of only GB 
(Figure D26F). It is also interesting to note that the presence of PVP/VA 
facilitated the release of more drug after 5 h. Similar effects were noted for GB 
with 2.5 %, w/w of EC. The 50 % drug release was achieved in a shorter 
duration of 16.9 min, compared to 35.2 min for only GB. Nevertheless, the 
release of IBU did not reach completion after 5 h, akin to the situation with 














Table D13. T50 %, T75 % and T90 % of the unsieved spray-congealed SLMs produced 
from the various formulations of drug carrier. 
 
* Suffix numerals refer to the percentages by weight. 
 
Drug carrier* 







CA 100 < 1.00 6.47 25.7 
CA 97.5 PVP/VA 2.5 1.03 10.1 53.7 
CA 95 PVP/VA 5 3.28 22.4 88.6 
CA 92.5 PVP/VA 7.5 2.99 15.1 44.8 
CA 90 PVP/VA 10 < 1.00 3.93 25.2 
CA 97.5 EC 2.5 1.44 7.07 18.6 
CA 95 EC 5 1.50 12.9 50.7 
CA 92.5 EC 7.5 3.42 18.8 54.1 
    
SA 100 21.8 83.9 188 
SA 97.5 PVP/VA 2.5 6.18 37.7 112 
SA 95 PVP/VA 5 2.62 24.7 95.2 
SA 92.5 PVP/VA 7.5 < 1.00 12.3 68.7 
SA 90 PVP/VA 10 < 1.00 6.55 51.3 
SA 97.5 EC 2.5 9.34 54.0 155 
SA 95 EC 5 12.9 74.6 213 
SA 92.5 EC 7.5 16.8 78.1 196 
    
GB 100 35.2 126 273 
GB 97.5 PVP/VA 2.5 26.0 112 268 
GB 95 PVP/VA 5 10.1 59.8 174 
GB 92.5 PVP/VA 7.5 6.45 44.3 141 














Figure D26. Drug release profiles of the unsieved 20 %, w/w IBU-loaded spray-
congealed SLMs of (A) CA, SA and GB; (B) CA with 2.5, 5, 7.5 and 10 %, w/w 
PVP/VA; (C) CA with 2.5, 5, 7.5 %, w/w EC; (D) SA with 2.5, 5, 7.5 and 10 %, w/w 
PVP/VA; (E) SA with 2.5, 5, 7.5 %, w/w EC; (F) GB with 2.5, 5, 7.5 %, w/w 
PVP/VA and (G) GB with 2.5 %, w/w EC. 
 
D4.1.3.  Drug release study (180-250 μm size fraction) 
 
In order to eliminate the influence of particle size on drug release, spray-
congealed SLMs were sieved and the size fraction of 180-250 μm was used for 
dissolution studies. In Figure D27A and Table D14, it is apparent that similar 
to the unsieved data, CA had the weakest release sustaining ability. The release 
profiles of SA and GB were indicative of a significantly better sustained 
release behaviour, with GB being the best of the three. CA and SA were able 
to achieve significantly higher total amount of drug released compared to GB 
at the end of 5 h. Additionally, when compared with their unsieved 
counterparts, the drug release was found to be relatively more sustained. This 
can be attributed to the sieved fraction having a larger proportion of larger 
sized particles than the unsieved product. 
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For the CA formulations, in contrast to the release profiles of the 
unsieved product, the trend with PVP/VA was more straightforward. 
Generally, as PVP/VA concentration increased, the drug release was 
accelerated to such an extent that with 10 %, w/w PVP/VA drug release was 
almost completed in less than 5 min (Figure D27B). Conversely, the only CA 
matrix required more than 92.2 min. From 0 % to 7.5 %, w/w of EC, the drug 
release profiles were not significantly altered (Figure D27C). This stood in 
stark contrast to their unsieved counterparts which exhibited a greater 
sustaining ability with more EC. 
 
In the case of SA, drug release in the presence of PVP/VA was 
enhanced, akin to their unsieved counterparts (Figure D27D). With 10 %, w/w 
of PVP/VA, IBU was almost completely released after 10.1 min while it took 
more than 5 h with only SA as matrix. Additionally, despite the larger size 
fraction used, these PVP/VA containing SLMs released  drug faster than they 
did before sieving.The situation with EC followed a similar trend, although the 
effect of accelerating drug release was more diminished compared to PVP/VA 
(Figure D27E). At 7.5 %, w/w EC, the drug was almost completely released 
only after 111 min whereas it took 26.1 min with 7.5 %, w/w PVP/VA (Table 
D14). Similarly, the sieved SLMs released IBU faster than they did before 
sieving. 
 
With reference to Figure D27F, the situation with GB was very similar to 
CA or SA with respect to the addition of PVP/VA. As PVP/VA content 
increased from 0 % to 7.5 %, w/w, the sustaining ability of GB was 
compromised to such an extent that by 7.16 min, 75 % of drug had been 
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released compared to 162 min for only GB as matrix (Table D14). Comparing 
with the unsieved counterparts, it was also apparent that the sieved SLMs 
generally released IBU faster. With 2.5 %, w/w of EC (Figure D27G), drug 








Figure D27. Drug release profiles of the 20 %, w/w IBU-loaded spray-congealed 
SLMs (size fraction 180-250 μm) of (A) CA, SA and GB; (B) CA with 2.5, 5, 7.5 and 
10 %, w/w PVP/VA; (C) CA with 2.5, 5, 7.5 %, w/w EC; (D) SA with 2.5, 5, 7.5 and 
10 %, w/w PVP/VA; (E) SA with 2.5, 5, 7.5 %, w/w EC; (F) GB with 2.5, 5, 7.5 %, 
w/w PVP/VA and (G) GB with 2.5 %, w/w EC. 
 
D4.1.4.  Drug release modelling 
 
From Table D15, it is apparent that CA-based formulations fitted best to 
the Weibull model of drug release, with the sole exception occuring with 10 %, 
w/w PVP/VA. For the SA-based formulations, the Korsmeyer-Peppas model 
emerged as the best fitting model regardless of additives and their 
concentrations. GB formulations showed almost equally good fit to both the 










Table D14. T50 %, T75 % and T90 % of the spray-congealed SLMs produced from the  
various formulations of drug carrier (180-250 μm size fraction). 
 
Drug carrier* 







CA 100 3.63 24.2 92.2 
CA 97.5 PVP/VA 2.5 < 1.00 2.07 41.9 
CA 95 PVP/VA 5 < 1.00 < 1.00 6.28 
CA 92.5 PVP/VA 7.5 < 1.00 < 1.00 < 1.00 
CA 90 PVP/VA 10 < 1.00 < 1.00 1.25 
CA 97.5 EC 2.5 1.09 12.4 54.1 
CA 95 EC 5 < 1.00 15.3 92.1 
CA 92.5 EC 7.5 < 1.00 4.28 30.0 
    
SA 100 62.3 185 > 300 
SA 97.5 PVP/VA 2.5 5.86 23.1 62.3 
SA 95 PVP/VA 5 6.88 17.2 33.6 
SA 92.5 PVP/VA 7.5 < 1.00 6.49 26.1 
SA 90 PVP/VA 10 2.46 5.55 10.1 
SA 97.5 EC 2.5 7.40 62.6 163 
SA 95 EC 5 4.74 52.8 156 
SA 92.5 EC 7.5 2.65 34.9 111 
    
GB 100 57.2 162 > 300 
GB 97.5 PVP/VA 2.5 18.3 121 > 300 
GB 95 PVP/VA 5 7.10 64.9 > 300 
GB 92.5 PVP/VA 7.5 < 1.00 7.16 43.7 
GB 97.5 EC 2.5 11.0 72.9 235 





Table D15. Best-fitting models for IBU release from spray-congealed SLMs 




Coefficient of determination (R
2










CA 100 0.513 0.482 0.492 0.887 0.989 -30.5 
CA 97.5 PVP/VA 2.5 0.526 0.489 0.501 0.890 0.976 -22.6 
CA 95 PVP/VA 5 0.653 0.596 0.615 0.954 0.995 -8.97 
CA 92.5 PVP/VA 7.5 0.612 0.559 0.577 0.937 0.996 -9.03 
CA 90 PVP/VA 10 0.507 0.470 0.483 0.876 0.773 -25.0 
CA 97.5 EC 2.5 0.603 0.545 0.565 0.909 0.982 -15.8 
CA 95 EC 5 0.612 0.548 0.569 0.913 0.983 -13.1 
CA 92.5 EC 7.5 0.652 0.572 0.599 0.934 0.994 -6.00 
       
SA 100 0.820 0.698 0.741 0.988 0.985 0.355 
SA 97.5 PVP/VA 2.5 0.719 0.644 0.670 0.973 0.727 -3.17 
SA 95 PVP/VA 5 0.715 0.661 0.680 0.978 0.696 -7.75 
SA 92.5 PVP/VA 7.5 0.666 0.622 0.637 0.965 0.676 -17.6 
SA 90 PVP/VA 10 0.622 0.587 0.599 0.949 0.675 -29.0 
SA 97.5 EC 2.5 0.822 0.729 0.762 0.993 0.974 -1.99 
SA 95 EC 5 0.770 0.673 0.707 0.982 0.996 -1.26 
SA 92.5 EC 7.5 0.826 0.719 0.757 0.993 0.986 -0.229 
       
GB 100 0.732 0.558 0.621 0.932 0.973 0.701 
GB 97.5 PVP/VA 2.5 0.748 0.603 0.655 0.953 0.993 0.254 
GB 95 PVP/VA 5 0.756 0.670 0.700 0.982 0.996 -2.03 
GB 92.5 PVP/VA 7.5 0.688 0.614 0.640 0.963 0.999 -3.63 
GB 97.5 EC 2.5 0.792 0.696 0.730 0.988 0.998 -1.12 
* Suffix numerals refer to the percentages by weight. 
Values were reflected in bold print to represent the highest coefficient of determination (R
2
 value) of a 
particular formulation among the models fitted. 
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D4.1.5.  Surface characteristics of microparticles (pre- and post-
dissolution) 
 
As mentioned previously, with the addition of 20 %, w/w IBU, numerous 
rough protuberances appeared on the surface of CA-based SLMs whereas the 
surface of SA-based and GB-based SLMs remained smooth and exhibited no 
significant changes. It was established that IBU has a solubility limit of about 
10 %, w/w in CA and over 30 %, w/w in SA and GB. Therefore, at 20 %, w/w 
IBU, a portion of IBU existed as dispersed precipitates in solid CA. These 
undissolved IBU precipitates accounted for the rough protuberances observed 
on the surface of CA-based SLMs.  
 
There were significant changes to the surface morphologies of CA- and 
SA-based SLMs at the end of the dissolution run. For CA with/without 
PVP/VA or EC, the SLMs appeared to be fragmented or deformed (Figures 
D28A, D, E). For SA-based SLMs, the general spherical shape was retained, 
albeit with some evidence of surface erosion (Figures D28B, F, G). For the 
GB-based SLMs (Figures D28C, H and I), there were no perceivable 
modifications to the SLM surface and the particles remained intact. 
 
 
20 %, w/w IBU-loaded 
SLM formulation 
Pre-dissolution Post-dissolution 
A CA only 




20 %, w/w IBU-loaded 
SLM formulation 
Pre-dissolution Post-dissolution 
  B SA only 
      
C GB only 
       
D CA + 5 %, w/w PVP/VA 
       
E CA + 5 %, w/w EC 
       
F SA + 5 %, w/w PVP/VA 
       
G SA + 5 %, w/w EC 
       
H GB + 5 %, w/w PVP/VA 




20 %, w/w IBU-loaded 
SLM formulation 
Pre-dissolution Post-dissolution 
I GB + 2.5 %, w/w EC 
       
 
Figure D28. SEM images of pre- and post-dissolution 20 %, w/w IBU-loaded spray-
congealed SLMs of (A) CA; (B) SA; (C) GB; (D) CA with 5 %, w/w PVP/VA; (E) CA 
with 5 %, w/w EC; (F) SA with 5 %, w/w PVP/VA; (G) SA with 5 %, w/w EC; (H) GB 
with 5 %, w/w PVP/VA and (I) GB with 2.5 %, w/w EC. [Note: Images were captured at 
different magnifications to better depict the surface morphologies]. 
 
D4.1.6.  Impact of polymorphism and aging on drug release of GB solid 
lipid microparticles 
 
In Part D3, it was established that freshly spray-congealed GB-based 
SLMs consisted of GB in the α-polymorph. Upon storage, GB underwent 
polymorphic transition to the stable β‘-polymorph. Since polymorphism 
represents a shift in the crystal structure of the matrix and might lead to 
changes in the drug release profile, dissolution studies were conducted to 
compare the dissolution profiles between freshly spray-congealed GB-based 
SLMs and those that have been stored for a year. 
 
With reference to Figure D29, about 50 % of the drug was released from 
the freshly spray-congealed GB-based SLMs after about 30 minutes. On aging 
(1 year), the release profile showed minimal change from that of the freshly 
spray-congealed microparticles, except for a slightly slower rate of release for 







Figure D29. Dissolution curves of freshly spray-congealed 20 %, w/w IBU-
loaded GB SLMs and the same SLMs after a year of storage; T50 %, T75 % and T 
90% of fresh and aged 20 %, w/w IBU-loaded GB-based SLMs. 
 
D4.2.  Discussion 
 
D4.2.1.  Influence of lipid matrix type on drug release 
 
Drug release characteristics of polymer-based sustained drug delivery 
systems have been well reported, but less focus in reported studies were paid 
on the physical mechanisms involved in the release of drug from lipid-based 
delivery systems
1
. In this part of the study, drug release of IBU from IBU-
loaded CA-, SA- and GB-based SLMs were examined. In addition, the effects 








20 %, w/w IBU-loaded GB-based SLMs (fresh) 28.1 119 284 
20 %, w/w IBU-loaded GB-based SLMs (1 year) 35.2 126 273 
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characteristics of SLMs and modulation of drug release behaviour  were also 
determined. Drug release from SLMs can be affected by several factors, 
namely drug content, SLM size, lipophilicity of the matrix and nature of the 
dissolution medium (pH and osmolality). It has however been reported that the 
most important factor influencing drug release was the physical properties and 
chemical composition of the lipophilic matrix itself, i.e. drug release rate is 




With reference to the unsieved SLMs, CA had the least ability to sustain 
the release of IBU among the three lipids investigated. On the other hand, SA 
and GB exhibited significant sustaining ability, with GB as the best of the 
three. Since SLM size, or more specifically, specific surface area can influence 
drug release behaviour, dissolution studies were also conducted using a 
specific size fraction to remove the possible influence by SLM size. Similarly, 
CA was unable to sustain the release of IBU, unlike SA or GB. However, 
relative to the unsieved CA-based SLMs, drug release from the fractionated 
CA-based SLMs was significantly slower. Since the size fraction of 180-250 
μm used was significantly larger than the median particle size (93.6 μm, 
presented in Part D2) of CA-based SLMs, these results demonstrated that 
larger particles led to a slower drug release in accordance with the reduction in 
surface area to volume ratio. Interestingly, the release profiles of SA and GB 
overlapped once the size factor was removed. Although GB is a much more 
lipophilic and bulkier lipid than SA, it failed to sustain the release of IBU any 
more than SA. This suggests that despite the role of lipophilicity in prolonging 




D4.2.2.  Influence of drug miscibility with solid lipid matrix materials on 
drug release 
 
IBU was also previously found (Part D3) to exist as a solid solution with 
SA and GB but existed as a solid dispersion with CA. This was supported by 
the SEM images of the respective SLMs. The rough surface of IBU-loaded 
CA-based SLMs was attributed to the presence of abundant drug crystals 
adhering on the SLM surface. As such, the drug crystals were easily wetted 
and dissolved, resulting in a relatively large burst effect with a large 
percentage of the drug released within 30 min. Subsequently, the rest of the 
SLM could be easily broken apart or deformed by the entry of dissolution 
media due to the combination of the lower lipophilicity of CA and the many 
open pores left behind once the drug crystals were dissolved. This was 
substantiated by the highly eroded nature of the SLMs at the end of the 
dissolution run. On the other hand, the lipophilicity of SA and GB retarded 
access to the drug by the medium and generally maintained the particle 
integrity during dissolution. It was reported elsewhere that molecularly 
dispersed drug in solid solutions (e.g. SA-IBU and GB-IBU systems) have 
been described as having limited movement
184
. This can severely impede the 
passage of drug molecules out of the matrix and into the dissolution medium, 
resulting in a slow rate and significant prolongation of drug release. This point 
is reinforced in the case of GB-based SLMs which were unable to fully release 
all of the entrapped drug, instead levelling off at around 80 % drug release. 
SA-based SLMs fared better, and from the SEM images it was suggestive that 
the slight erosion of the SA-based SLMs in some part facilitated the escape of 
drug from deep within the microparticles, whereas the completely intact GB-
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based SLMs impeded diffusion of drug from deep within the matrix to the 
surrounding dissolution medium. 
 
D4.2.3.  Influence of polymeric additives and particle size on drug release 
 
Additives were frequently added to matrix systems to modify drug 
release behaviour. For instance, lactose was dispersed as a hydrophilic additive 
in hydrogenated cottonseed oil to modulate theophylline release from the 
resultant spray-congealed SLMs
77
. Hydroxypropylmethylcellulose, a swellable 
hydrophilic excipient has also been used to investigate matrix swelling effect 
on drug release
39
. Surfactacts were also commonly utilized as additives in an 
attempt to improve wettability of the embedded drug
76
. However, studies on 
the effect of polymeric additives on molten lipid matrix materials and 
characteristics of the resultant spray-congealed SLMs produced were very 
limited. In this present study, two polymeric additives, one hydrophilic 
(PVP/VA) and the other hydrophobic (EC), were used. From preliminary 
screening, both additives were identified as polymeric materials able to form 
homogeneous, clear melts with the three lipids investigated. 
 
The addition of a polymeric additive, PVP/VA or EC increased the 
viscosity of the melt significantly in a concentration-dependent manner as 
shown previously (Part D2). Consequently, this led to the production of larger-
sized SLMs compared to those of lipid-only matrices. The effects of these two 
polymeric additives were more clearly shown by dissolution studies performed 
on the sieved SLMs where the effect of size was removed. PVP/VA invariably 
hastened the release of IBU from all three lipid matrices. This was attributed to 
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the hydrophilicity imparted by PVP/VA, which drastically increased the 
wettability/hydrophilicity of the SLMs in the dissolution medium and the 
amount of drug released increased with the concentration of PVP/VA used. In 
addition PVP/VA is water-soluble and was likely to dissolve and open up 
channels facilitating the penetration of the dissolution media into the SLMs 
and the subsequent diffusion of drug out of the particle. This effect was most 
significant for CA, where SLMs containing PVP/VA showed catastrophic 
breakdown at the end of the dissolution run. The effect of size once again 
exerted its influence when the unsieved PVP/VA-containing CA-based SLMs 
were subjected to dissolution studies. In this case, the increase in SLM size due 
to increasing PVP/VA content led to a slower drug release. However, with the 
addition of 10 %, w/w PVP/VA, the increase in wettability/hydrophilicity 
overwhelmed the effect of particle size, thereby leading to faster drug release. 
EC is well known as a hydrophobic, water-insoluble cellulose derivative, and 
would be expected to improve the sustained release ability of the matrix 
material. When added to CA, EC prolonged drug release significantly. 
However, this effect was greatly diminished in the sieved fraction, suggesting 
that the prolongation of drug release was largely due to the larger sized 
products obtained as more EC was added. 
 
The findings for SA and GB were similar to each other but counter 
intuitive, in that EC actually hastened drug release. The prevailing explanation 
here would be that EC, despite being regarded as hydrophobic, still contains 
polar oxygen atoms in its molecular structure in a larger percentage than that 
of SA and GB. As such, addition of EC may have reduced the lipophilicity of 
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the SA- and GB-based SLMs, thus reducing the retardation in access of 
dissolution medium to the encapsulated IBU.  
 
It was notable that in general, for all formulations containing PVP/VA or 
EC, the drug release of the sieved fraction was always faster than that of the 
unsieved product, despite the sieved fraction containing a much larger 
percentage of large SLMs. The reason for this was likely due to aggregation of 
the smaller SLMs of the unsieved product in the dissolution medium, as 
PVP/VA and EC conferred a certain degree of tackiness to the SLMs. Such 
aggregations within the dissolution medium would prolong drug release since 
the aggregates would expose a smaller surface area to the dissolution medium, 
effectively acting as large particles. 
 
D4.2.4.  Mechanisms of drug release from lipid matrices 
 
Drug release modelling studies were frequently performed on tablet 
dosage forms. In this case, modelling studies were performed on the spray-
congealed SLMs as a means to assist in the elucidation of drug release 
mechanisms. Modelling the drug release profiles of the formulations 
investigated showed that they were clearly not of zero or first order release. 
CA-based formulations closely adhered to the Weibull model of drug release. 
The Weibull model (Equation 8) has been used to describe drug release from a 
matrix, and the value of the constant b (shape parameter) describes the mode 
of drug release
228
. If b>1, the release occurs via complex mechanisms and the 
drug release profile manifests as a sigmoidal curve. If b=1, the model 
approximates a first order type release and if b<1, it indicates the presence of a 
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burst release at the beginning, followed by a release profile that approximates 
that of first order release. The CA-based formulations produced b values 
around 0.35, indicating a strong burst effect (Table D16). This corroborated 
with the above discussion where IBU crystals on the surface of the CA-based 
SLMs dissolved rapidly on contact with the dissolution medium, followed by 
further release as the matrix became compromised through deformation and 
fragmentation.  
 
GB-based formulations showed close fitting with the Weibull model as 
well, with b-values slightly higher than those of CA-based formulations. A 
small burst effect is indicated here, and the increase in polymer concentration 
apparently increased  this effect as b values decreased with a corresponding 
increase in polymeric additive content. 
 
On the other hand, the Korsmeyer-Peppas model showed good fit for 
SA-based formulations. The Korsmeyer-Peppas model (Equation 7) has been 
used mainly to describe drug release that occur from insoluble polymeric 
matrices via diffusion, whether Fickian (n<0.5) or non-Fickian (0.5<n<1)
229
. 
Since IBU existed as a solid solution with SA, and the SEM images of post-
dissolution SLMs showed relatively intact particles, it may be inferred that 
drug release mainly occurred by slow diffusion out of the matrix, akin to that 
experienced by drugs embedded in a polymeric matrix. Additionally, the n 
values obtained for all SA-based formulations were less than 0.5, indicating 
Fickian-like diffusional release for these SLMs. A noteworthy point here is 
that GB-based formulations also showed good fit with the Korsmeyer-Peppas 
model, albeit slightly less so than the Weibull model. The n values obtained for 
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the GB-based formulations were also less than 0.5. The Fickian-like 
diffusional release implied here could explain the ability of GB-based SLMs in 
sustaining release of IBU after the slight initial burst effect. 
 
Table D16. Weibull shape parameter values (b-values) for spray-congealed IBU-
loaded CA- and GB-based microparticles. 
 
Drug carrier* 
   (%, w/w) 
b-value 
CA 100 0.35 
CA 97.5 PVP/VA  2.5 0.30 
CA 95 PVP/VA 5 0.36 
CA 92.5 PVP/VA 7.5 0.41 
CA 90 PVP/VA 10 0.79 
CA 97.5 EC 2.5 0.39 
CA 95 EC 5 0.30 
CA 92.5 EC 7.5 0.37 
  
GB 100 0.61 
GB 97.5 PVP/VA 2.5 0.50 
GB 95 PVP/VA 5 0.44 
GB 92.5 PVP/VA 7.5 0.42 
GB 97.5 EC 2.5 0.37 
* Suffix numerals refer to the percentages by weight. 
 
D4.2.5.  Influence of matrix polymorphism of GB on drug release 
 
Among the 3 lipids, only GB exhibited polymorphic change from its 
stable orthorhombic β‘-polymorph to its unstable hexagonal α-polymorph 
when subjected to spray congealing (Part D3). Polymorphic changes can lead 
to variability in drug release profiles, with the unstable polymorphic form 
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releasing drug faster than the stable form due to looser crystal packing. 
However, in this case, there was no significant difference in the release of IBU 
from the freshly spray-congealed SLMs (α-polymorph of GB) and the aged 
SLMs (β‘-polymorph of GB), eliminating worries about the effects of GB 
polymorphism on drug release.  
 
D4.3.  Conclusion of Part D4 
 
This part of the study has identified  three crucial factors that affect drug 
release from spray-congealed SLMs: nature of the lipid matrix materials, SLM 
size and hydrophilicity or hydrophobicity of the additive. It was affirmed that 
SA and GB are useful lipid matrix materials for the production of sustained 
release SLMs of IBU and possibly, for other similar drugs. CA may find utility 
as a lipid matrix for relatively rapid drug release. Drug-matrix miscibility was 
important in that solid dispersions seemed to result in a burst effect owing to 
drug precipitates on the SLM surface, whereas solid solutions effectively 
embedded the drug within a relatively impenetrable matrix which thus 
sustained drug release. It was found that larger SLMs (with higher additive 
concentration) led to slower drug release provided that the additives were 
similar in terms of hydrophobicity. Polymeric additives, PVP/VA and EC are 
useful as release modifying agents but their effects are not easily generalizable. 
SEM images taken pre- and post- dissolution and drug release modelling 
established that diffusion was the main mechanism of drug release for SA and 
GB-based SLMs, although a small amount of surface erosion was evident for 
SA. Drug release from CA-based SLMs was characterized by an initial burst 
effect which released the bulk of the encapsulated drug followed by a loss of 
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integrity of the SLM structure which led to a generally faster release. In all, 
this part of the study has shown that lipids are amenable as excipients to 
manufacture sustained release dosage forms. It has also provided new insights 
into drug release from SLMs as well as strategies to modulate drug release 
behaviour. The findings highlighted here will be of value to the pharmaceutical 





























The viscosity-temperature profiles of hydrophobic, low melting lipid 
materials (CA, SA and GB) with/without drug (IBU) and/or polymeric additive 
(PVP/VA and EC) follow a biexponential model. A novel temperature-
independent parameter (Tp) derived from this model was characteristic of the 
test material. The Tp values of the various lipid-based formulations had good 
correlations with viscosities and correlated better than viscosity with the 
median size of resultant SLMs produced. 
 
Addition of IBU raised the Tp (lowered the viscosity) of the lipid-based 
formulation, with the largest viscosity lowering effect on CA. This was 
attributed to the ‗lubricating‘ effect brought about by the non-polar IBU 
‗dimers‘. In contrast, addition of PVP/VA or EC decreased the Tp (increased 
the viscosity) of the lipid-based formulations. This viscosity-enhancing effect 
was attributed to hydrogen bonding between the lipid and polymeric additive. 
The Tp of lipid-based formulations may be modified using additives to 
produce spray-congealed SLMs of the desired size.  
 
Spray congealing resulted in the conversion of crystalline IBU to 
amorphous form, transition of GB to a less stable polymorph but had no effect 
on CA and SA. The less stable GB polymorph reverted to the stable form 
within a month of storage. Addition of IBU did not affect the polymorphism of 
the 3 lipids. The polymeric additives exerted various effects. In the presence of 
PVP/VA or EC, CA experienced a temporary expansion of its unit cell, while 
SA was not affected. PVP/VA hastened the transition of GB to the stable 
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polymorph whereas EC delayed it. IBU was more soluble in solid SA and GB 
than in solid CA, forming solid solutions and solid dispersions respectively at 
20 %, w/w IBU in the lipid matrix.   
 
The nature of the lipid-based formulation, size of SLMs and nature of 
polymeric additive were important variables affecting drug release. In general, 
drug release from a hydrophobic matrix that formed a solid solution with the 
drug was more sustained. Larger SLMs tend to release drug more slowly due 
to their lower specific surface areas. A more hydrophilic and water-soluble 
additive (e.g. PVP/VA) also led to a faster drug release. The various lipid-
based formulations showed different release mechanisms. The release profile 
of CA-based SLMs was characterized by burst effect followed by diffusion 
from the gradually deforming particle. SA and GB-based SLMs exhibited 
Fickian-type drug diffusion, with SA-based SLMs undergoing some surface 
erosion. 
 
This study has established the use of low melting lipids as viable matrix 
materials for spray congealing. With judicious choice of additives and an 
awareness of the drug-matrix miscibility, a variety of modified release 
formulations are possible. The novel Tp parameter is a useful rheological 
characteristic for optimization of lipid-based formulations to obtain spray-
























F. FURTHER STUDIES 
 
A possible future direction for this study is to explore the influence of 
other spray congealing process parameters on the resultant microparticle size 
and useful yield. For comprehensive investigation, separate experiments 
spanning different levels of multiple variables are necessary. Therefore, the 
Design of Experiment (DoE) approach can be a useful tool in determining the 
most important experiments to be conducted. For this work, possible variables 
can include air flow rate, spraying temperature (atomization air temperature), 
nozzle tip size and feed delivery rate. The current work in this thesis had fixed 
air flow rate at 3 kg/h, but air flow rate as low as 2 kg/h or as high as 5 kg/h 
were possible. As a greater airflow rate exerts a greater shearing force on the 
liquid stream, it is believed that the resultant microparticle size will be 
inversely proportional to it. Useful yield is expected to decrease concurrently 
since the higher kinetic energy possessed by the droplets will lead to more 
particles impacting upon the chamber walls. Spraying temperature had been 
held at 10°C above the melting point of the lipid matrix material used. 
Likewise, this can be varied from as low as 5°C to as high as 20°C (in light of 
drug degradation issues). Increasing spraying temperature will result in lower 
melt viscosity, which facilitates breakup of the liquid stream into smaller 
droplets. It is hence expected that smaller microparticles will be produced. At 
the same time, the increased temperature creates a larger gradient for cooling 
and can compromise cooling efficiency, resulting in a lower percentage of 
useful yield. A larger nozzle tip size reduces the back pressure and increases 
the delivery rate of the molten feed. Higher feed delivery rate reduces 
atomization efficiency and is likely to produce larger microparticles. At the 
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end of this investigation, it will be possible to determine which of the process 
parameter exerts the greatest influence on microparticle size. 
 
In the early part of the study, it was observed that when the concentration 
of drug incorporated exceeded its solubility limit in the solid lipid matrix, as in 
the case of CA, drug precipitates were found on the SLM surface. If the drug 
incorporated is below its solubility limit, as in the case of SA and GB, 
microparticle surface remained smooth with no evidence of drug precipitates. 
Therefore, it would be interesting to study the surface morphology of SA and 
GB-based SLMs at a higher drug load of 40 %, w/w or higher, where the 
systems will now exist as a solid dispersion instead of a solid solution at 20 %, 
w/w drug. This extension of the study will also serve as a proof of concept 
with regards to the presence of surface drug precipitates in the solid dispersion 
model, and its absence in the solid solution model.  
 
The present work utilized three lipids, CA, SA and GB to encapsulate 
IBU and two polymeric additives, PVP/VA and EC as matrix and release 
modifying additives. SA and GB, which formed solution solids with IBU, were 
found to sustain the release of IBU well. CA formed solution dispersion with 
IBU and released it rapidly with a large burst effect. It will be interesting to 
investigate the drug-matrix solid miscibility of other lipids shortlisted in Part 
D1 of the study, i.e. myristyl myristate, glyceryl monostearate, hydrogenated 
soybean oil, hydrogenated cottonseed oil and hydrogenated vegetable oils. 
This can then be correlated with the ability of said matrix materials to sustain 
the release of IBU at a fixed concentration of drug where they either form solid 
solution or dispersion. This study can potentially broaden the application of 
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drug-matrix solid miscibility to guide the preparation of sustained release 
formulations using a wide variety of lipids. PVP/VA and EC were found to 
form melt solutions with all three lipids. Both additives were able to modify 
drug release from all three lipid matrices in different ways, and also affected 
their solid state characteristics. Besides polymeric additives, other excipients 
such as surfactants, swellable agents (HPMC, microcrystalline cellulose) or 
known channeling agents such as lactose or mannitol can be investigated as 
lipid matrix additives. It would be interesting to study the intermolecular 
interaction between such additives and lipid matrix materials, as well as their 
influence on drug release behaviour and drug and matrix solid state 
characteristics.  
 
Lastly, one possible application of these solid lipid microparticles is to 
compress them into tablets together with other functional excipients and study 
their drug release behaviour. However, SA and GB microparticles have been 
shown to exhibit strong sustained release behaviour currently. Compacting 
them into tablets can result in fusing of these lipid microparticles into a highly 
dense, hydrophobic compact which may compromise drug release. This can be 
exacerbated by the heat and friction generated in high speed tableting. In the 
worst case scenario, CA and SA, which have lower melting points, may 
liquefy partially during tableting, leading to significant sticking to dies and 
punches. In fact, these lipid microparticles are more suitable for formulating as 
multiparticulate capsules. One interesting area to explore would be combining 
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Figure H1. Representative DSC thermograms to reflect melting point depression of 














































Figure H2. Representative DSC thermograms to reflect melting point depression of 






















































Figure H3. Representative DSC thermograms to reflect melting point depression of 
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Figure H4. Graphs of span of spray-congealed microparticles against (A) Tp; (B) 
melt viscosity at spraying temperature; (C) melt viscosity at 76°C and (D) melt 











Table H1. Equations of the correlation of Tp with melt viscosities. 
Correlation Equation 
Tp with melt viscosity at 76°C y = -0.00002x + 0.0897 
Tp with melt viscosity at 80°C y = -0.00001x + 0.0752 
Tp with melt viscosity at 85°C y = -0.00001x + 0.0530 
Tp with melt viscosity at 90°C y = -0.000007x + 0.0426 
 
Table H2. Equations of the correlation of microparticle size with Tp and melt 
viscosities. 
Correlation Equation 
Microparticle size with Tp y = -0.024x + 220 
Microparticle size with melt viscosity at 76°C y = 983x + 109 
Microparticle size with melt viscosity at 80°C y = 1238x + 106 
Microparticle size with melt viscosity at 85°C y = 2074x + 96 
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